先端医療シリーズ25 肝・胆・膵疾患 肝・胆・膵疾患の最新医療

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

5,133 円(税込)

購入する

商品紹介

本書は肝、胆、膵疾患領域における先端医療、すなわち医療の現時点での到達点に焦点をしぼり編集された。(序文より）

目次

  • 表紙
  • 口絵
  • 執筆者一覧
  • 本書を推薦する
  • 序文
  • 目次
  • 序章 肝・胆・膵疾患治療の課題と展望
  • 1. 内科的治療
  • 1.1 はじめに
  • 1.2 C型肝炎治療の課題と展望
  • 1.2.1 抗ウイルス療法
  • 1.2.2 抗線維化療法
  • 1.3 肝細胞癌の予防と治療の課題と展望
  • 1.3.1 肝細胞癌の予防
  • 1.3.2 肝細胞癌の治療
  • 1.4 胆道疾患
  • 1.4.1 胆道腫瘍診断
  • 1.4.2 胆道腫瘍治療
  • 1.4.2.1 放射線化学療法
  • 1.4.2.2 expandable metallic stent(EMS)
  • 1.4.3 総胆管結石症
  • 1.5 膵疾患
  • 1.5.1 急性膵炎
  • 1.5.2 慢性膵炎
  • 1.5.2.1 慢性膵炎における内視鏡治療
  • 1.5.2.2 慢性膵炎の線維化
  • 1.5.3 自己免疫性膵炎
  • 1.5.4 膵癌の化学療法
  • 1.5.5 膵管内乳頭粘液性腫瘍(intraductal papil-lary mucinous tumor : IPMT)
  • 1.6 おわりに
  • 2. 外科的治療
  • 2.1 はじめに
  • 2.2 肝胆膵疾患外科治療の特色
  • 2.2.1 新しい術式の導人
  • 2.2.2 早期診断法の欠如
  • 2.2.3 科学性に基づいたエビデンスと個別化医療
  • 2.2.4 集学的治療の併用
  • 2.3 臓器移植
  • 2.3.1 悪性腫瘍に対する肝移植
  • 2.3.2 生体ドナーの危険性と脳死臓器提供推進
  • 2.4 終わりに
  • 第1章 課題と展望(トピックス)
  • 1. 消化器癌に対する遺伝子治療の現状
  • 1.1 はじめに
  • 1.2 遺伝子治療臨床研究
  • 1.3 本邦における遺伝子治療臨床研究
  • 1.4 本邦における遺伝子治療臨床治験の審査体制
  • 1.5 遺伝子治療の光と影
  • 1.6 ex vivo遺伝子治療とin vivo遺伝子治療
  • 1.7 癌に対する遺伝子治療
  • 1.8 癌抑制遺伝了治療
  • 1.9 免疫遺伝子治療
  • 1.10 自殺遺伝子治療
  • 1.11 自己増殖性ウイルス治療
  • 1.12 肝癌に対する遺伝子治療の試みと現状
  • 1.13 その他の消化器癌に対する遺伝子治療臨床研究
  • 1.14 おわりに
  • 2. 胚性幹細胞の肝細胞への分化誘導と臨床応用への展望
  • 2.1 はじめに
  • 2.2 ES細胞について
  • 2.2.1 ES細胞の未分化性
  • 2.2.2 ES細胞の分化誘導
  • 2.3 マウスES細胞の肝細胞への分化誘導
  • 2.3.1 培養系による分化誘導
  • 2.3.2 移植による分化誘導
  • 2.4 霊長類ES細胞の肝細胞への分化誘導
  • 2.5 ヒトES細胞の肝疾患への臨床応用の展望
  • 2.5.1 肝疾患への適応と可能性
  • 2.5.2 問題点
  • 2.6 おわりに
  • 3. 骨髄非破壊的同種幹細胞移植
  • 3.1 はじめに
  • 3.2 ミニ移植の理論
  • 3.3 ミニ移植の実際
  • 3.4 ミニ移植の合併症
  • 3.4.1 急性GVHD
  • 3.4.2 慢性GVHD
  • 3.4.3 感染症
  • 3.5 固形腫瘍に対する同種移植
  • 3.5.1 固形腫瘍に対する免疫療法
  • 3.5.2 転移性腎細胞癌
  • 3.5.3 その他の固形腫瘍
  • 3.5.4 問題点
  • 3.6 おわりに
  • 4. 癌特異的免疫療法-肝癌の予防を中心に-
  • 4.1 はじめに
  • 4.2 樹状細胞と抗腫瘍免疫の誘導
  • 4.3 樹状細胞を用いた癌免疫療法
  • 4.4 樹状細胞ワクチンを用いた肝癌の再発予防
  • 4.5 おわりに
  • 5. 進行肝細胞癌に対するインターフェロン併用化学療法
  • 5.1 はじめに
  • 5.2 IFN α 併用化学療法の歴史的背景
  • 5.3 高度門脈腫瘍栓合併肝細胞癌に対するIFN α併用動注化学療法
  • 5.4 進行肝細胞癌に対する肝動注化学療法
  • 5.5 補助療法としてのIFN α併用動注化学療法
  • 5.6 今後の課題
  • 5.7 おわりに
  • 6. Drug Delivery Systemの進歩
  • 6.1 はじめに
  • 6.2 リポソーム
  • 6.3 ミセル体
  • 6.4 遺伝子治療におけるGene Delivery System(GDS)
  • 6.5 DDS, GDSの世界の動向
  • 7. 陽子線・重粒子線治療
  • 7.1 荷電重粒子線の特徴
  • 7.2 肝胆膵疾患における荷電重粒子線治療の利点
  • 7.3 荷電重粒子線治療の実際
  • 7.4 代表的治療成績(肝細胞癌)
  • 7.4.1 陽子線
  • 7.4.2 炭素線
  • 7.5 適応
  • 7.6 今後の展望
  • 第2章 肝疾患の分子生物学
  • 1. cDNAアレイを用いた肝細胞癌発症の分子機構
  • 1.1 はじめに
  • 1.2 cDNAマイクロアレイ法を用いた肝細胞癌の遺伝子解析
  • 1.3 肝細胞癌のトランスクリプトーム解析
  • 1.3.1 SAGE法を用いた正常肝組織、慢性肝炎、肝癌の解析
  • 1.3.2 cDNAマイクロアレイ法を用いた慢性肝炎、肝癌例の解析
  • 1.4 おわりに
  • 2. 原発性胆汁性肝硬変における樹状細胞ケモカイン受容体発現制御
  • 2.1 はじめに
  • 2.2 樹状細胞とは
  • 2.3 ケモカイン、ケモカインレセプターとは
  • 2.4 原発性胆汁性肝硬変と樹状細胞
  • 2.5 原発性胆汁性肝硬変とケモカイン
  • 2.6 おわりに
  • 3. B型肝炎の遺伝子解析-遺伝子型分類とその臨床的意義-
  • 3.1 はじめに
  • 3.2 HBV genotype分類法
  • 3.3 我が国におけるHBV genotypeの分布と病態
  • 3.4 Genotype Bの亜型Bj型、Ba型のウイルス学的、臨床的特徴
  • 3.5 最後に
  • 4. C型肝炎の遺伝子解析
  • 4.1 はじめに
  • 4.2 C型肝炎ウイルスの遺伝子構造
  • 4.2.1 コア蛋白
  • 4.2.2 エンベロープ蛋白
  • 4.2.3 非構造蛋白
  • 4.3 HCV遺伝子型
  • 4.3.1 肝疾患進行速度、脂質代謝と遺伝子型
  • 4.3.2 遺伝子型とインターフェロン効果
  • 4.4 HCV遺伝子の変異
  • 4.4.1 エンベロープ遺伝子HVR
  • 4.4.2 ISDR変異
  • 4.4.3 NS5B中の変異
  • 4.5 細胞遣伝子多型性とC型肝炎の病像
  • 第3章 再生医学
  • 1. 組織幹細胞の肝疾患への応用
  • 1.1 はじめに
  • 1.2 ラットにおける小型肝細胞
  • 1.3 ヒトにおける小型肝細胞
  • 1.4 肝細胞を利用した再生医療および今後の展望
  • 2. 人工肝臓と医療用形質転換ブタの開発
  • 2.1 人工肝臓の概念と歴史
  • 2.1.1 人工肝臓とは
  • 2.1.2 人工肝臓開発の歴史
  • 2.1.3 人工肝臓に用いる組織の種の問題
  • 2.2 肝機能代替部の開発
  • 2.2.1 全肝収納装置
  • 2.2.2 肝細胞浮遊システム
  • 2.2.3 固定化型バイオリアクター
  • 2.2.4 肝機能代替部の相互比較
  • 2.3 体外灌流法の開発
  • 2.3.1 異種全血直接灌流法(XDHP)
  • 2.3.2 交差血漿灌流法(CPP)
  • 2.3.3 スタンダードになり得る人工肝臓システム
  • 2.4 人工肝臓に用いる形質転換ブタの開発
  • 2.4.1 導入用遺伝子の構築
  • 2.4.2 形質転換ブタの作出
  • 2.4.3 形質転換ブタ作出の意義
  • 2.5 展望
  • 3. 膵臓の再生医学
  • 3.1 はじめに
  • 3.2 膵臓の発生
  • 3.3 組織幹細胞からのβ細胞の再生
  • 3.4 遺伝子導入によるインスリン産生細胞の再生
  • 3.5 細胞移植の材料としてのES細胞
  • 3.6 ES細胞からのインスリン産生細胞の再生
  • 3.7 今後の展望
  • 4. 肝臓における幹細胞生物学
  • 4.1 はじめに
  • 4.2 肝幹細胞の分離と特性解析
  • 4.3 実用化への展望
  • 5. 再生膵島細胞移植
  • 5.1 膵島移植
  • 5.2 再生医療による糖尿病治療
  • 5.2.1 異種膵島移植
  • 5.2.2 幹細胞からインスリン分泌細胞への分化誘導
  • 5.2.3 ES細胞からの分化誘導
  • 5.2.4 組織幹細胞からの分化誘導
  • 5.3 おわりに
  • 第4章 肝疾患の最新医療
  • 1. B型肝炎のラミブジン治療
  • 1.1 はじめに
  • 1.2 ラミブジンの作用機序と抗ウイルス効果
  • 1.3 ラミブジンのB型慢性肝炎に対する臨床効果
  • 1.4 治療効果の持続性
  • 1.5 ラミブジン耐性HBV
  • 1.6 ラミブジン耐性ウイルスの高感度検出系
  • 1.7 ラミブジン投与の適応
  • 1.8 ラミブジンの投与法
  • 1.8.1 ラミブジン短期投与
  • 1.8.2 ラミブジン長期投与
  • 1.8.3 ラミブジンとインターフェロンの併用療法
  • 1.9 おわりに
  • 2. C型肝炎のインターフェロン治療
  • 2.1 はじめに
  • 2.2 リバビリン(ribavirin : RBV)
  • 2.3 RBVの代謝経路
  • 2.4 RBVの作用機序
  • 2.5 IFN α-2b+RBV併用療法の治療成績
  • 2.6 PEG-IFN+RBV併用療法
  • 2.7 RBVの副作用
  • 2.8 C型慢性肝疾患の治療標準化(厚生労働省2003年度版)
  • 2.9 おわりに
  • 3. C型肝炎ウイルスに対する中和抗体の開発
  • 3.1 はじめに
  • 3.2 HCVの性状
  • 3.3 HCVのワクチン開発の現状
  • 3.4 HCV感染のin vitroアッセイ系の開発
  • 3.5 ヒト型中和抗体の開発
  • 3.6 HCVの細胞融合活性を中和するヒト抗体の作製
  • 3.7 おわりに
  • 4. わが国における脂肪肝炎の実態 : 発生機序とその治療
  • 4.1 急増する脂肪肝炎
  • 4.2 肥満人口の増加と肝臓の脂肪化
  • 4.3 脂肪肝の診断
  • 4.4 肝臓における脂肪酸の出納バランス
  • 4.5 脂肪肝炎の分類と診断
  • 4.6 脂肪肝炎の発生機序
  • 4.7 脂肪肝炎の治療
  • 第5章 肝硬変
  • 1. 肝線維化のメカニズム
  • 1.1 はじめに
  • 1.2 肝星細胞について
  • 1.2.1 正常肝における肝星細胞
  • 1.2.2 障害肝における肝星細胞-活性化に伴う変化-
  • 1.2.3 肝星細胞の活性化機序
  • 1.3 おわりに
  • 2. 門脈圧亢進症の治療
  • 2.1 はじめに
  • 2.2 食道静脈瘤の内視鏡的療法(EIS, EVL)
  • 2.2.1 適応および禁忌
  • 2.2.2 食道静脈瘤に対するEISLの手技の実際
  • 2.2.3 食道静脈瘤内視鏡的治療の治療成績と合併症
  • 2.3 孤立性胃静脈瘤の治療法
  • 2.3.1 内視鏡的療法(EVLs+EISL, Histoacryl)
  • 2.3.1.1 胃静脈瘤のEVLs+EISL
  • 2.3.1.2 Histoacryl
  • 2.3.2 バルーン閉鎖下逆行性経静脈的塞栓術(B-RTO)
  • 2.4 経皮的肝内門脈静脈短絡術(TIPS)
  • 2.5 経門脈的食道・胃静脈瘤塞栓術(PTO・TIO)
  • 2.6 外科的手術
  • 2.7 薬物療法
  • 3. 肝性脳症の治療
  • 3.1 はじめに
  • 3.2 肝性脳症の臨床病型と病態
  • 3.3 治療
  • 3.3.1 基本方針
  • 3.3.2 薬物療法
  • 3.3.3 人工肝補助、肝移植
  • 4. 難治性腹水の治療
  • 4.1 はじめに
  • 4.2 難治性腹水の定義
  • 4.3 難治性腹水の鑑別
  • 4.4 難治性腹水の治療
  • 4.4.1 新しい薬物療法
  • 4.4.2 腹膜頸静脈(PV)シャント
  • 4.4.3 腹水穿刺排液・アルブミン静注法
  • 4.4.4 腹水濾過濃縮再静注法
  • 4.4.5 経頸静脈肝内門脈大循環シャント術(Transjugular intra-hepatic portacaval stent shunt;TIPS)
  • 4.5 利尿剤不耐性腹水の背景因子、治療、予後
  • 4.6 肝予備能と腹水治療
  • 4.7 おわりに
  • 第6章 肝腫瘍の治療
  • 1. 肝の良性腫瘤性病変
  • 1.1 はじめに
  • 1.2 上皮性腫瘍 : 上皮性腫瘍は胆管上皮由来の腫瘍と肝細胞由来の腫瘍に大別できる
  • 1.2.1 胆管上皮性腫瘍
  • 1.2.2 肝細胞性腫瘍
  • 1.3 肝細胞性の腫瘍類似病変
  • 1.3.1 慢性肝疾患(慢性肝炎、肝硬変)を合併していない症例
  • 1.3.2 慢性肝疾患(慢性肝炎、肝硬変)を合併している症例
  • 1.4 非上皮性腫瘍
  • 1.4.1 海綿状血管腫
  • 1.4.2 血管筋脂肪腫
  • 1.4.3 その他
  • 1.5 非上皮性の腫瘍類似病変
  • 1.5.1 炎症性偽腫瘍(lnflammatory pseudotunior)
  • 1.5.2 孤立性壊死性結節(Solitary necrotic nodule)
  • 1.5.3 限局性脂肪浸潤(Focal fatty change)
  • 1.5.4 偽月旨肪腫 (Pseudolipoma)
  • 1.5.5 偽リンパ腫(Pseudolymphoma)
  • 1.6 おわりに
  • 2. 肝細胞癌とIVR
  • 2.1 はじめに
  • 2.2 肝細胞治療におけるIVRの種類
  • 2.3 カテーテル動脈塞栓術(TAE)
  • 2.3.1 TAEの適応・種類と選択基準
  • 2.3.2 TAEの実際
  • 2.3.2.1 選択的カテーテル挿人のポイント
  • 2.3.2.2 Lp-TAE、Segmental Lp-TAEのポイント
  • 2.3.2.3 術後管理
  • 2.3.2.4 治療効果と再TAEの判定
  • 2.4 進行症例に対するTAEと他のIVRとの併用
  • 2.4.1 Ablation治療
  • 2.4.2 複合IVR
  • 2.4.2.1 胆管閉塞
  • 2.4.2.2 門脈閉塞
  • 2.5 動注化学療法-リザーバー留置を中心に-
  • 2.5.1 適応
  • 2.5.2 方法
  • 2.5.2.1 血流改変術
  • 2.5.2.2 カテーテル留置法
  • 2.5.2.3 カテーテル留置後の管理と投与薬剤
  • 2.5.2.4 合併症
  • 2.6 まとめ
  • 3. 肝細胞癌の局所治療
  • 3.1 はじめに
  • 3.2 経皮的エタノール注入療法
  • 3.2.1 適応
  • 3.2.2 方法
  • 3.2.3 治療成績
  • 3.2.4 合併症
  • 3.2.5 transcatheter arterial embolization(TAE)とPEIのcombination therapy
  • 3.3 経皮的マイクロ波凝固療法
  • 3.3.1 適応
  • 3.3.2 方法
  • 3.3.3 治療成績
  • 3.3.4 合併症
  • 3.4 経皮的ラジオ波熱凝固療法
  • 3.4.1 適応
  • 3.4.2 方法
  • 3.4.3 治療成績
  • 3.4.4 合併症
  • 3.4.5 RFAの今後の展開
  • 3.5 経皮的局所療法の使い分け
  • 3.6 おわりに
  • 4. 肝細胞癌の外科治療
  • 4.1 はじめに
  • 4.2 術前肝細胞癌の診断
  • 4.3 術前肝機能の評価
  • 4.4 肝流入血の遮断
  • 4.5 術中エコー
  • 4.6 解剖学的切除
  • 4.7 肝切除に対する肝静脈枝の重要性について
  • 4.8 術前門脈枝塞栓術
  • 4.9 門脈腫瘍栓合併肝癌に対する肝切除
  • 4.10 再発肝癌に対する肝切除
  • 4.11 肝癌に対する肝移植
  • 4.12 おわりに
  • 第7章 肝移植
  • 1. 肝癌に対する肝移植
  • 1.1 はじめに
  • 1.2 肝癌に対する脳死肝移植
  • 1.2.1 肝癌に対する初期の脳死肝移植
  • 1.2.2 ミラノ基準
  • 1.2.3 ミラノ基準の拡大
  • 1.3 肝癌に対する生体肝移植
  • 1.3.1 生体肝移植の利点
  • 1.3.2 わが国における肝癌に対する生体肝移植
  • 1.4 周術期補助療法と免疫抑制療法
  • 1.4.1 周術期補助療法
  • 1.4.2 免疫抑制療法
  • 1.5 おわりに
  • 2. 肝硬変(B型肝炎)に対する肝移植
  • 2.1 はじめに
  • 2.2 肝移植後のB型肝炎再発
  • 2.3 移植後再発予防
  • 2.3.1 抗HBV免疫グロブリン(HBIG)
  • 2.3.2 ラミブジン
  • 2.3.3 HBIGとラミブジン併用療法
  • 2.4 京都大学でのB型肝硬変に対する生体肝移植の現況
  • 2.5 今後の課題と展望
  • 3. 肝硬変(C型肝炎)に対する肝移植
  • 3.1 はじめに
  • 3.2 脳死肝移植
  • 3.2.1 再発と予後因子
  • 3.2.2 再発に対する内科治療
  • 3.2.3 再移植
  • 3.3 生体肝移植-当科での取り組み
  • 3.4 C型肝炎に対する移植で、生体と脳死とでは本当に違うのか?
  • 3.5 併存する肝細胞癌への対策
  • 3.5.1 脳死肝移植
  • 3.5.2 生体肝移植
  • 3.6 おわりに
  • 4. 先天性疾患に対する肝移植
  • 4.1 はじめに
  • 4.2 小児における肝移植の問題点
  • 4.3 胆汁うっ滞性疾患
  • 4.3.1 胆道閉鎖症
  • 4.3.2 アラジール症候群
  • 4.3.3 バイラー病
  • 4.4 代謝性疾患
  • 4.4.1 ウィルソン病
  • 4.4.2 家族性アミロイドポリノロパチー
  • 4.4.3 シトルリン血症
  • 4.4.4 オルニチントランスカルバミラーゼ欠損症
  • 4.4.5 チロシン病
  • 4.4.6 糖原病
  • 4.4.7 その他
  • 4.5 その他の先天性疾患
  • 4.6 おわりに
  • 5. ドミノ肝移植
  • 5.1 はじめに
  • 5.2 ドミノ肝移植とは
  • 5.3 FAPとは
  • 5.4 ドミノ肝移植の医学的根拠
  • 5.5 FAP患者の肝臓を用いたドミノ肝移植の適応症例
  • 5.6 APOLTとは
  • 5.7 ドミノ肝移植の手術手技の要点
  • 5.7.1 一次ドナーの手術
  • 5.7.2 一次レシピエント=二次ドナーの手術
  • 5.7.3 二次レシピエントの手術
  • 5.8 通常の生体肝移植とドミノ肝移植の手技的差異について
  • 5.9 一次レシピエントの術中術後管理に関して
  • 5.10 二次レシピエントの術後のfollow up
  • 5.11 ドミノ肝移植の問題点
  • 5.12 おわりに
  • 第8章 胆道疾患と胆石症
  • 1. 胆道感染症(胆嚢炎、胆管炎)
  • 1.1 はじめに
  • 1.2 原因・病因
  • 1.3 病態
  • 1.3.1 急性胆嚢炎
  • 1.3.2 急性胆管炎
  • 1.4 臨床症状
  • 1.4.1 急性胆嚢炎
  • 1.4.2 急性胆管炎
  • 1.5 検査成績
  • 1.5.1 血液検査所見
  • 1.5.2 X線検査
  • 1.5.3 腹部超音波検査(US)
  • 1.5.4 腹部CT検査
  • 1.5.5 MRCP
  • 1.5.6 超音波内視鏡検査(EUS)
  • 1.5.7 ERCP
  • 1.5.8 肝胆道シンチグラフィ
  • 1.6 診断
  • 1.7 治療
  • 1.7.1 急性胆嚢炎
  • 1.7.2 急性胆管炎
  • 2. 胆道運動異常症
  • 2.1 はじめに
  • 2.2 SODの分類
  • 2.3 臨床症状
  • 2.3.1 コレシストキニン(cholecystokinin : CCK)誘発試験
  • 2.3.2 胆道シンチグラフィー
  • 2.3.3 内視鏡的胆道内圧測定法
  • 2.4 診断手順
  • 2.5 治療
  • 3. 良性胆道閉塞(狭窄)-先天性、後天性
  • 3.1 はじめに
  • 3.2 先天性胆道閉塞(狭窄)
  • 3.2.1 先天性胆道閉鎖(閉塞)症
  • 3.2.2 先天性胆道拡張症
  • 3.3 後天性胆道閉塞(狭窄)
  • 3.3.1 術後胆道閉塞
  • 3.3.1.1 術中胆道損傷に基づく狭窄
  • 3.3.1.2 胆道再建後吻合部狭窄
  • 3.3.2 炎症性胆道閉塞(狭窄)
  • 3.3.2.1 Mirizzi症候群
  • 3.3.2.2 膵疾患
  • 3.3.2.3 肝内結石
  • 3.3.2.4 乳頭炎(papillitis)
  • 3.3.3 原発性硬化性胆管炎(primary sclerosing cholangitis)
  • 3.3.4 医原性
  • 3.3.5 その他
  • 4. 胆道出血
  • 4.1 はじめに
  • 4.2 その原因疾患
  • 4.3 症状
  • 4.4 診断における初歩的アプローチ
  • 4.5 確定診断
  • 4.6 治療
  • 4.7 胆道出血の予後
  • 4.8 症例
  • 4.9 おわりに
  • 5. 膵胆管合流異常と発癌
  • 5.1 はじめに
  • 5.2 合流異常における胆嚢上皮の変化
  • 5.2.1 胆嚢上皮の病理組織学的変化
  • 5.2.2 合流異常と胆嚢粘膜過形成
  • 5.2.3 胆嚢粘膜過形成の発生機序
  • 5.2.4 胆嚢粘膜過形成の細胞増殖能
  • 5.2.5 胆嚢粘膜過形成の遺伝了異常
  • 5.3 手術後長期観察例における発癌の検討
  • 5.3.1 総胆管嚢腫切除後の胆管癌発生率
  • 5.3.2 総胆管嚢腫切除後の胆管癌発生要因
  • 5.3.3 胆管非拡張型合流異常の手術後長期観察例
  • 5.4 おわりに
  • 6. 胆石症の内科的治療
  • 6.1 はじめに
  • 6.2 無治療で経過観察
  • 6.3 コレステロール胆石溶解療法
  • 6.3.1 歴史
  • 6.3.2 経口胆石溶解療法の適応
  • 6.3.3 投与量
  • 6.3.4 UDCAとCDCAの溶解機序
  • 6.3.5 UDCAとCDCAの併用療法
  • 6.3.6 治療成績
  • 6.3.7 再発率
  • 6.3.8 体外衝撃波胆石破砕術(ESWL)と経口胆石溶解療法の併用療法
  • 6.3.9 経口胆石溶解療法の現況
  • 6.4 直接胆石溶解法
  • 7. 胆石症の外科的治療
  • 7.1 はじめに
  • 7.2 手術適応
  • 7.3 術前検査
  • 7.4 インフォームドコンセント(IC)
  • 7.5 術式の選択
  • 7.6 開腹手術
  • 7.6.1 皮膚切開
  • 7.6.2 視野の展開
  • 7.6.3 胆嚢摘出法
  • 7.6.3.1 底部より行うもの(いわゆる典型的胆嚢摘出術)cholecystectomy from the fundus(so-called nomlograde cholecystectomy)
  • 7.6.3.2 胆嚢管処置より行うもの(いわゆる逆行性胆嚢摘出術)cholecystectomy from the cysticus (so-called retrograde cholecystectomy)
  • 7.6.4 胆道損傷
  • 7.6.5 困難な胆嚢摘出術例
  • 7.7 腹腔鏡下胆嚢摘出(Laparoscopic Cholecys-tectomy : LC)
  • 7.7.1 手術適応
  • 7.7.2 手術手技
  • 7.8 おわりに
  • 8. 内視鏡的砕石法の進歩
  • 8.1 はじめに
  • 8.2 経乳頭的アプローチ
  • 8.2.1 経乳頭的アプローチをするにあたって
  • 8.2.1.1 内視鏡的乳頭切開術 : EST
  • 8.2.1.2 内視鏡的乳頭バルーン拡張術
  • 8.2.2 ESTとEPBDの選択
  • 8.2.3 合併症
  • 8.2.4 問題点
  • 8.3 砕石法
  • 8.3.1 機械式砕石法
  • 8.3.1.1 砕石目的のバスケット鉗子
  • 8.3.1.2 採石目的のバスケット鉗子
  • 8.3.1.3 その他の鉗子
  • 8.3.2 電気水圧衝撃波結石砕右法
  • 8.3.3 レーザー砕石法
  • 8.4 まとめ
  • 9. 体外衝撃波胆石破砕術の進歩
  • 9.1 はじめに
  • 9.2 衝撃波発生装置
  • 9.3 胆嚢内結石のESWL
  • 9.3.1 胆嚢内結石に対するESWLの適応
  • 9.3.2 胆嚢内結石に対する治療の実際
  • 9.3.3 胆嚢内結石の治療成績
  • 9.4 総胆管結石に対するESWL
  • 9.4.1 総胆管結石に対するESWLの適応
  • 9.4.2 総胆管結石に対するESWLの治療の実際
  • 9.4.3 総胆管結石に対するESWI.の治療成績
  • 9.5 おわりに
  • 第9章 胆道癌の治療
  • 1. 分子標的治療
  • 1.1 はじめに
  • 1.2 MUC1とCD3を標的とした二重特異性抗体
  • 1.2.1 一本鎖抗体(scFv)とbispecific scFv(diabody)の遺伝子工学的作製
  • 1.2.2 細菌性スーパー抗原SEAの導入
  • 1.3 EGFRとCD3を標的とした二重特異性抗体
  • 1.4 おわりに
  • 2. 外科治療
  • 2.1 はじめに
  • 2.2 術前診断
  • 2.2.1 進展度診断
  • 2.2.2 術前リスク判定
  • 2.3 手術術式
  • 2.3.1 標準術式
  • 2.3.2 消化管再建術式
  • 2.3.3 拡大手術の適応と術式
  • 2.4 胆道癌に対する肝切除の周術期管理
  • 2.4.1 術前管理
  • 2.4.2 術前貯血
  • 2.4.3 合併症を防止するための手術手技
  • 2.4.4 術後管埋
  • 2.5 再発の早期発見と対策
  • 3. 化学療法の現状と問題点
  • 3.1 はじめに
  • 3.2 適応
  • 3.3 治療成績
  • 3.3.1 単剤
  • 3.3.2 多剤併用療法
  • 3.3.3 randomized control trial
  • 3.3.4 臨床試験での問題点
  • 3.3.5 当教室での試み
  • 3.4 胆道癌化学療法の今後の課題
  • 第10章 重症急性膵炎
  • 1. 重症度診断
  • 1.1 急性膵炎の重症度判定の意義
  • 1.2 重症度判定の経緯
  • 1.3 急性膵炎の診療ガイドライン
  • 1.4 急性膵炎の診断
  • 1.5 厚生労働省の急性膵炎の重症度判定基準・重症度スコア
  • 1.6 重症度判定における問題点
  • 1.6.1 臨床兆候
  • 1.6.2 血液検査所見
  • 1.6.3 CT
  • 1.7 今後の課題
  • 2. 重症化メカニズム
  • 2.1 急性膵炎重症化機序 : 疫学調査から
  • 2.2 早期合併症の発症機序
  • 2.2.1 膵酵素の活性化量と重症化
  • 2.2.2 重症化における全身反応
  • 2.2.3 モデル動物を用いた重症化機序の解析
  • 2.3 後期合併症の発症機序
  • 2.3.1 重症急性膵炎と単核球の機能障害
  • 2.3.2 重症急性膵炎とアポトーシス
  • 2.3.3 重症急性膵炎と抗炎症性サイトカイン
  • 2.4 まとめ
  • 3. 特殊療法
  • 3.1 はじめに
  • 3.2 蛋白分解阻害薬・抗菌薬持続動注療法
  • 3.2.1動注療法の基礎的研究
  • 3.2.2 動注療法の臨床的研究
  • 3.3 持続的血液濾過透析(CHDF)
  • 3.3.1 CHDFの基礎的研究
  • 3.3.2 CHDFの臨床的研究
  • 3.4 選択的消化管除菌(SDD)
  • 3.4.1 SDDの基礎的研究
  • 3.4.2 SDDの臨床的研究
  • 3.5 その他の特殊療法
  • 3.6 おわりに
  • 4. 重症急性膵炎に対する外科治療
  • 4.1 はじめに
  • 4.2 急性膵炎の診療ガイドラインにおける外科治療の要点
  • 4.2.1 感染性膵壊死
  • 4.2.2 膵膿瘍
  • 4.2.3 仮性嚢胞
  • 4.3 感染性膵壊死に対するネクロセクトミー
  • 4.3.1 ネクロセクトミーとは何か?
  • 4.3.2 無菌性膵壊死に対するネクロセクトミーの適応
  • 4.3.3 手術のタイミング
  • 4.3.4 手術のプランニング
  • 4.3.5 膵への到達法
  • 4.3.6 ネクロセクトミー
  • 4.3.7 ネクロセクトミー後の処置
  • 4.3.8 持続的局所洗浄(continuous closed lavage)
  • 4.3.9 オープンドレナージ
  • 4.3.10 合併症対策
  • 4.3.11 栄養管理、創の閉鎖
  • 第11章 慢性膵炎の最新治療
  • 1. 疼痛対策
  • 1.1 はじめに
  • 1.2 慢性膵炎の臨床症状
  • 1.3 慢性膵炎の病期と治療の基本方針
  • 1.4 痙痛の発生機序と治療の考え方
  • 1.4.1 膵管内圧の上昇
  • 1.4.2 膵組織の反復する炎症
  • 1.4.3 膵内神経の変性
  • 1.4.4 膵仮性嚢胞、胆管狭窄
  • 1.5 疼痛治療の実際
  • 1.5.1 成因の除去
  • 1.5.2 膵外分泌の抑制
  • 1.5.2.1 食事療法
  • 1.5.2.2 消化酵素薬
  • 1.5.2.3 制酸薬
  • 1.5.2.4 ソマトスタチン誘導体
  • 1.5.2.5 CCK受容体拮抗薬
  • 1.5.2.6 鎮痙薬
  • 1.5.3 鎮痛薬
  • 1.5.4 蛋白分解酵素阻害薬
  • 1.5.5 膵管内圧の低下
  • 1.5.5.1 COMT阻害薬
  • 1.5.5.2 蛋白栓、膵石の除去
  • 1.5.5.3 膵管狭窄の改善
  • 1.5.6 神経ブロック
  • 1.5.7 向精神薬
  • 1.5.8 生活指導
  • 1.6 疼痛に対する外科治療
  • 1.7 疼痛の予後
  • 1.8 おわりに
  • 2. 自己免疫性膵炎の内科的治療
  • 2.1 はじめに
  • 2.2 概念・定義
  • 2.3 臨床分類
  • 2.4 臨床症状・病態
  • 2.5 診断の手順
  • 2.5.1 血液学的所見
  • 2.5.2 膵の病理組織学的所見
  • 2.5.3 画像診断
  • 2.6 病因
  • 2.7 治療と予後
  • 2.7.1 治療方針の立て方
  • 2.7.2 食事療法
  • 2.7.3 内視鏡的治療
  • 2.7.4 薬物療法
  • 2.8 おわりに
  • 3. 腫瘤形成性膵炎
  • 3.1 はじめに
  • 3.2 腫瘤形成性膵炎の病理組織学的特徴
  • 3.3 腫瘤形成性膵炎の診断
  • 3.3.1 病歴
  • 3.3.2 腫瘍マーカー
  • 3.3.3 腹部超音波、超音波内視鏡
  • 3.3.4 CT
  • 3.3.5 膵管造影(ERP)、胆管造影(ERC, PTC)
  • 3.3.6 血管造影
  • 3.3.7 造影超音波
  • 3.3.8 PET
  • 3.3.9 膵生検
  • 3.3.10 MRCP
  • 3.4 腫瘤形成性膵炎と膵癌の術前鑑別診断は可能か?
  • 3.4.1 症例呈示
  • 3.4.2 当科で経験した診断に難渋した膵腫瘤性病変11例の検討
  • 3.5 治療
  • 3.6 おわりに
  • 4. 外科治療
  • 4.1 はじめに
  • 4.2 膵頭部ペースメーカー説の台頭
  • 4.3 合理的な手術への進展
  • 4.4 十二指腸温存膵頭切除術
  • 4.4.1 Beger手術
  • 4.4.2 Takadals modification
  • 4.5 拡大膵管ドレナージ手術
  • 4.5.1 Prinzの手術
  • 4.5.2 膵頭部芯抜きを伴う膵管空腸側々吻合術(Frey手術)
  • 4.5.3 V-shaped excision
  • 4.5.4 Bem modification
  • 4.6 外科治療の成績
  • 4.6.1 幽門温存膵頭f二指腸切除術(PPPD)vs十二指腸温存膵頭切除術(Beger手術)vs膵頭部芯抜きを伴う膵管空腸側々吻合術(Frey手術)
  • 4.6.2 V-shaped exision
  • 4.7 まとめ
  • 5. 膵管ステント
  • 5.1 はじめに
  • 5.2 膵管の解剖学的特徴
  • 5.3 適応
  • 5.4 膵管ステント
  • 5.4.1 ステントの種類
  • 5.4.2 ステントの選択
  • 5.5 ステント留置法
  • 5.5.1 手技
  • 5.5.2 管理
  • 5.6 ステント合併症
  • 5.7 症例
  • 5.8 考察
  • 5.9 おわりに
  • 第12章 膵癌の治療と治療法選択
  • 1. 膵癌に対する免疫療法
  • 1.1 はじめに
  • 1.2 能動免疫療法
  • 1.2.1 腫瘍抗原ペプチド・タンパクによる免疫
  • 1.2.2 樹状細胞を用いた免疫
  • 1.2.3 その他の能動免疫法
  • 1.3 受動免疫療法
  • 1.4 同種造血幹細胞移植・同種巾血球輸注によるGVT効果
  • 1.5 免疫操作による抗腫瘍免疫応答促進
  • 1.6 おわりに
  • 2. 放射線治療
  • 2.1 はじめに
  • 2.2 膵癌の臨床病期と放射線治療の役割
  • 2.2.1 切除可能能膵癌に対する術前照射
  • 2.2.2 切除可能膵癌に対する術後照射
  • 2.2.3 切除可能膵癌に対する術中照射
  • 2.2.4 局所進行膵癌に対する5-FU併用化学放射線療法
  • 2.2.5 局所進行膵癌に対する新規抗癌剤併用化学放射線療法
  • 2.2.6 局所進行膵癌に対する術中照射
  • 2.2.7 転移性膵癌に対する姑息的照射
  • 2.3 膵癌における放射線治療の基礎と実際
  • 2.3.1 照射線量と線量分割法
  • 2.3.2 照射体積の定義
  • 2.3.3 照射野の設定
  • 2.3.4 膵癌の放射線治療計画の実際
  • 2.4 おわりに
  • 3. 膵臓移植
  • 3.1 はじめに
  • 3.2 膵臓移植の歴史と背景
  • 3.3 膵臓移植の種類と適応
  • 3.4 膵臓移植のドナー手術
  • 3.4.1 脳死ドナーからの肝膵腎摘出法
  • 3.4.2 Back tableにおける肝膵分離法
  • 3.5 膵臓移植のレシピエント手術
  • 3.5.1 膵臓のBench surgery
  • 3.5.2 膵腎1司時移植術
  • 3.6 免疫抑制と拒絶反応
  • 3.7 急性拒絶反応の病理
  • 3.8 世界における膵臓移植、膵腎同時移植の現状
  • 3.9 日本における10例の膵臓移植の特徴
  • 3.10 本邦症例の摘出手技と血行再建
  • 3.11 脳死体からの膵腎同時移植の実例
  • 3.12 まとめ
  • 4. 局所進行膵癌に対する治療法選択
  • 4.1 はじめに
  • 4.2 膵癌に対する治療法のdecision tree model
  • 4.3 遠隔転移のある膵癌の治療法選択
  • 4.4 16番リンパ節転移陽性あるいは高度動脈浸潤膵癌患者の治療法選択
  • 4.5 局所進行膵癌に対する切除手術の適応
  • 4.6 切除手術における郭清
  • 4.7 切除手術後の補助放射線療法の位置づけ
  • 4.8 切除手術後の補助化学療法の位置づけ
  • 4.9 局所進行膵癌に対する手術以外の治療法
  • 4.10 切除術後再発に対する治療
  • 5. 切除可能膵癌に対する切除範囲の決定
  • 5.1 はじめに
  • 5.2 通常型膵癌に対する手術の現況
  • 5.3 切除可能膵頭部膵管癌に対する切除範囲
  • 5.3.1 膵、胃切除範囲
  • 5.3.2 血管合併切除
  • 5.3.3 神経叢郭清
  • 5.3.4 リンパ節郭清
  • 5.4 切除可能膵頭部膵管癌に対する切除の実際
  • 5.4.1 Kocherの授動
  • 5.4.2 門脈、上腸問膜静脈の剥離
  • 5.4.3 上腸間膜動脈(SMA)の露出
  • 5.4.4 SMA周囲神経叢縦割り操作
  • 5.4.5 神経叢切離
  • 5.5 おわりに
  • 6. 切除可能膵癌に対する補助化学療法
  • 6.1 はじめに
  • 6.2 補助療法について
  • 6.2.1 補助療法の原理
  • 6.2.2 補助療法の限界
  • 6.3 臨床研究とエビデンス
  • 6.4 膵癌の補助療法に関する臨床研究の問題点
  • 6.5 これまでに報告された主な無作為化比較試験
  • 6.5.1 GITSG
  • 6.5.2 ノルウェー・グループ
  • 6.5.3 EORTC
  • 6.5.4 ESPAC
  • 6.6 膵癌に対する補助療法の現状と研究の在り方
  • 6.7 おわりに
  • 7. 切除不能膵癌に対する治療
  • 7.1 はじめに
  • 7.2 膵癌の病態と治療の選択
  • 7.3 化学療法
  • 7.3.1 抗癌剤の種類と投与方法
  • 7.3.2 化学療法の対象
  • 7.3.3 治療効果の判定
  • 7.3.4 各抗癌剤の単剤での効果
  • 7.3.5 5-FUを中心とした多剤併用療法
  • 7.3.6 Gemcitabineを中心とした多剤併用療法
  • 7.4 局所進行例に対する治療
  • 7.5 まとめ
  • 第13章 診断のニューテクノロジー
  • 1. 膵・胆道癌における腫瘍マーカー-癌関連遺伝子を中心に-
  • 1.1 はじめに
  • 1.2 膵・胆道癌の診断に有用な腫瘍マーカーの種類と分類
  • 1.3 膵・胆道癌における血清腫瘍マーカーの有用性
  • 1.4 K-rαs遺伝子
  • 1.5 p53遺伝子
  • 1.6 Telomeraseとh-TERT
  • 1.7 癌関連遺伝子のメチル化異常
  • 2. 肝胆膵のMRI診断
  • 2.1 はじめに
  • 2.2 肝臓
  • 2.2.1 肝転移(liver metastasis)
  • 2.2.2 肝細胞癌(hepatocellular carcinoma : HCC)
  • 2.2.3 限局性結節性過形成(focal nodular hyper-plasia : FNH)
  • 2.2.4 肝血管腫(liver hemangioma)
  • 2.3 胆道系、膵
  • 2.3.1 胆道系
  • 2.3.1.1 胆嚢腺筋腫症(adenomyomatosis)
  • 2.3.1.2 総胆管結石(CBD stone)
  • 2.3.1.3 膵胆管合流異常
  • 2.3.1.4 原発性硬化性胆管炎(primary sclerosing cholangitis : PSC)
  • 2.3.2 膵
  • 2.3.2.1 白己免疫性膵炎(autoimmune pancre-atitis)
  • 2.3.2.2 漿液性嚢胞腺腫(serous cystadenoma)
  • 2.3.2.3 IPMT(intraductal papillary mucinoustumor)
  • 2.4 Parallel imaging
  • 2.5 CTとMRIの使い分け
  • 3. 肝・胆・膵のマルチスライスCT診断
  • 3.1 はじめに
  • 3.2 肝
  • 3.2.1 マルチスライスCTによる肝腫瘍の診断
  • 3.2.2 マルチスライスCTによる肝のE次元画像診断
  • 3.3 胆道
  • 3.3.1 マルチスライスCTによる胆道系腫瘍の診断
  • 3.3.2 マルチスライスCTによる胆道系の三次元画像診断
  • 3.3.3 マルチスライスCTによるCT cholangiography
  • 3.4 膵
  • 3.4.1 マルチスライスCTによる膵腫瘍の診断
  • 3.4.2 マルチスライスCTによる膵の三次元画像診断
  • 3.5 おわりに
  • 4. 肝・胆・膵のPET診断
  • 4.1 はじめに
  • 4.2 FDG-PETの原理と撮影法
  • 4.2.1 FDG腫瘍集積の機序
  • 4.2.2 PETの原理
  • 4.2.3 FDG-PET撮影の実際
  • 4.2.4 FDG-PET診断の実際
  • 4.3 肝胆膵疾患の臨床PET診断
  • 4.3.1 肝細胞癌のPET診断
  • 4.3.2 転移性肝癌のPET診断
  • 4.3.3 胆道疾患の腫瘍PET診断
  • 4.3.4 膵臓癌のPET診断
  • 4.3.5 膵臓嚢胞性疾患のPET診断
  • 4.4 おわりに
  • 5. 肝・胆・膵の超音波診断
  • 5.1 はじめに
  • 5.2 腹部におけるニューテクノロジー
  • 5.2.1 血流の表示
  • 5.2.2 造影超音波検査
  • 5.2.3 3次元表示
  • 5.2.4 Tissue characterization
  • 5.2.5 超音波検査と内視鏡との融合 : EUS, IDUS
  • 5.2.6 超音波検査と穿刺技術 : Interventional Ultrasonography
  • 5.2.7 超音波検査と手術 : 術中超音波検査
  • 5.2.8 超音波による治療
  • 5.2.9 超音波機器の小型化
  • 5.3 おわりに
  • 第14章 各種製品の臨床評価
  • 1. 分岐鎖アミノ酸製剤の最近の動向-輸液の効果を左右する因子と経口剤における使い分けを中心に-
  • 1.1 はじめに
  • 1.2 BCAA輸液製剤の効果を左右する因子
  • 1.2.1 重症度別のBCAA輸液療法の意識覚醒効果
  • 1.2.2 BCAA輸液療法の有無による完全覚醒までの日数
  • 1.2.3 肝性脳症の予後の差異
  • 1.2.4 完全覚醒ならびに肝性脳症の予後に関与する因子
  • 1.3 経口BCAA療法の実際と問題点
  • 1.3.1 経口BCAA製剤の種類
  • 1.3.2 BCAA製剤の使い分け
  • 1.3.3 服薬コンプライアンスの問題点と対策
  • 2. 新しい腹腔鏡用細径(3mm)トラカール(EZバルーン、 EZポート)の開発
  • 2.1 はじめに
  • 2.2 開発の経緯
  • 2.2.1従来の細径トラカール
  • 2.2.2 腹壁固定性の必要性
  • 2.3 開発の実際
  • 2.3.1 対象
  • 2.3.2 開発における問題点
  • 2.4 本トラカールの特徴
  • 2.4.1 EZバルーンの特徴
  • 2.4.2 EZポートの特徴
  • 2.5 本トラカールを用いた実際の手技
  • 3. 肝細胞癌の腫瘍マーカーについて-PIVKA-IIの有用性に関する考察-
  • 3.1 はじめに
  • 3.2 PIVKA-IIとは
  • 3.3 各種肝疾患におけるPIVKA-IIの濃度分布
  • 3.4 PIVKA-IIの感度、特異度、正診率
  • 3.5 PIVKA-IIとAFPの相補性
  • 3.6 小肝細胞癌におけるPIVKA-II測定の意義
  • 3.7 肝細胞癌の早期診断を目的としたPIVKA-II, AFPの交互測定
  • 3.8 肝細胞癌の異時性多中心性発癌と腫瘍マーカー値
  • 3.9 PIVKA-IIを用いた診断における留意点
  • 3.10 終わりに
  • 4. 注射用ニューキノロン薬シプロキサン注
  • 4.1 はじめに
  • 4.2 開発の経緯
  • 4.3 胆道感染症に対する有用性
  • 4.3.1 抗菌カ
  • 4.3.2 胆汁への移行性
  • 4.3.3 臨床試験成績
  • 4.4 まとめ
  • 技術資料編
  • 1. フルマリン(R)キットの有用性
  • 1 はじめに
  • 2 抗菌作用と作用機序
  • 2.1 抗菌作用
  • 2.2 作用機序
  • 3 フルマリンキットの用法・用量
  • 4 臨床成績
  • 5 フルマリンキットの特徴
  • 6 フルマリンキットの操作方法
  • 7 フルマリンキットの利便性・効率性・保管性
  • 7.1 利便性
  • 7.2 効率性
  • 7.3 保管性
  • 8 まとめ
  • 2. H2受容体拮抗剤ガスター(R)について
  • 1 はじめに
  • 2 製品の特性
  • 2.1 開発の経緯
  • 2.2 薬理学的特徴
  • 2.3 製剤的特徴(主に口腔内崩壊錠について)
  • 3 有効性
  • 3.1 酸分泌抑制効果の特徴
  • 3.2 胃粘膜に対する作用
  • 3.3 各種疾患に対する臨床効果
  • 4 安全性
  • 4.1 副作用
  • 4.2 使用上の注意など
  • 5 おわりに
  • 3. 5-HT3受容体拮抗型制吐剤 : 塩酸ラモセトロンナゼア(R)注射液、OD錠
  • 1 はじめに
  • 2 開発の経緯
  • 3 薬効・薬理
  • 3.1 5-HT3受容体拮抗作用
  • 3.2 抗悪性腫瘍剤誘発嘔吐抑制効果
  • 4 作用機序
  • 5 臨床試験
  • 6 安全性
  • 7 おわりに
  • 4. 制酸・緩下剤「マグラックス(R)錠」
  • 1 はじめに
  • 2 薬理作用
  • 3 用法・用量
  • 4 緩下剤について
  • 5 臨床試験成績
  • 5.1 便秘
  • 5.2 痔疾患術後の排便コントロール
  • 6 副作用
  • 7 製剤の安定性
  • 8 おわりに
  • 5. JOSTENT(R)Selfx
  • 1 はじめに
  • 2 ステントの特長
  • 2.1 柔軟性
  • 2.2 短縮率
  • 2.3 視認性
  • 2.4 ラジアルフォース
  • 2.5 メッシュの通過性
  • 3 デリバリーシステムの特徴
  • 3.1 ステントリリース時の抵抗
  • 3.2 ガイドワイヤーの追従性
  • 3.3 マーカー位置
  • 3.4 アウターチューブ
  • 4 おわりに
  • 企業一覧(技術資料編)
  • 索引
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序章 肝・胆・膵疾患治療の課題と展望

P.7 掲載の参考文献
1) Pepinsky RB, LePage DJ, Gill A et al:Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. J Pharmacol Exp Ther 297:1059-1066, 2001
PubMed
2) Osborn BL, Olsen HS, Nardelli B et al:Pharmacokinetic and phamiacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomogus monkey. J Pharmacol Exp Ther 303:540-548, 2002
 
3) Watson J:Prospects for hepatitis C virus therapeutics:levovirin and viramidine as improved derivatives of ribavirin. Curr Opin Investig Drug 3:680-683, 2002
PubMed
4) McHutchson JG, Patek K:Future therapy of hepatitis C. Hepatology 36 (Suppl 5):S 245-252, 2002
 
5) Kamada Y, Tamura S, Kiso S et al:Angiotensin II stimulates the nuclear translation of Smad2 and induces PAI-1 mRNA in rat hepatic stellate cells. Hepatol Res 25:296-305, 2003
 
6) Yoshiji H, Kuriyama S, Yoshii J et al:Angiotensin H type 1 receptor interaction is a major regulation for liver fibrosis development in rats. Hepatology 34:745-750, 2001
 
7) Terui Y, Saito T, Watanabe H et al:Effect of angiotensin receptor anatagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 36:1022, 2002
 
8) Imai Y, Kawata S, Tamura S et al:Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 129:94-99, 1998
PubMed
9) Yabuuchi I, Imai Y, Kawata S et al:Long-term responders without eraadication of hepatitis C virus after interferon therapy:characterization of clinical profiles and incidence of hepatocellular carcinoma. Liver 20:290-295, 2000
PubMed
10) Nishiguchi S, Kuroki T, Otani S et al:Randomized trial of effect of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346:1051-1055, 1995
 
11) Muto Y et al:Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 334:1561-1567, 1996
PubMed
12) Shiratori Y, Shiina S, Teratani T et al:Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis c viruses. Ann Intern Med 134:299-306, 2003
 
13) Sakon M, Nagano H, Dono K et al:Combined intraarterial 5-fluorouracil and subcutaneous interferon-α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 94:435-442, 2002
 
14) Poneros JM, Teamey GJ, Shiskov M et al:Optical coherence tomography of the biliary tree during ERCP. Gstrointest Endosc 55:84-88, 2002
 
15) Fujita N, Maguchi H, Komatsu Y et al:Endoscopic sphincterotomy and endoscopic papillary balloon dilatation for bile duct stones. Gastrointest Endosc 57:151-155, 2003
PubMed
16) Mallavarapu R, Habib TH, Elton E et al:Resolution of mediastinal pancreatic pseudocysts with transpapillary stent placement. Gastrointest Endosc 53:367-370, 2001
PubMed
17) Okazaki K, Chiba T:Autoimmune related pancreatitis. Gut 51:1-4, 2002
PubMed
18) 自己免疫性膵炎診断基準検討委員会:日本膵臓学会自己免疫性膵炎診断基準2002年. 膵臓 17:585-587, 2002
 
19) Ikeda M, Okada S, TokUuye k et al:A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 86:1551-1554, 2002
PubMed
P.11 掲載の参考文献
1) Traverso LW, Longmire WP Jr:Preservation of the pylorus in pancreaticoduodenectomy. Surg Gynecol Obstet. Jun 146 (6):959-62, 1978
PubMed
2) Banks RE, Dunn MJ, Hochstrasser DF et al:Proteomics:new perspectives, new biomedical opportunities. Lancet 356:1749-1756, 2000
PubMed
3) Srinivas PR, Srivastava S, Hanash S et al:Proteomics in early detection of cancer. Clin. Chem 47:1901-1911, 2001
PubMed
4) Fortner JG:Regional resection of cancer of the pancreas:a new surgical approach. Surgery 73 (2):307-20, 1973
PubMed
5) Yamada T, S Nakamori, Monden M et al:"Outcome of pancreatic cancer patients based on genetic lymph node staging."Int J Oncol 16 (6):1165-71, 2000
PubMed
6) Takemasa I, H Higuchi, Monden M et al:"Construction of preferential cDNA microarray specialized for human colorectal carcinoma:molecular sketch of colorectal cancer"Biochem Biophys Res Commun 285 (5):1244-9, 2001
 
7) Morimoto O, H Nagano Monden M et al:"Diagnosis of intrahepatic metastasis andmulticentric carcinogenesis by microsatellite lossof heterozygosity in patients with multiple andrecurrent hepatocellular carcinomas."JHepatol 39 (2):215-21, 2003
 
8) Sakon M, H Nagano, Monden M et al:"Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches."Cancer 94 (2):435-42, 2002
 
9) Takaoka A, Hayakawa S, Yanai H et al:Integrationof interferon-alpha/beta signalling to P 53 responsesin tumour suppression and antiviral defence. Nature 424 (6948):516-23, 2003
 
10) Mazzaferro V et al:Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. New Engl J Med 334:693-699, 1996
PubMed
11) 池上俊彦, 川崎誠治:肝細胞癌に対する肝移植. 肝蔵 43:266-271, 2002
 
12) Umeshita K, Fujiwara K, Kiyosawa K, Makuuchi M, Satomi S, Sugimachi K, Tanaka K, Monden M:Operative morbidity of living liver donors in Japan. Lancet 362 (9385):687-90, 2003
PubMed

第1章 課題と展望(トピックス)

P.18 掲載の参考文献
1) Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G et al:Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669-672, 2000
PubMed
2) Kay MA, Manno CS, Ragni MV et al:Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 24:257-261, 2000
PubMed
3) Nakatani T, Kuriyama S, Tominaga K et al:Assessment of efficiency and safety of adenovirus mediated gene transfer into normal and damaged murine livers. Gut 47:563-570, 2000
PubMed
4) Tsujinoue H, Kuriyama S, Tominaga K et al:Intravenous readministration of an adenoviral vector performed long after the initial administration failed to induce re-expression of the original transgene in rats. Int J Oncol 18:575-580, 2001
PubMed
5) Kuriyama S, Tominaga K, Kikukawa M et al:Transient cyclophosphamide treatment before intraportal readministration of an adenoviral vector can induce re-expression of the original gene construct in rat liver. Gene Ther 6:749-757, 1999
PubMed
6) Kuriyama S, Tominaga K, Mitoro A et al:Immunomodulation with FK506 around the time of intravenous re-administration of an adenoviral vector facilitates gene transfer into primed rat liver. Int J Cancer 85:839-844, 2000
 
7) Cao G, Kuriyama S, Du P et al:Complete regression of established murine hepatocellular carcinoma by in vivo tumor necrosis factor α gene transfer. Gastroenterology 112:501-510, 1997
 
8) Kuriyama S, Nakatani T, Masui K et al:Evaluation of prodrugs ability to induce effective ablation of cells transduced with viral thymidine kinase gene. Anticancer Res 16:2623-2628, 1996
PubMed
9) Kuriyama S, Nakatani T, Masui K et al:Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma. Hepatology 22:1838-1846, 1995
PubMed
10) Kuriyama S, Masui K, Sakamoto T et al:Bystander effect caused by cytosine deaminase gene and 5-fluorocytosine in vitro is substantially mediated by generated 5-fluorouracil. Anticancer Res 18:3399-3406, 1998
PubMed
11) Kuriyama S, Sakamoto T, Masui K et al:Tissue-specific expression of HSV-tk gene can induce efficient antitumor effect and protective immunity to wild-type hepatocellular carcinoma. Int J Cancer 71:470-475, 1997
PubMed
12) Kuriyama S, Kikukawa M, Masui K et al:Cancer gene therapy with HSV-tk/GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumor cells in Vivo. Int J Cancer 83:374-380, 1999
 
13) Kuriyama S, Kikukawa M, Masui K et al:Cytosine deaminase/5-fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude mice. Int J Cancer 81:592-597, 1999
 
14) Kuriyama S, Yoshikawa M, Ishizaka S et al:A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector. Cell Struct Funct 16:503-510 , 1991
 
15) Huber BE, Richards CA, Krenitsky TA:Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma:an innovative approach for cancer therapy. Proc Natl Acad Sci USA 88:8039-8043, 1991
PubMed
16) Kuriyama S, Tsujinoue H, Nakatani T et al:Gene therapy for hepatocellular carcinoma:recent advancements and problems to overcome. Tsuji T, Higashi T, Zeniya M, Meyer zum Buschenfelde K-H eds:Molecular Biology and Immunology in Hepatology. Elsevier, Amsterdam, p 147-168, 2002
 
17) Yoshiji H, Kuriyama S, Yoshii J et al:Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology 28:1489-1496, 1998
PubMed
18) Yoshiji H, Kuriyama S, Hicklin DJ et al:KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology 30:1179-1186, 1999
PubMed
19) Yoshiji H, Kuriyama S, Ways DK et al:Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development. and angiogenesis. Cancer Res 59:4413-4418, 1999
PubMed
20) Yoshiji H, Kuriyama S, Yoshii J et al:Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinonla. Hepatology 35:834-842, 2002
PubMed
21) Habib NA, Mitry RR, Sadri R:p 53 and gene therapy for hepatocellular carcinoma. Adv Exp Med Biol 451:499-504, 1998
 
22) Habib N, Salama H, Abd El Latif Abu Median A et al:Clinical trial of ElB-deleted adenovirus (dl 1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther 9:254-259, 2002
 
23) Mulvihill S, Warren R, Venook A et al:Safety and feasibility of inj ection with an EIB-55kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas:a phase I trial. Gene Ther 8:308-315, 2001
 
24) Reid T, Galanis E, Abbruzzese J et al:Intra-arterial administration of a replication-selective adenovirus (dl 1520) in patients with colorectal carcinoma metastatic to the liver:a phase I trial. Gene Ther 8:1618-1626, 2001
 
P.26 掲載の参考文献
1) Evans MJ, Kaufman MH:Establishment in culture of pluripotential cells from mouse embryos. Nature 292:154-156, 1981
PubMed
2) Thomson JA, Itskovitz-Eldor J, Shapiro SS et al:26 Embryonic stem cell lines derived from human blastocysts. Science 282:1145-1147, 1998
 
3) Bain G, Kitchens D, Yao M et al:Embryonic stem cells express neuronal properties in vitro. Dev Biol 168:342-357, 1995
PubMed
4) Brustle O, Jones KN, Learish RD et al:Embryonic stem cell-derived glial precursors:a source of myelinating transplants. Science 285:754-756, 1999
PubMed
5) Hirashima M, Kataoka H, Nishikawa S et al:Maturation of embryonic stem cells into endothelial cells in an in vitro model of vasculogenesis. Blood 93:1253-1263, 1999
 
6) Klug MG, Soonpaa MH, Koh GY et al:Genetically selected cardiomyocytes from differentiating embronic stem cells form stable intracardiac grafts. J Clin Invest 98:216-224, 1996
PubMed
7) Muthuchamy M, Pajak L, Howles P et al:Developmental analysis of tropomyosin gene expression in embryonic stem cells and mouse embryos. Mol Cell Biol 13:3311-23, 1993
PubMed
8) Nishikawa SI, Nishikawa S, Hirashima M et al:Progressive lineage analysis by cell sorting and culture identifies FI. Kl+VE-cadherin+cells at a diverging point of endothelial and hemopoietic lineages. Development 125:1747-1757, 1998
 
9) Dani C, Smith AG, Dessolin S et al:Differentiation of embryonic stem cells into adipocytes in vitro. J Cell Sci 110:1279-1285, 1997
PubMed
10) Yamane T, Kunisada T, Yamazaki H et al:Development of osteoclasts from embryonic stem cells through a pathway that is c-fms but not c-kit dependent. Blood 90:3516-3523, 1997
 
11) Lumelsky N, Blondel O, Laeng P et al:Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science 292:1389-1394, 2001
PubMed
12) Chinzei R, Tanaka Y, Shimizu-Saito K et al:Embryoid-body cells derived from a mouse embryonic stem cell line show differentiation into functional hepatocytes. Hepatology 36:22-29, 2002
PubMed
13) Rajagopal J, Anderson WJ, Kume S et al:Insulin staining of ES cell progeny from insulin uptake. Science 299:363, 2003
PubMed
14) Hamazaki T, Iiboshi Y, Oka M et al:Hepatic maturation in differentiating embryonic stem cells in vitro. FEBS Lett 497:15-19, 2001
PubMed
15) Jung J, Zheng M, Goldfarb M et al:Initiation of mammalian liver development from endoderm by fibroblast growth factors. Science 284:1998-2003, 1999
PubMed
16) Schuldiner M, Yanuka O, Itskovitz-Eldor J et al:Effects of eight growth factors on the differentiation of cells derived from human embryonic stem cells. Proc Natl Acad Sci USA 97:11307-11312, 2000
PubMed
17) Rambhatla L, Chiu CP, Kundu P et al:Generation of hepatocyte-like cells from human embryonic stem cells. Cell Transplant 12:1-11, 2003
PubMed
18) Groth CG, Arborgh B, Bjorken C et al:Correction of hyperbilirubinemia in the glucuronyltransferase-deficient rat by intraportal hepatocyte trans-plantation. Transplant Proc 9:313-316, 1977
 
19) Strom SC, Fisher RA, Thompson MT et al:Hepatocyte transplantation as a bridge to orthotopic liver transplantation in terminal liver failure. Transplantation 63:559-569, 1997
PubMed
20) Hubner K, Fuhrmann G, Christenson LK et al:Derivation of oocytes from mouse embryonic stem cells. Science 300:1251-1256, 2003
PubMed
21) Okamoto R, Yajima T, Yamazaki M et al:Damaged epithelia regenerated by bone marrow-derived cells in the human gastrointestinal tract. Nat Med 8:1011-1017, 2002
PubMed
22) Kakinuma S, Tanaka Y, Chinzei R et al:Human umbilical cord blood cells as a source of transplantable hepatic progenitor cells. Stem Cells 21:217-227, 2003
PubMed
P.34 掲載の参考文献
1) Horowitz MM, Gale RP, Sondel PM et al:Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555-562, 1990
PubMed
2) Kolb HJ, Mittermuller J, Clemm C et al:Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462-2465, 1990
PubMed
3) Stewart FM, Crittenden RB, Lowry PA et al:Pearson-White S, Quesenberry PJ. Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice. Blood 81 (10):2566-71, 1993
PubMed
4) Tsaroucha AK, Ricordi C, Noto TA et al:Donor peripheral blood stem cell infusions in recipients of living-related liver allografts. Transplantation 64 (2):362-4, 1997
PubMed
5) Storb R, Yu C, Wagner JL et al:Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immuno-suppression after marrow transplantation. Blood 89 (8):3048-54, 1997
 
6) Sandmaier BM, McSweeney P, Yu C et al:Non-myeloablative transplants:preclinical and clinical results. Semin Oncol 27 (2 Suppl. 5):78-81, 2000
 
7) Lazarus HM, Vogelsang GB, Rowe JM et al:Prevention and treatment of acute graft-versus-host disease:the old and the new. A report from the Eastern Cooperative Oncology Group (ECOG). Bone Marrow Transplant 27:437-444, 2001
 
8) Slavin S, Nagler A, Naparstek E et al:Nonmyelo-ablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756-763, 1998
 
9) Childs R, Chernoff A, Contentin N et al:Regression of metastatic renal-cell carcinoma after non-myeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750-758, 2000
 
10) Nakai K, Mineishi S, Saito T et al:Comparison of immune recovery after allogeneic PBSCT between reduced-intensity transplant (RIST) with or without antithymocyte globulin (ATG) and conventional transplant (CT) , Blood 98:409a, 2001
PubMed
11) Morishima Y, Morishita Y, Tanimoto M et al:Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings;possible role of genetic homogeneity. The Nagoya Bone Marrow Trans-plantation Group. Blood 74:2252-2256, 1989
 
12) Nakai K, Kanda Y, Mineishi S et al:Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin. Bone Marrow Transplant 29 (3):237-41, 2002
PubMed
13) Kanda Y, Mineishi S, Nakai K et al:Frequent detection of rising cytomegalovirus antigenemia after allogeneic stem cell transplantation following a regimen containing antithymocyte globulin. Blood 97 (11):3676-7, 2001
PubMed
14) Junghanss C, Marr KA:Infectious risks and outcomes after stem cell transplantation:are nonmyeloablative transplants changing the picture?Curr Opin lnfect Dis 15 (4):347-53, 2002
PubMed
15) Motzer RJ, Bander NH, Nanus DM:Renal-cell carcinoma. New England Journal of Medicine 335 (12):865-75, 1996
PubMed
16) Kankuri M, Pelliniemi TT, Pyrhonen S et al:Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma:a phase H study. Cancer 92 (4):761-7, 2001
 
17) Childs R, Chernoff A, Contentin N et al:Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. New England Journal of Medicine 343 (11):750-8, 2000
PubMed
18) Therasse P, Arbuck SG, Eisenhauer EA et al:New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
 
19) Bregni M, Dodero A, Peccatori J et al:Nonmyelo-ablative conditioning followed by hematopoietic cell allografting and donor lyrnphocte infusions for patients with metastatic renal and breast cancer. Blood 99:4234-4236, 2002
 
20) Teshima T, Ordemann R, Reddy P et al:Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nature Medicine 8 (6):575-81, 2002
 
P.39 掲載の参考文献
1) Banchereau J, Steinman M:Dendritic cells and the control of immunity. Nature 392:245-252, 1998
 
2) Steinman RM, Hawiger D, Liu K et al:Dendritic cell function in vivo during steady state:a role inperipharal tolerance. Ann NY Acad Sci 987:15-25, 2003
 
3) 1haba K, Inaba M, Romani R et al:Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophagecolony stimulation factor. J Exp Med 176:1693-1702, 1992
 
4) Sallusto F, Lanzavecchia A:Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med 179:1109-1118, 1994
 
5) Rosenburg SA:Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18:175-182, 1997
 
6) Van der Bruggen P, Traversari C, Chmez P et al:A gene encoding an antigen recognized by cytotoxic T lymphocytes on human melanoma. Science 254:1643-1647, 1991
 
7) Steinman RM, Dhodapkar M:Active immunization against cancer with dendritic cells:the near future. Int J Cancer 94:459-473, 2001
PubMed
8) Jefford M, Maraskovsky E, Cebon J et al:The use of dendritic cells in cancer therapy. Lancet Oncol 2:343-353, 2001
PubMed
9) Hackstein H, Morelli AE, Thomson AW:Designer dendritic cells for tolerance induction:guided not misguided missiles. Trends Immunol 22:437-442, 2001
 
10) Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP:Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3:483-490, 1997
PubMed
11) Lopez JA, Hart DN:Current issues in dendritic cell cancer immunotherapy. Curr Opin Mol Ther 4:54-63, 2002
PubMed
12) Cabrera T, Lopez-Nevot MA, Gaforio JJ et al:Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother 52:1-9, 2003
PubMed
13) Gong J, Chen D, Kashiwaba M et al:Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3:558-561, 1997
PubMed
14) Homma S, Toda G, Gong J et al:Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J Gastroenterol 36:764-771, 2001
PubMed
15) Tatsumi T, Takehara T, Kanto T et al:Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccine in mouse hepatocellular carcinoma. Cancer Res 61:7563-7567, 2001
PubMed
16) Lee WC, Wang HC, Jeng LB et al:Effective treatment of small murine hepatocellular carcinoma by dendritic cells. Hepatology 34:896-905, 2001
PubMed
17) Rosenberg SA, White DE:Vitiligo in patients with melanoma:normal tissue antigens can be targets for cancer immunotherapy. J immunother Emphasis Tumor Immunol 19:81-84, 1996
 
18) Diefenbach A, Raulet DH:The innate immune responses to tumors and its role in the induction of T-cell immunity. Immunol Rev 188:9-21, 2002
PubMed
P.44 掲載の参考文献
1) 日本肝癌研究会:第 15 回全国原発性肝癌追跡調査報告. 進行印刷川版, 京都, 2002
 
2) Llovet JM, Bustamante J, Castells A et al:Natural history of untreated nonsurgical hepatocellular carcinoma:rationale for the design and evaluation of therapeutic trials. Hepatology 29:62-67, 1999
PubMed
3) Urabe T, Kaneko S, Matsushita E et al:Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology 55:39-47, 1998
PubMed
4) Sakon M, Nagano H, Dono K et al:Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 94:435-442, 2002
PubMed
5) Lai CL, Lau JY, Wu PC et al:Recombinant interferon-alpha in inoperable hepatocellular carcinoma:a randomized controlled trial. Hepatology 17:389-394, 1993
PubMed
6) 左近賢人, 永野浩昭, 門田守人:インターフェロン+5-FUによる治療. 肝臓 44:273-278, 2003
 
7) Miyamoto A, Umeshita K, Sakon M et al:Advanced hepatocellular carcinoma with distant metastases, successfully treated by a combination therapy of alpha-interferon and oral tegafur/uracil. J Gastroenterol Hepatol 15:1447-1451, 2000
PubMed
8) Kaneko S, Urabe T, Kobayashi K:Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. Oncology 62 Suppl 1:69-73, 2002
 
9) Chung YH, Song IH, Song BC et al:Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 88:1986-1991, 2000
 
10) 永野浩昭, 左近賢人, 門田守人:肝細胞癌 (Hepatocellular Carcinoma) の集学的治療. 癌の臨床47:1115-1120, 2001
 
11) 小尾俊太郎, 椎名秀-郎, 寺谷卓為ほか:門脈浸潤 (VP3, 4) を伴う進行肝細胞癌に対するIFN併用5FU動注化学療法の有用性. 第 39 回日本肝癌研究会抄録集:pp 115, 2003
 
12) 卜部 健, 金子周.-, 小林健-二門脈腫瘍栓合併肝細胞癌に対するインターフェロン併用化学療法を中心とした集学的治療による治療成績. 肝臓 38 suppl (3):44, 1997
 
13) Ando E, Tanaka M, Yamashita F et al:Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Analysis of 48 cases. Cancer 95:588-595, 2002
PubMed
14) Itamoto T, Nakahara H, Tashiro H et al:Hepatic44 arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. JSurg Oncol 80:143-148, 2002
PubMed
15) Yamasaki T, Kurokawa F, Shirahashi H et al:Novel arterial infusion chemotherapy using cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma. Hepatol Res 23:7-17, 2002
PubMed
16) 永野浩昭, 左近賢人, 門爪守人:肝細胞癌に対する新治療法の開発研究. 日本臨M< 60:2237-2244, 2002
 
17) 山下竜也, 柿木嘉.:r. 太, 鍛冶恭介ほか:進行肝細胞癌に対する Cisplatin, インターフェロン併用動注化学療法-Randomized control study-. 第39回日本肝癌研究会抄録集:pp 115, 2003
 
P.51 掲載の参考文献
1) Matsumura Y, Maeda H:Anew concept for macromolecular therapeutics in cancer chemotherapy:Mechanism of tumoritopic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387-6392, 1986
 
2) Maeda H, Matsumura Y:Tumoritropic and lympho-tropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 6;193-210, 1989
 
3) Muggia FM:Doxorubicin-polymer conjugates:Further demonstration of the concept of enhanced permeability and retention. Clin Cancer Res 5:7-8, 1999
PubMed
4) Matsumura Y, Kimura M, Yamamoto T et al:Involvement of the kinin-generating cascade and enhanced vascular permeability in tumor tissue. Jpn. 」. Cancer Res 79:1327-1334, 1988
 
5) Matsumura Y, Maruo K, Kimura M et al:Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn J Cancer Res 82:732-741, 1991
PubMed
6) Dvorak HF, Nagy JA, Dvorak JT et al:Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am j Pathol 133:95-109, 1988
PubMed
7) Dvorak HF:Tumors:wounds that do not heal:similarities between tumor stroma generation and wound healing 315:1650-1659, 1986
 
8) Gabizon A, Chemla M, Tzemach D et al:Liposome longevity and stability in circulation:effects on the in vivo delivery to tumor and therapeutic efficacy of encapsulated anthracyclines. J Drug Targeting 3:391-398, 1996
PubMed
9) Sakakibara T, Chen FA, Kida H et al:Doxorubicin encapsulated in sterically stabilized liposomes in superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts. Cancer Res 56:3743-3746, 1996
PubMed
10) Unezaki S, Maruyama K, Hosoda JI et al:Direct measurement of the extravasation of poly-ehyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy. Int J Pharmaceut 144:11-17, 1996
 
11) Lasic D:Doxorubicin in sterically stabilized liposomes. Nature:561-562, 1996
PubMed
12) Harrington KJ, Mohammadtaghi S, Uster PS et al:Effective targeting of solid tumors in patients with locally adcanced cancers by radiolabeled pegylated hposomes. Clin Cancer Res 7:243-254, 2001
 
13) Koukourakis MI, Koukouraki S, Giatramanolaki A et al:Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol 17:3512-3521, 1999
PubMed
14) Northfelt DW, Martin FJ, Working P:Doxorubicin encapsulated in liposomes containing surface-bound polyet. hylene glycol:pharmacokinetics. Tumor localization, and safety in patients with AIDS-related Kaposiis sarcoma. J Clin Pharmacol 36:55-63, 1996
 
15) Safra T, Muggia F, Jeffers S et al:Pegylated liposomal doxorubicin (doxil):reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2:. Annals Oncol 11:1029-1033, 2000
PubMed
16) Northfelt D, Dezube B, Thommes J et al:Efficacy of pegylated-liposomal doxorubicin in the treatment of AID-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 15:653-659, 1997
 
17) Harrison M, Tomlinson D, Stewart S:Liposomal-entarapped doxorubicin:an active agent in AIDS-related Kaposi Is sarcoma. J Clin Oncol 13:914-920, 1995
PubMed
18) Cheung TW, Remick SC, Azarnia N et al:AIDS-related Kaposi's sarcoma:a phase n study of liposomal doxorubicin. Clin Cancer Res 5:3432-3437, 1999
 
19) Tulpule A, Yung RC, Wemz J et al:Phase H trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi:s sarcoma. J CIin Oncol 16:3369-3374, 1998
 
20) Ellerhorst J, Bedikian A, Ring S et al:Phase II trial of doxil for patients with metastatic melanoma refractory to frontile therapy. Oncol Reports 6:1097-1099, 1999
PubMed
21) Tsiara S, Kapasali E, Christou L et al:Administration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicine and dexamethasone to multiple myeloma patients:preliminary data. Eur J Haematol 65:118-122, 2000
 
22) Toma S, Tucci A, Villani G et al:Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas:a phase H study of the Italian Sarcoma Group (ISG). Anticancer Res 20:485-491, 2000
 
23) Judson I, Radford JA, Harris M et al:Randomized phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma:astudy by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J cancer 37:870-877, 2001
PubMed
24) Samantas E, Kalofonos H, Linardou H et al:Phase II study of pegylated liposomal doxorubicin:Inactive in recurrent small-cell lung cancer with sterically stabilized liposomal doxorubicin:Inactive in recurrent small-cell lung cancer. Ann Oncol 11:1395-1397, 2000
 
25) Ranson M, Carmicheal J, OIByrne K et al:Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin:results of a multicenter phase II trial. J Clin Oncol 16:811-812, 1998
 
26) Shapairo C, Ervin T, Welles L et al:Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyt. e colony-stimulating factor in metastatic breast cancer. J Clin Oncol 17:1435-1441, 1999
 
27) Valero V, Buzdar AU, Theriault RL et al:Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol 17:1425-1434, 1999
PubMed
28) Treat J, Greenspan A, Forst D et al:Antitumor activity of liposome-encapsulated doxorubicin in advanced beast cancer:phase II study. J Natl cancer Inst 82:1706-1710, 1990
 
29) Markeman M, Kennedy A, Webster K et al:Phase II trial of liposomal doxorubicin in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 78:369-372, 2000
 
30) Alan NG, Granai CO, Rose PG et al:Phase II study of liposomal doxorubicin in platinum and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18:3093-3100, 2000
 
31) Muggia FM, Hainsworth JD, Jeffers S et al:Phase II study of liposomal doxorubicin in refractory ovarian cancer:antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987-993, 1997
PubMed
32) Batist G, Ramakrishnan G, Rao CS et al:Reduced cardiotoxicity and preserved antitumor efficacy of liposome encapsulated doxorubicin and cyclophospahmide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19:1444-1454, 2001
 
33) Northfelt DW, Dezube BJ, Thommes JA et al:Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma:results of a randomized phase III clinical trial. J Clin Oncol 16:2445-2451, 1998
PubMed
34) Stewart S, Jablonowski H, Goebel F et al:Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 16:683-691, 1998
 
35) Gill PS, Wernz J, Scadden DT et al:Randomized phase m trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi:s sarcoma. J Clin Oncol 14:2353-2364, 1996
 
36) Gordon AN, Fleagle JT, Guthrie D et al:Recurrent epithelial ovarian carcinoma:a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312-3322, 2001
 
37) Ryan C, Fleming G, Janisch L et al:A phase I study of liposomal doxorubicin (DOXIL) with topotecan. Arn J Clin Oncol 23:297-300, 2000
 
38) Burstein HJ, Ramirez MJ, Petros WP et al:Phase I study of doxil and vinorelbine in metastatic breast cancer. Ann Oncol 10:1113-1116, 1999
PubMed
39) Simon R, Freidlin B, Rubinstein L et al:Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147, 1997
PubMed
40) Yokoyama M, Inoue S, Kataoka K et al:Preparation of adriamycin-conjugated poly (ethylene glycol)-poly (aspartic acid) block copolymer. Makromol Chem Rapid Commun 8:431-435, 1987
 
41) Yokoyama M, Miyauchi M, Yamada N et al:Characterization and anticancer activity of the micelle-forming Polymeric anticancer drug adriamycin-conjugated poly (ethylene glycol)-poly (aspartic acid) block copolymer. Cancer Res 50:1693-1700, 1990
PubMed
42) Mizumura Y, Matsumura Y, Hamaguchi T et al:Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity. Jpn J Cancer Res 92; 328-336, 2001
PubMed
43) Matsumura Y, Yokoyama M, Kataoka K et al:Reduction of the side effects of an antitumor agent, KRN5500, by incorporation of the drug into polymeric micelles. Jpn J Cancer Res 90:122-128, 1999
PubMed
44) Kataoka K, Togawa A, Harada A et al:Spontaneous formation of polyion complex micelles with narrow distribution from antisense oligonucleotide and cationic block copolymer in physiological saline. Macromolocules 29:8556-8557, 1996
 
45) Takakura Y, Hashida M:Macromolecular carrier systems for targeted drug delivery:pharma-cokinetic considerations on biodistribution. Pharm Res 13:820-831, 1996
 
46) Hashida M, Mahato R, Kawabata K et al:Pharmacokinetics and targeted delivery of proteins and genes. J Controlled Release 41:91-97, 1996
 
P.57 掲載の参考文献
1) Ingold JA, Reed GB, Kaplan HS et al:Radiation hepatitis. Am J Roentgenol 93:200-208, 1965
 
2) Reed JGB, Cox JAD:The human liver after radiation injury:A form of veno-occlusive disease. Am J Pathol 48:597-611, 1966
 
3) Rewin K, Millis RR:Human radiation hepatitis. Arch Pathol 96:21-26, 1973
 
4) Ohara K, Okumura T, Akisada M et al:Irradiation synchronized with respiration gate. Int J Radiat Oncol Biol Phys 17:853-857, 1989
PubMed
5) Tsujii H, Tsuji H, Inada T et al:Clinical results of fractionated proton therapy. Int J Radiat Oncol Biol Phys 25:49-60, 1992
 
6) Matsuzaki Y, Osuga T, Saito Y et al:Anew, effective, and safe therapeutic option using Proton irradiation for hepatocellular carcinoma. Gastroenterol 106:1032-1041, 1994
 
7) http://www.pmrc.tsukuba.ac.jp/
 
8) Slater JM, Archambeau JO, Miller DW et al:The proton treatment center at Loma Linda University Medical Center:Rationale and description of its development. Int J Radiat Oncol Biol Phys 22:383-389, 1991
 
9) (Personal communication)
 
10) 荻野 尚:国立がんセンターにおける陽子線治療の計画. Biotherapy 13:266-268, 1999
Medical*Online
11) (Unpublished data)
Medical*Online
12) 加藤博敏:肝細胞癌に対する重イオン線治療. 医学のあゆみ 196:799-800, 2001
Medical*Online

第2章 肝疾患の分子生物学

P.64 掲載の参考文献
1) Takeo S, Arai H, Kusano N et al:Examination of oncogene amplification by genomic DNA microarray in hepatocellular carcinomas:comparison with comparative genomic hybridization analysis. Cancer Genet Cytogenet 130:127-132, 2001
PubMed
2) Yamashita T, Hashimoto S, Kaneko S et al:Comprehensive gene expression profile of a normal human liver. Biochem Biophys Res Commun 269:110-6, 2000
PubMed
3) Yamashita T, Kaneko S, Hashimoto S et al:Serial analysis of gene expression in chronic hepatitis C and hepatocellular carcinoma. Biochem Biophys Res Commun 282:647-54, 2001
PubMed
4) Honda M, Kaneko S, Kawai H et al:Differential gene expression between chronic hepatitis B and Chepatic lesion. Gastroenterology 120:955-66, 2001
PubMed
5) Shirota Y, Kaneko S, Honda M et al:Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays. Hepatology 33:832-40, 2001
PubMed
6) 0kabe H, Satoh S, Kato T et al:Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray:identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 61:2129-37, 2001
 
7) Delpuech O, Trabut JB, Carnot F et al:Identification, using cDNA macroarray analysis, of distinct gene expression profiles associated with pathological and virological features of hepatocellular carcinoma. Oncogene 21:2926-37, 2002
PubMed
8) Iizuka N, Oka M, Yamada-Okabe H et al:Comparison of gene expression profiles between hepatitis B virus-and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res 62:3939-44, 2002
PubMed
9) Terasaki, S, Kaneko, S, Kobayashi K et al:Histological features predicting malignant transformation of nonmalignant hepatocellular nodules:a prospective study. Gastroenterology 115:1216-1222, 1998
PubMed
P.68 掲載の参考文献
1) 稲葉カヨ, 瀧川雅浩:樹状細胞, 南江堂, 東京, 2000
 
2) 茄原順,:ケモカインと疾患, 医薬ジャーナル社, 大阪, 2000
 
3) Matsuno K, Ezaki T:Dendritic cell dynamics in the liver and hepatic lymph. Int Rev Cytol 197:83-136, 2000
PubMed
4) Yoneyama H, Matsuno K, Zhang Y ct al:Regulation by chemokines of circulating dendritic cell precursors, and the formation of portal tract-associated lymphoid tissues, in a granulomatous liver disease. J Exp Med 193:35-49, 2001
 
5) Demetris AJ, Sever C, Kakizoe S et al:S-100 protein positive dendritic cells in primary biliary cirrhosis and other chronic inflammatory liver diseases. Am J Pathol 134:741-747, 1989
PubMed
6) Ballardini G, Fallani M, Bianchi FB et al:Antigen presenting cells in liver biopsies from patients with primary biliary cirrhosis. Autoimmunity 3:135-144, 1989
PubMed
7) Tanimoto K, Akbar SM, Michitaka K et al:Immunohistochemical localization of antigen presenting cells in liver from patients with primary biliary cirrhosis;highly restricted distribution of CD83-positive activated dendritic cells. Pathol Res Pract 195:157-162, 1999
PubMed
8) Yamada G, Hyodo I, Tobe K et al:Ultrastructural immunocytochemical analysis of lymphocytes infiltrating bile duct epithelia in primary biliary cirrhosis. Hepatology 6:385-391, 1986
PubMed
9) Yasoshima M, Nakanuma Y, Tsuneyama K et al:Immunohistochenlical analysis of adhesion molecules in the micro-environment of portal tracts in the relation to aberrant expression of PDC-E2 and HLA-DR on the bile ducts in primary biliary cirrhosis. J Pathol l 75:319-325, 1995
 
10) Simoda S, Van de Water J, Ansari A et al:Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest 102:1831-1840, 1998
 
11) Kita H, Matsumura S, He XS et al:Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest 109:1231-1240, 2002
PubMed
12) Kita H, Lian ZX, Van de Water J et al:Identification of HLA-A2-restricted CD8 cytotoxic T cell responses in primary biliary cirrhosis:T cell activation is augmented by immune complexes cross-presented by dendritic cells. J Exp Med 195:113-123, 2002
PubMed
13) Morland MC, Fear J, McNab G et al:Promotion of leukocyte transendothelial cell migration by chemokine derived from human biliary epithelial cells in vitro. Proc Assoc Am Physicians lO9:372-382, 1997
 
14) Marra F, DeFranco R, Grappone C et al:Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis:correlation with monocyte infiltration. Am J Pathol 152:423-430, 1998
PubMed
15) Tsuneyama K, Harada K, Yasoshima M et al:Monocyte chemotactic protein-1,-2, and-3 are distinctively expressed in portal tracts and granulomata in primary biliary cirrhosis:implications for pathogenesis. J Pathol 193:102-109, 2001
PubMed
16) Murai M, Yoneyama H, Harada A et al:Active participation of CCR5-CD8:T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J Clin Invest 104:49-57, 1999
PubMed
17) Terada R, Yamamoto K, Hakoda T et al:Stromal cell-derived factor-1 from biliary epithelial cells recruits CXCR4-positive cells:implications for inflammatory liver diseases. Lab Invest 83:665-672, 2003
PubMed
P.73 掲載の参考文献
1) Orito E, Mizokami M, Ina Y et al:Host-independent evolution and a genetic classification of the hepadnavirus family based on nucleotide sequences. Proc Natl Acad Sci USA 86:7059-62, 1989
 
2) Arauz-Ruiz P, Norder H, Robertson BH et al:Genotype H:a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 83:2059-73, 2002
 
3) Sugauchi F, Orito E, Ichida T et al:Hepatitis BVirus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol 76:5985-92, 2002
 
4) Orito E, Mizokami M, Sakugawa H et al:A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 33:218-23, 2001
 
5) Orito E, Ichida T, Sakugawa H et al:Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 34:590-4, 2001
PubMed
6) Mizokami M, Nakano T, Orito E et al:Hepatitis B virus genotype assignment using restriction fragment length polymolphism patterns. FEBS Lett 450:66-71, 1999
PubMed
7) Usuda S, Okamoto H, Iwanari H et al:Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS 2-region product. J Virol Methods 80:97-112, 1999
 
8) Kao JH, Chen PJ, Lai MY et al:Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118:554-9, 2000
PubMed
9) Sugauchi F, Orito E, Ichida T et al:Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 124:925-32, 2003
PubMed
10) Kao JH, Chen PJ, Lai MY et al:Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 124:327-34, 2003
PubMed
P.77 掲載の参考文献
1) Moriya K, Shintani Y, Fujie H et al:Hepatitis C virus core protein induces hepatocellular carcinoma in transgenic mice. Nature Med 4:1065-1068, 1998
PubMed
2) Lerat H, Honda M, Beard MR et al:Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 122:352-365, 2002
PubMed
3) Koike K, Moriya K, Yotsuyanagi H et al:Sialadenitis resembling Sjogren's syndrome in mice transgenic for hepatitis C virus envelope genes. Proc Natl Acad Sci USA 94:233-236, 1997
 
4) Gale M Jr, Blakely CM, Kwieciszewski B et al:Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein:molecular mechanisms of kinase regulation. Mol Cell Biol 18:5208-5218, 1998
PubMed
5) Enomoto N, Sakuma 1, Asahina Y et al:Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus lb infection. N Engl J Med 334:77-81, 1996
 
6) Rubbia-Brandt L, Quadri R, Abid K et al:Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 33:106-115, 2000
PubMed
7) Nakano I, Fukuda Y, Katano Y et al:Interferon responsiveness in patients infected with hepatitis C virus 1b differs depending on viral subtype. Gut 9:263-267, 2001
 
8) Horiike N, Michitaka K, Masumoto T, Okura I, Akbar SM, Onji M:Relationship between the effect of interferon therapy and the change of hepatitis C virus non-structural 5B gene. J Gastroenterol Hepatol 14:345-351, 1999
 
9) Kuzushita N, Hayashi N, Kanto T et al:Involvement of transporter associated with antigen processing 2 (TAP2) gene polymorphisms in hepatitis C virus infection. Gastroenterology 116:1149-1154, 1999
PubMed
10) Yee LJ, Tang J, Gibson AW et al:Interleukin 10 polymoiphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 33:708-712, 2001
PubMed
11) Powell EE, Edwards-Smith CJ, Hay JL et al:Host genetic factors influence disease progression in chronic hepatitis C Hepatology 31:828-833, 2000
PubMed
12) Wang Y, Kato N, Hoshida Y et al:Interleukin-1beta gene polymorphisms associated with hepato-cellular carcinoma in hepatitis C virus infection. Hepatology 37:65-71, 2003
 

第3章 再生医学

P.81 掲載の参考文献
1) Barrandon Y, Green H:Three clonal types of keratinocytes with different capacities for multiplication. Proc Natl Acad Sci USA 84:2302-2306, 1987
 
2) Sato H et al:Pleiotrophin as a Swiss 3T3 cell-derived potent mitogen for adult rat hepatocytes. Exp Cell Res 246:152-164, 1999
PubMed
3) Tateno C, Yoshizato K:Growth and differentiation in culture of clonogenic hepatocytes that express both phenotypes of hepatocytes and biliary epithelial cells. Am J Pathol 149:1593-1605, 1996
PubMed
4) Tateno C et al:Heterogeneity of growth potential of adult rat hepatocytes in vitro. Hepatology 31:65-74, 2000
PubMed
5) Sigal SH et al:Evidence for a terminal differentiation process in the rat liver. Differentiation 59:35-42, 1995
PubMed
6) Fausto N:Hepatocyte differentiation and liver progenitor cells. Curr Opin Cell Biol 2:1036-1042, 1990
PubMed
7) Katayama S et al:Size-dependent in vivo growth potential of adult rat hepatocytes. Am J Pathol 15:97-105, 2001
 
8) Hino H et al:Along-term culture of human hepatocytes which show a high growth potential and express their differentiated phenotypes. Biochem Biophys Res Commun 256:184-191, 1999
 
9) 厚生労働省, 平成14年人U動態統計年報, 2003
 
10) Strom SC et al:Hepatocyte transplantation as a bridge to orthotopic liver transplantation in terminal liver failure. Transplantation 63:559-569, 1997
PubMed
11) Grossman M et al:Successful ex vivo gene therapy directed to liver in a patient with familiar hypercholesterolaemia. Nat Genet 6:335-341, 1994
 
12) Grossman M et al:A pilot study of ex vivo gene therapy for homozygous familial hypercholeserolaemia. Nat Med 1:1148-1154, 1995
 
13) Habibullah CM et al:Human fetal hepatocyte transplantation in patients with fulminant hepatic failure. Transplantation 58:951-952, 1994
PubMed
14) Bilir BM et al:Hepatocyte transplantation in acute liver failure. Liver Transp 16:32-40, 2000
 
15) Soriano HE et al:Hepatocellularn transplantation (HCT) in children with fulminant liver failure (FLF). Hepatology 26:443, 1997
 
16) Strom SC, Chowdhury JR, Fox IJ:Hepatocyte transplantation for the treatment of human disease. Semin Liver Dis 19:39-48, 1999
 
17) Fox IJ et al:Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med 14 (338):1422-1426, 1998
 
18) Mito M, Kusano M, Kawaura Y:Hepatocyte transplantation in man. Transplant Proc 24:3052-3053, 1992
PubMed
19) Sussmann NL et al:The hepatic extracorporeal liver assist device:initial clinical experience. Artf Organs 18:390-6, 1994
 
20) Sauer IM, Gerlach JC:Modular extracorporeal liver support. Artif Organs 26:703-706, 2002
PubMed
21) Watanabe FD et al:Clinical experience with a bioartificial liver in a treatment of sever liver failure. A phase I clinical trial. Ann Surg 225:484-494, 1997
 
P.91 掲載の参考文献
1) Kolff WJ et al:Artificial kidney:Treatment of acute and chronic uremia. Cleveland Clinic Quartery 17:216, 1950
 
2) Kimoto S:The artificial liver:experiments and clinical application, Trans Am Soc Artif Intern Organs 5:102-109, 1959
 
3) Ozawa K, Kamiyama Y, Tobe T et al:Clinical experience of postoperative hepatic failure treatment with pig or baboon liver cross-hemodialysis with an interposed membrane. Artif Organs 6:433-446 1982
PubMed
4) 寺岡 慧, 阿岸鉄三, 太田和夫ほか:生物学的人工肝補助装置-肝不全治療における体外肝灌流の効果と問題点. 最新医学 42:1630-1639, 1987
Medical*Online
5) Eisemann B, Liem DS, Raffucci F:Heterologous liver perfusion in treatment of hepatic failure. Ann Surg 162:329-345, 1965
 
6) Abouna GM, Serrou B, Boehmig HG et al:Long-term hepatic support by intermittent multi-species liver perfusions. Lancet 2:391-396, 1970
PubMed
7) Neuhaus P, Blumhardt G:Extracorporeal liver perfusion:applications of an improved model for experimental studies of the liver. Int J Artif Organs 16:729-739, 1993
 
8) Rozga J, Moscioni AD, Demetriou AA et al:Development of a hybrid bioartificial liver. Ann. Surgery 217:502-511, 1993
PubMed
9) Sussmann NL, Chong MG, Kelly JH et al:Reversal of fuluminant hepatic failure using an extracorporeal liver assist device. Hepatology 16:60-65, 1992
 
10) Gerlach J:Development of a hybrid liver support system:a review. Int J Artif Organs 19:645-654, 1996
 
11) Naruse K, Sakai Y, Makuuchi M et al:Development of a new extracorporeal whole liver perfusion system. J Artif Organs 2003, in press.
 
12) Matsumura KN, Guevara GR, Matsumura BA et al:Hybrid bioartificial liver in hepatic failure:preliminary clinical report. Surgery 101:99-103, 1987
 
13) Naruse K, Sakai Y, Muto T et al:Development of a new bioartificial liver module filled with porcine hepatocytes immobilized on non-woven fabric. Int J Artif Organs 6:347-352, 1996
PubMed
14) Naruse K, Sakai Y, Makuuchi M et al:Development of a xenogeneic direct hemoperfusion method in a bioartificial liver system. J Artif Organs 5:257-264, 2002
 
15) Naruse K, Sakai Y, Makuuchi M et al:Xenogeneic direct hemoperfusion using whole swine liver for liver failure in dogs. J Surg Res l 11:229-235, 2003
 
16) Paradis K, Landford G, Long Z et al:Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living Pig tissue. Science 285:1236-1241, 1999
 
17) van der Laan LJ, Lockey C, Griffeth BC et al:Infection by porcine endogenous retrovirus after islet-xenotransplantation in SCID mice. Nature 407:90-94, 2000
PubMed
18) Perry ACF, Wakayama T, Kishikawa H et al:Mammalian transgenesis by intracytoplasmic sperm injection. Nature 284:1180-1183, 1999
 
19) Kobayashi K, Kuwase S, Ohya T et al:High-level expression of recombinant human serum albumin from the methylotrophic yeast Pichia pastoris with minimal protease production and activation. J Biosci Bioeng 89:55-61, 2000
 
P.98 掲載の参考文献
1) Grapin-Botton A, Majithia AR, Melton DA:Key events of pancreas formation are triggered in gut endoderm by ectopic expression of pancreatic regulatory genes. Genes Dev 15:444-454, 2001
PubMed
2) Sharma A, Zangen DH, Reitz P et al:The homeodomain protein IDX-1 increases after an early burst of proliferation during Pancreatic regeneration. Diabetes 48:507-513, 1999
PubMed
3) Sander M, Germart MS:The beta cell transcription factors and development of the pancreas. J Mol Med 75:327-340, 1997
 
4) Bonner-Weir S, Taneja M, Weir GC et al:In vitro cultivation of human islets from expanded ductal tissue. Proc Natl Acad Sci USA 97:7999-8004, 2000
PubMed
5) Ramiya VK, Maraist M, Arfors KE et al:Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells. Nature Med 6:278-282, 2000
PubMed
6) Zulewski H, Abraham EJ, Gerlach MJ et al:Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes. Diabetes 50:521-533, 2001
PubMed
7) Tashiro F, Niwa H, Miyazaki J:Constructing adenoviral vectors by using the circular forrn of the adenoviral genome cloned in a cosmid and the CreloxP recombination system. Hum Gene Ther 10:1845-1852, 1999
 
8) Taniguchi H, Yamato E, Tashiro F et al:β-cell neogenesis induced by adenovirus-mediated gene delivery of transcription factor pdx-1 into mouse pancreas. Gene Ther 10:15-23, 2003
 
9) Ferber S, Halkin A, Cohen H et al:Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia. Nature Med 6:568-572, 2000
PubMed
10) Kojima H, Fujimiya M, Matsumura K et al:Neuro D-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice. Nature Med 9:596-603, 2003
 
11) Martin GR:Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci USA 78:7634-7638, 1981
PubMed
12) Bradley A et al:Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines. Nature 309:255-256, 1984
PubMed
13) Keller G:In vitro differentiation of embryonic stem cells. Curr Opin Cell Biol 7:862-869, 1995
PubMed
14) Thomson JA, Itskovitz-Eldor J, Shapiro SS et al:Embryonic stem cell lines derived from human blastocysts. Science 282:1145-1147, 1998
PubMed
15) Lumelsky N, Blondel O, Laeng P et al:Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science 292:1389-1394, 2001
PubMed
16) Rajagopal J, Anderson WJ, Kume S et al:Insulin staining of ES cell progeny from insulin uptake. Science 299:363, 2003
PubMed
17) Moritoh Y, Yamato E, Yasui Y et al:Analysis of insulin-producing cells during in vitro differentiation from feeder-free embryonic stem cells. Diabetes 52:1163-1168, 2003
PubMed
18) Hori Y, Rulifson IC, Tsai BC et al:Growth inhibitors promote differentiation of insulin-producing tissue from embryonic stem cells. Proc Natl Acad Sci USA 99:16105-16110, 2002
PubMed
19) Blyszczuk P, Czyz J, Kania G et al:Expression of Pax4 in embryonic stem cells promotes differentiation of nestin-positive progenitor and insulin-producing cells. Proc Natl Acad Sci USA 100:998-1003, 2003
PubMed
20) Assady S, Maor G, Amit M et al:Insulin production by human embryonic stem cells. Diabetes 50:1691-1697, 2001
PubMed
P.101 掲載の参考文献
1) Taniguchi H, Toyoshima T, Fukao K et al:Presence of hematopoietic stem cells in the adult liver. Nature Medicine 2 (2):198-203, 1996
PubMed
2) Osawa M, Hanada K, Hamada H et al:Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell Science 273:242-245, 1996
PubMed
3) Taniguchi H, Kondo R, Suzuki A et al:Clonogenic colony forming ability of flowcytometrically isolated hepatic stem/progenitor cells in the murine fetal liver. Cell Transplantation 9 (5):697-700, 2000
 
4) Taniguchi H, Kondo R, Suzuki A et al;Evidence for the presence of hepatic stem cells in the murine fetal liver. Transplantation Proceedings 31 (1-2):454, 1999
 
5) Suzuki A, Zheng YW, Kondo R et al:Flowcytometric separation and enrichment of multipotent hepatic progenitor cells in mouse developing liver. Hepatology 32 (6):1230-1239, 2000
 
6) Suzuki A, Zhen YW, Kaneko S et al:Clonal identification and characterization of self-renewing pluripotent stem cells in the developing liver. The Joumal of Cell Biology 156 (1):173-184, 2002
 
P.108 掲載の参考文献
1) Shapiro AMJ, Lakey JRT, Ryan EA et al:Islet transplantation in seven patients withtype 1 diabetes mellitus using a glucocorticoid-free immunosuppresive regimen. N Eng J Med 343:230-238, 2000
 
2) Wang WJ, Gu YJ, Miyamoto M et al:Effect of basic fibroblast growth factor on insulin secretion from microcapsulated pancreatic islet;An in Vitro study. Cell Transplantation 10:465-471, 2001
 
3) Kawakami Y, Iwata H, Gu YJ et al:Successful subcutaneous pancreatic islet transplantation using angiogenic growth factor releasing device. Pancreas 23:375-381, 2001
PubMed
4) Wang WJ, Gu YJ, Tabata Y et al:Reversal of diabetes in mice by xenotransplantation of bioartificial pancreas in a prevascularized subcutaneous site. Transplantation 73:122-129, 2002
 
5) Valdes R:Xenotransplantation trials. Lancet 359:2281, 2002
PubMed
6) Sandrin MS, Fodor WL, Mouhtouris E et al:Enzyme remodelling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and coplement-mediated cytlysis. Natl Med 160:1261-1267, 1995
 
7) Tanemura M, Miyagawa S, Koyota S et al:Reduction of the major swine xenoantigen, the alpha-galactosyl epitope by transfection of the alpha 2, 3-sialyltransferase gene. J Biol Chen 273:16421-16425, 1998
 
8) Miyagawa S, Tanemura M, Koyota S et al:Masking and reduction of the Galactose-alpha 1, 3-Galactose (alpha-Gal) epitope, the major xenoantigen in swine, by the glycosyltransferase gene transfection. Biochem Biophys Res Commun 264:611-614, 1999
 
9) Tanemura M, Miyagawa S, Ihara Y et al:Significant downregulation of the major swine xenoantigen by N-acetylglucosaminyltransferase III gene trasfection. Biochem Biophys Res Commun 235:359-364, 1997
 
10) Chen RH, Naficy S, Logan JS et al:Hearts from transgenic pigs constructed with CD59/DAF genomic clones demonstrate improved survival in primitives. Xenotransplantation 6:194-200, 1999
 
11) 中西喜彦:異種間移植にかける夢. 実験医学 17:36-41, 1999
Medical*Online
12) Soria B, Roche E, Berna G et al:Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetes mice. Diabetes 49:157-162, 2000
PubMed
13) Lumelsky N, Blondel O, Laeng P et al:Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreas islets. Science 292:1398-1394, 2001
 
14) 金 度動, 顧 元駿, 石井通予ほか:マウスES 細胞からインスリン分泌クラスターへの分化. 日本.再生医療学会雑誌 1:76, 2002
 
15) Assady S, Maor G, Amit M et al:Insulin production by human embryonic stem cells. Diabetes 50:1691-1697, 2001
PubMed
16) Niwa H, Miyazaki J, Smith AG:Quantitative expression of Oct-3/4 defines differetiation, dedifferetiation or self-renewal of ES cells. Nat Genet 24:372-376, 2000
 
17) Thomson JA, Itskovitz-Eldor J, Shapiro SS et al:Embryonic stem cell lines derived from human blastocytes. Science 283:1145-1147, 1998
 
18) Shamblott MJ, Axelman J, Wang S et al:Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc Natl Acad Sci USA 95:13726-13731, 1998
PubMed
19) Smith A:Cell thrapy:in search of pluripotency. Curr Biol 8:802-804, 1998
 
20) Ramiya VK, Maraist M, Arfors KE et al:Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells[see comments]. Nat Med 6:278-282, 2000
 
21) Bonner-Weir S, Taneja M, Weir GC et al:In vitro cultivation of human islets from expanded ductal tisseu. Proc Natl Acad Sci USA 97:7999-8004, 2000
PubMed
22) Zulewski H, Abraham EJ, Gerlach MJ et al:Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes. Diabetes 50:52 1-533, 2001
 
23) Taniguchi H, Yamato E, Tashiro F et al:β-cell neogenesis induced by adenovirus-mediated gene delivery of transcription factor PDX-1 into mouse pancreas. Gene Ther 10:15-23, 2003
 
24) Ferber S, Halkin A, Cohen H et al:Pancreatic and duodenal homeobox gene linduces expression oh insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia. Nat Med 6:568-572, 2000
 
25) Yang L, Li S, Hatch H et al:In vitro trans-differentiation of adult hepatic stem cells into pancreatic endocrine hormone-producing cells. Proc Natl Acad Sci USA 99:8078-8083, 2002
PubMed
26) Yamada S, Kojima H, Fujimiya M et al:Differentiation of immature enterocytes into entero-endocrine cells by Pdx-10verexpression. Am J Physiol Gastroenterol Liver Physiol 281:G 229-G 236, 2001
 
27) Kojima H, Nakamura T, Fujita Y et al:Combined expression of pancreatic duodenal homeobox l and islet factor-1 induces immature entrocytes to produce insulin. Diabtes 51:1398-1408, 2002
 

第4章 肝疾患の最新医療

P.114 掲載の参考文献
1) 岡上 武:肝硬変に対する抗ウイルス療法. 日消誌 99:139-144, 2002
Medical*Online
2) 谷川久一:lamivudine. 臨床医 23:1032-1035, 1997
 
3) Lai CL, Chien RN, Leung NWY et al:A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339:61-68, 1998
 
4) Dienstag JL, Schiff ER, Wright TL et al:Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256-1263, 1999
PubMed
5) Schalm SW, Heathcote J, Cianciara J et al:Lamivudine and alpha interferon combinatgion treatment of patients with chronic hepatitis B infection:a randomized trial. Gut 46:562-568, 2000
PubMed
6) Conjeevaram HS, Lok ASF:Management of chronic hepatitis B. J Hepatol 38:S 90-S 103, 2003
 
7) Dienstag JL, Cianciara J, Karayalcin S et al:Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 37:748-755, 2003
PubMed
8) Song BC, Suh DJ, Lee HC et al:Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32:803-806, 2000
 
9) Lee CM, Ong GY, Lu SN et al:Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol 37:669-674, 2002
PubMed
10) Lok ASF, Heathcote EJ, Hoofnagle JH:Management of hepatitis B:2000-Summary of a workshop. Gastroenterology 120:1828-1853, 2001
 
11) Ling R, Mutimer D, Ahmed M et al:Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24:711-713, 1996
PubMed
12) Tipples GA, Ma MM, Fischer KP et al:Mutations in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24:714-717, 1996
PubMed
13) Melegari M, Scaglioni PP, Wands JR:Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633, 1998
PubMed
14) Ono SK, Kato N, Shiratori Y et al:The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 107:449-455, 2001
PubMed
15) Kirishima T, Okanoue T, Daimon Y et al:Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol 37:259-265, 2002
PubMed
16) Bock CT, Tillmann HL, Torresi J et al:Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 122:264-273, 2002
PubMed
17) 熊川博光:慢性肝炎に対する抗ウイルス療法. 日消誌 99:131-138, 2002
 
18) Santantonio T, Niro GA, Sinisi E et al:Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients:a controlled pilot study. J Hepatol 36:799-804, 2002
PubMed
19) Schiff ER, Dienstag JL, Karayalcin S et al:Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 38:818-826, 2003
PubMed
20) Serfaty L, Thabut D, Zoulim F et al:Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone:results of a pilot study. Hepatology 34:573-577, 2001
 
P.122 掲載の参考文献
1) Tsubota A, Chayama K, Ikeda K, et al:Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 19:1088-1094, 1994
 
2) Tsubota A, Kumada H, Chayama K, et al:Relationship between pretreatment viremia level and response to interferon-alpha therapy in chronic hepatitis C differs in viral type 1 and 2 infections. Dig. Dis. Sci 41:1925-1932, 1996
PubMed
3) Sidwell RW, Huffman JH, Khare GP, et al:Broad-spectrum antiviral activity of Virazole:1-beta-D-ribofuranosy 1-1, 2, 4-triazole-3-carboxamide. Science 177:705-706, 1972
 
4) Patterson JL, Fernandez-Larsson R:Molecular mechanisms of action of ribavirin, Rev Infect Dis 12:1132-1146, 1990
 
5) Reichard O, Norkrans G, Fryden A, et al:Randomized, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet 351:83-87, 1998
 
6) Hutchison JG, Gordon SC, Schiff ER, et al:Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485-1492, 1998
PubMed
7) Poynard T, Marcellin P, Lee SS, et al:Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432, 1998
PubMed
8) Davis GL, Esteban-Mur R, Rustgi V, et al:Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 339:1493-1499, 1998
PubMed
9) Cheng SJ, Bonis PAL, Lau J, et al:Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy:a meta-analysis of controlled and uncontrolled trials. Hepatology 33:231-240, 2001
 
10) Khakoo S, Glue P, Grellier L, et al:Ribavirin and interferon alfa-2b in chronic hepatitis C:assessment of possible pharmacokinetics and pharmacodynamic interactions. Br J Clin Pharmacol 46:563-570, 1998
PubMed
11) Tsubota A, Akuta N, Suzuki F, et al:Viral dynamics and pharmacokinetics in combined interferon alpha-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load. Intervirology 45:33-42, 2002
PubMed
12) Tsubota A, Hirose Y, Izumi N, et al:Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Br J Clin Pharmacol 55:360-367 , 2003
PubMed
13) Jen JF, Glue P, Gupta S, et al:Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 22:555-565, 2000
PubMed
14) Cramp ME, Rossol S, Chokshi S, et al:Hepatitis C virus-specific T-cell reactivity diring interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118:346-355, 2000
 
15) Yee LJ, Tang J, Gibson AW, et al:Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 33:708-712, 2001
PubMed
16) Fried MW, Shiffman ML, Reddy KR, et al:Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982, 2002
PubMed
17) Glue P, Rouzier-Pallis R, Raffanel C, et al:A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 32:647-53, 2000
 
18) Manns MP, McHutchison JG, Gordon SC, et al:Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomised trial. Lancet 358:958-968, 2001
PubMed
P.126 掲載の参考文献
1) Saito I et al:Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 87:6547-6549, 1990
PubMed
2) Houghton M:Hepatitis C viruses. In:Fields BN, Knipe DM, Howley PM eds:Fields Virology, 3rd ed, Lippincott-Raven, Philadelphia, p 1035-1058, 1996
 
3) Chiba J, Ohba H, Matsuura Y et al:Serodiagnosis of hepatitis C virus (HCV) infection with an HCV core protein molecularly expressed by a recombinant baculovirus. Proc Natl Acad Sci USA 88:4641-4645, 1991
PubMed
4) Miyamura T, Matsuura Y:Structural proteins of hepatitis C. Trends in Microbiol 1:229-231, 1993
PubMed
5) Choo QL et al:Vaccination of Chimpanzees Against Infection by the Hepatitis C Virus. Proc Natl Acad Sci USA 91:1294-1298, 1994
PubMed
6) Pileri P et al:Binding of hepatitis C virus to CD81. Science 282:938-941, 1998
PubMed
7) Rosa D et al:A quantitative test to estimate neutralizing antibodies to the hepatitis C virus:cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci USA 93:1759-1763, 1996
 
8) Ishii K et al:High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology 28:1117-1120, 1998
PubMed
9) Cooper S et al:Analysis of a successful immune response against hepatitis C virus. Immunity 10:439-449, 1999
PubMed
10) Takikawa S et al:Cell fusion activity of hepatitis C virus envelope proteins. J Virol 74:5066-5074, 2000
PubMed
11) Matsuura Y et al:Characterization of Pseudotype VSV Possessing HCV Envelope Proteins. Virology 286:263-275, 2001
PubMed
12) Stefania C et al:Inhibition of Natural Killer Cells through Engagement of CD81 by the Major Hepatitis C Virus Envelope Protein. J Exp Med 195:35-41, 2002
 
13) Chien-Te KT et al:Binding of the Hepatitis C Virus Envelope Protein E2 to CD81 Inhibits Natural Killer Cell Function. J Exp Med 195:43-49, 2002
 
14) Peter CT:Antibody therapy for rheumatoid arthritis. Curr Opin in Pharma 3:1-6, 2003
 
15) Burioni R et al:Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments. Hepatology 28:810-814, 1998
PubMed
16) Hadlock KG et al:Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes J Virol 74:10407-10416, 2000
PubMed
17) Mendez MJ et al:Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nature Genet 15:146-156, 1997
PubMed
18) Birke B et al:Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1-E2 Envelope Protein Complexes. J Exp Med 197:633-642, 2003
 
19) Burioni R et al:Diverging Effects of Human Recombinant Anti-Hepatitis C Virus (HCV) Antibody Fragments Derived from a single patient on the Infectivity of a Vesicular Stomatitis Virus/HCV Pseudotype. J Virol 76:11775-11779, 2002
PubMed
P.132 掲載の参考文献
1) Ludwig J et al:Nonalcoholic steatohepatitis. Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55:434-438, 1980
 
2) Shimada M, Hashimoto E, Taniai M, Hasegawa K, Okuda H, Hayashi N, Takasaki K, Ludwig J:Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 37:154-160, 2002
PubMed
3) Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M:Expanding the natural history of nonalcoholic steatohepatitis:from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123:134-140, 2002
PubMed
4) Kanazawa M, Yoshiike N, Osaka T, Numba Y, Zimmet P, Inoue S:Criteria and classification of obesity in Japan and Asia-Oceania. Asia Pacific J Clin Nutr 11:S 732-S 737, 2002
 
5) Yommossi ZM et al:Nonalcoholic fatty liver disease:an agenda for clinical research. Hepatology 35:746-752, 2002
 
6) Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ:The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123:745-750, 2002
PubMed
7) Nemoto Y, Toda K, Ono M, Adachi K, Saibara T, Onishi S, Enzan H, Okada T, Shizuta Y:Altered constitutive expression of fatty acid-metabolizing enzymes in aromatase-deficient (ArKO) mice. J Clin Invest 105:1819-1825, 2000
 
8) Saibara T, Onishi S, Ogawa Y, Yoshida S, Enzan H:Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. Lancet 353:1802, 1999
PubMed
9) Murata Y, Ogawa Y, Saibara T, Nishioka A, Fujiwara Y, Fukumoto M, Inomata T, Enzan H, Onishi S, Yoshida S:Unrecognized hepaticsteatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol Rep 7:1299-1304, 2000
 
10) Neuschwander-Tetri BA, Caldwell SH:Nonalcoholic steatohepatitis:summary of an AASLD Single Topic Conference. Hepatology 37:1202-1219, 2003
PubMed
11) Robertson G, Leclercq I, Farrell GC:Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 281:G 1135-1139, 2001
 
12) Argiles JM et al:Joumey from cachexia to obesity by TNF. FASEB J 11:743-751, 1997
PubMed
13) Dresner A et al:Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 103:253-259, 1999
PubMed
14) Jiang C et al:PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86, 1998
 
15) Marchesini G et al:Metformin in non-alcoholic steatohepatitis. Lancet 358:893-894, 2001
PubMed

第5章 肝硬変

P.138 掲載の参考文献
1) Blouin A, Bolender RP, Weibel ER:Distribution of organelles and membranes between hepatocytes and nonhepatocytes in the rat liver parenchyma. A atereological study, J Cell Biol 72:441-455, 1977
PubMed
2) Johnson SJ, Hines JE, Burt AD:Immunolocalization of proliferating Perisinusoidal cells in rat liver. Histochemical J 24:67-72, 1992
 
3) Milani S, Herbst H, Schuppan D:Cellular sources of extracellular matrix proteins in normal and fibrotic liver. Studies of gene expression by in situ hybridization. J Hepatol 22:71-76, 1995
PubMed
4) Goodmann DS et al:Biosynthesis, absorption and hepatic metabolism of retinal. In:The Retinoids, Vol 2:1-39 Academic Press, Orland, 1984
 
5) Blaner WS, Olson J:Retinol and retinoic acid metabolism In:Spon M, Roberts A, Goodmann DS. The Retinoids. New York:Raven 229-256, 1994
 
6) Mercier M, Forget A, Grolier P:Hydrolysis of retinyl esters in rat liver. Description of a lysosomal activity. Biochim Biophys Acta 1212 (2):176-182, 1994
PubMed
7) Kawada N, Tran-Thi TA, Deker K:The contraction of hepatic stellate cells stimulated with vasoactive substances. possible involvement of endothelin-1 and nitric oxide in the regulation of sinusoidal tonus. Eur J Biochem 213:815-823, 1993
 
8) Rocky DC, Chung JJ:Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing. J CIin Invest 98:1381-1388, 1996
 
9) Suzuki C, Sakaida I, Okita k:Charateristics of the cell proliferation profile of activated rat hepatic stellate cells in vitro in contrast to their fibrogenesis activity. J Gastroenterol 36:322-329, 2001
 
10) Milani S, Herbst H, Schuppan D:In situ hybridization for procollagen type I, III and IV mRNA in noumal and fibrotic rat liver:evidence for predominant expression in nonparenchymal cells. Hepatology 10:84-92, 1989
 
11) 弘中孝治, 坂井出 功, 沖田 極.:肝胆膵肝疾患, と月干星糸田月包 40 (2):255-261, 2000
 
12) Vyas SK, Leyland H, Arthur MJP:Rat hepatic lipocytes synthesize and secrete transin (stromelysin) is expressed in early primary culture. Gastroenterology 109:889-898, 1995
 
13) Iredale JP, Goddard S, Arthur MJP:Tissue inhibitor of metalloproteinase-1 and interstitial collagenase expression in autoimmune chronic active hepatitis and activated human hepatic lipocyte. Clin Sci 89:75-81, 1995
 
14) Iredale JP, Benyon RC, Arthur MJP:Tissue inhibitor of metalloproteinase-1 messenjer RNA expression is enhanced relative to interstitial collagenase messenjer RNA in experimental liver injury and fibrosis. Hepatology 24:176-184, 1996
 
15) Benyon RC, Iredare JP, Arthur MJP:Progelatinase Ais produced and activated by rat hepatic stellate cells and promotes their proliferation. Hepatology 30:977-986, 1999
 
16) Friedman SL:The cellular basis of hepatic fibrosis. Mehanism and treatment strategies. New Engl J Med 328:1828-1835, 1993
 
17) Reeves HL, Friedman SL:Activation of hepatic stellate cell-A key issue in liver fibrosis Front Biosci Apr 1;7:d 808-826, 2002
 
18) Pinzani M, Marra F:Semin Liver Dis 21:397-416, 2001
PubMed
19) Olaso E, Labrador JP, Wang L:Disccoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2. J Biol Chem 1;277:3606-3613, 2002
 
20) Sakaida I, Jinhua S, Okita K:Leptin receptor-deficient Zucker ( fa/fa) rat retards the development of pig serum-induced liver fibrosis with Kupffer cell dysfuction. Life Sci (in press)
 
P.144 掲載の参考文献
1) Stiegmam GV, Cambre T, Sun JH:A new endoscopic elastic band ligation device. Gastrointest. Endosc 32:230, 1986
 
2) Nishikawa Y, Hosokawa Y, Doi T et al:Simultaneous combination of endoscopic sclerotherapy and endoscopic ligation for esophageal varices. Gastrointest Endosc 42:358-360, 1995
PubMed
3) 消化器内視鏡ガイドライン第2版, 監修:日本消化器内視鏡学会, 医学書院, 2002
 
4) Yoshida T, Harada T, Shigemitsu T et al:Endoscopic management of gastric varices using a detachable snare and simultaneous endoscopic sclerotherapy and O-ring ligation. J Gastroenterol hepatol 14:730-735, 1999
PubMed
5) Soehendra N, Grimm H, Nam VC et al:N-butyl-2-cyanoacrylate:a supplement to endoscopic sclerotherapy. Endoscopy 19:221-224, 1987
 
6) 金川博史, 美馬聡昭, 香山明-ほか:バルーン下逆行性経静脈的塞栓術 (B-RTO) による胃静脈瘤の治療. 肝臓32:442, 1991
 
P.151 掲載の参考文献
1) 佐藤俊一, 鈴木一幸:慢性肝不全. 最新内科学体系「肝機能不全」中山書店, 東京, p 174-191, 1991
 
2) Roger F:Butterworth:Pathogenesis of hepatic encephalopathy:new insights from neuroimaging and molecular studies. J Hepatol 39:278-285, 2003
PubMed
3) Gitlin N:Subclinical portal-systemic encephalopathy. Am J Gastroenterol 83:8-11, 1988
PubMed
4) 加藤章信, 岩井正勝, 佐原 圭ほか:肝性脳症の発生機序と潜在性肝性脳症の診断. 肝胆膵47:63-73, 2003
 
5) 金田泰一, 加藤章信, 鈴木一幸:潜在性肝性脳症の診断-脳波mapping, 誘発電位の検討. 肝臓35:408-415, 1994
 
6) 鈴木一幸:肝硬変による肝性脳症例の治療成績と今後の問題点. 「厚生労働科学研究費補助金肝炎等克服緊急対策研究事業 (肝炎分野) 末期肝硬変に対する治療に関する研究」平成14年度分担研究報告書, p 33-45, 2003
 
7) 鈴木一幸:肝性脳症と治療. 医薬ジャーナル35:1565-1570, 1999
 
8) 鈴木一幸:高アンモニア血症の治療法 (二糖類), 渡辺明治/佐伯武頼編集, 医科アンモニア学, メディカルレビュー社, 東京, p 258-269, 1995
 
9) 鈴木一幸:肝性脳症-成因からみた治療のあり方. 臨床医22:451-453, 1996
 
10) 池田亘政, 岩井正勝, 加藤章信:肝硬変の脳内物質代謝に対する分岐鎖アミノ酸高含有アミノ酸輸液の影響. 肝臓42:353-359, 2001
 
11) 鈴木一幸, 加藤章信, 盛合 理ほか:肝性脳症-特殊アミノ酸. 肝胆膵23:969-975, 1991
 
12) 佐藤俊一, 鈴木一幸:肝癌を合併した肝不全の治療, 織田敏次監修, 臨床肝癌第3巻 (下), 講談社, 東京, p 159-167, 1988
 
13) Swat GR, Zillikens MC, van Vuure JK et al:Effect of a late evening meal on nitrogen balance in patients with cirrhosis of the liver. Brit Med J 299:1202-1203, 1989
 
14) 渡辺明治:肝不全の栄養治療. 肝臓42:641-650, 2001
 
15) Reding P, Duchateau J, Bataille C:Oral zinc supplementation improves hepatic encephalopathy. Lancet ii:493-495, 1984
 
16) 片山和宏, 大岡優子, 吉川 澄ほか:慢性肝疾患の窒素代謝における亜鉛の意義についての検討. 肝蔵43:120-125, 2001
 
17) Pomier-Layrargues G, Giguere JF, Lavoie J et al:Flumazenil in cirrhotic patients in hepatic coma:a randomized double-blind placebo-controlled crossover trial. Hepatology 19:32-37, 1994
 
18) 坂井慈実, 池尻直幹, 古賀都利子ほか:アルコール性肝硬変に伴う肝性脳症に対するベンゾジアゼピン拮抗薬の持続投与の効果. 肝臓44:283-289, 2003
 
19) Miwa S, Hashikura Y, Mita A et al:Living-related liver transplantation for patients with fulminant and subfulminant hepatic failure. Hepatology 30:1521-1526, 1999
PubMed
20) Burra P, Dam M, Chierichetti F et al:18F-fluorodeoxyglucose positron emission tomography study of brain metabolism in cirrhosis:effect of liver transplantation. Transplantation Proceedings 31:418-420, 1999
PubMed
P.158 掲載の参考文献
1) Arroyo V, Gines P, Gerbes AL, Dudley FJ et al:Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Intemational Ascites Club. Hepatology 23:164-176, 1996
 
2) Pare P, Talbot J, Hoefs JC:Serum-ascites albumin concentration gradient:a physiologic approach to the differential diagnosis of ascites. Gastroenterology 85:240-244, 1983
 
3) Siersema PD, de Marie S, van Zeijl Jh et al:Blood culture bottles are superior to lysis-centrifugation tubes for bacteriological diagnosis of spontaneous bacterial peritonitis. J Chn Microbiol 30:667-669, 1992
 
4) Spahr L, Villeneuve JP, Tran HK et al:Furosemideinduced natriuresis as a test to identify cirrhoticpatients with refractory ascites. Hepatology 33:28-31, 2001
 
5) Gines P, Jimenez W:Aquaretic agents:a new potential treatment of dilutional hyponatremia incirrhosis. J Hepatol 24:506-512, 1996
PubMed
6) Gadano A, Moreau R, Pessione F et al:Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis. J Hepatol 32:38-42, 2000
PubMed
7) Guyader D, Patat A, Ellis-Grosse EJ et al:Pharmacodynamic effects of a nonpeptide antidiuretic hormone V? antagonist in cirrhotic patients with ascites. Hepatology 36:1197-1205, 2002
 
8) Wong F, Blei AT, Blendis LM et al:A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia:a multicenter, randomized, placebocontrolled trial. Hepatology 37:182-191, 2003
 
9) Angeli P, Volpin R, Piovan D et al:Acute effects ofthe oral administration of midodrine, an alpha adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 28:937-943, 1998
 
10) Hadengue A, Gadano A, Moreau R et al:Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 29:565-570, 1998
PubMed
11) Moreau R, Durand F, Poynard T et al:Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome:a retrospective multicenter study. Gastroenterology 122:923-930, 2002
PubMed
12) Gadano A, Moreau R, Vachiery F et al:Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. J Hepatol 26:1229-1234, 1997
 
13) Epstein M:Peritoneovenous shunt in the management of ascites and the hepatorenal syndrome. Epstein M ed The Kidney in Liver Disease, 4th ed, Philadelphia, Hanley&Belfus Inc, 491-506, 1996
 
14) 矢島義昭:肝硬変に伴う難治性腹水例に対する Peritoneo-Venous Shunt 造設後の凝固系の異常について. 東北止血.血栓研究会会誌14:17-23, 2000
 
15) 野口和典, 井上欣哉:肝硬変合併症対策:難治性腹水の成因と対策. 肝胆膵44:657-663, 2002
 
16) Zervos EE, McCormick J, Goode SE et al:Perito-neovenous shunts in patients with intractable ascites:palliation at what price? Am Surg 63:157-162, 1997
 
17) Luca A, Feu F, Garcia-Pagan JC et al:Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites. Hepatology 20:30-33, 1994
PubMed
18) Pozzi M, Osculati G, Boari G et al:Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites. Gastroenterology 106:709-719, 1994
PubMed
19) Pozzi M, Grassi G, Pecci V et al:Early effects of total paracentesis and albumin infusion on muscle sympathetic nerve activity in cirrhotic patients with tense ascites. J Hepatol 30:95-100, 1999
PubMed
20) Kravetz D, Romero G, Argonz J et al:Total volume paracentesis decreases variceal pressure, size, and variceal wall tension in cirrhotic patients. Hepatology 25:59-62, 1997
PubMed
21) Fernandez-Esparrach G, Guevara M, Sort P et al:Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo. J Hepatol 26:614-620, 1997
PubMed
22) Fukui H, Uemura M, Tsujii T:Pathophysiology and treatment of cirrhotic ascites. Yamanaka M, Toda G, Tanaka T eds, Liver cirrhosis update, Amsterdam, Elsevier, 63-76, 1998
 
23) Moreau R, Asselah T, Condat B et al:Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis:a randomised pilot study. Gut 50:90-94, 2002
PubMed
24) Graziotto A, Rossaro L, Inturri P et al:Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial Dig Dis Sci 42:1708-1714, 1997
PubMed
25) 高松正剛, 宮崎浩彰, 片山和宏ほか:難治性腹水に対する腹水濾過濃縮再静注法 (CART) の現況:特に副作用としての発熱に影響する臨床的因了の解析. 肝胆膵46:663-669, 2003
 
26) Borzio M, Romagnoni M, Sorgato G et al:A simple method for ascites concentration and reinfusion. Dig Dis Sci 40:1054-1059, 1995
PubMed
27) Gerbes AL, Gulberg V, Waggershauser T et al:Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis:comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology 28:683-688, 1998
PubMed
28) Ochs A, Rossle M, Haag K et al:The transj ugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 332:1192-1197, 1995
 
29) Quiroga J, Sangro B, Nunez M et al:Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites:effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology 21:986-994, 1995
PubMed
30) Somberg KA, Lake JR, Tomlanovich SJ et al:Transjugular intrahepatic portosystemic shunts for refractory ascites:assessment of clinical and hommonal response and renal function. Hepatology 21:709-716, 1995
PubMed
31) Van der Linden P, Le Moine O, Ghysels M et al:Pulmonary hypertension after transjugular intrahepatic portosystemic shunt:effects on right ventricular function. Hepatology 23:982-987, 1996
PubMed
32) Rodriguez-Laiz JM, Banares R, Echenagusia A et al:Effects of transjugular intrahepatic portasystemic shunt (TIPS) on splanchnic and systemic hemodynamics, and hepatic function in patients with portal hypertension. Preliminary results. Dig Dis Sci 40:2121-2127, 1995
PubMed
33) Gines P, Uriz J, Calahorra B et al:Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 123:1839-1847, 2002
PubMed
34) Wong F, Blendis L:Transjugular intrahepatic portosystemic shunt for refractory ascites:tipping the sodium balance. Hepatology 22:358-364, 1995
PubMed
35) Chalasani N, Clark WS, Martin LG et al:Detemminants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting. Gastroenterology 118:138-144, 2000
PubMed
36) Malinchoc M, Kamath PS, Gordon FD et al:A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31:864-871, 2000
 
37) Rossle M, Ochs A, Gulberg V et al:A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 342:1701-1707, 2000
PubMed
38) Zucker SD:Management of refractory ascites:are tips or taps tops? Gastroenterology 120:311-312, 2001
PubMed
39) Jeffries MA, Kazanjian S, Wilson M et al:Transjugular intrahepatic portosystemic shunts and liver transplantation in patients with refractory hepatic hydrothorax. Liver Transpl Surg 4:416-423, 1998
PubMed
40) Guardiola J, Baliellas C, Xiol X et al:External validation of a prognostic model for predicting survival of cirrhotic patients with refractory ascites. Am J Gastroenterol 97:2374-2378, 2002
PubMed

第6章 肝腫瘍の治療

P.164 掲載の参考文献
1) Atlas of pathlogy:Tumors of the Liver and Intrahepatic Bile Ducts. AFIP Fascicle;Ishak KG, Goodman ZD, Stocker JT, eds. Washigton D.C. Springer-Verlag, 2001
 
2) Iha H, Nakashima Y, Fukukura Y et al:Biliary hamartomas simulating multiple hepatic metastasis on imaging findings. Kurume medical journal 43:231-235, 1996
PubMed
3) Taguchi J, Yasunaga M, Kojiro M et al:Intrahepatic and extrahepatic biliary papillo-matosis. Arch Pathol Lab Med 117:944-947, 1993
 
4) 膵管内乳頭腫瘍と粘液産生嚢胞腫瘍の鑑別, 消化器画像Vol 3:No.3, 医学書院, 東京, 2001
 
5) 中島 収, 朽網留美子, 福光賞真ほか:大型高分化型肝細胞癌か肝細胞腺腫か?-欧米肝病理専門医による病理診断との比較検討-第38回肝臓学会総会抄録集 Vol.43 (1) suppl (1) A 217 (p-148)
 
6) Wanless IR, Maudsly C, Adams R:On the pathogenesis of focal nodular hyperplasia of the liver. Hepatology 5:1194-1200, 1985
 
7) 奥平定之:Focal nodular hyperplasia 23切除例の臨床病理学的検討. 肝臓34:621-629, 1993
 
8) Wanless IR:Micronodular transformation (nodular regenerative hyperplasia) of the liver:a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 11:787-797, 1990
 
9) 鹿毛政義, 荒川正博, 福田-典ほか:肝のpartial nodular transformationの1例-特発性門脈圧元進症との異同について-. 肝臓31:777-783, 1990
 
10) 日本肝癌研究会:臨床.病理;原発性肝癌取扱い規約, 第4版, 金原出版, 東京, 2001
 
11) International Working Party:Terminology of nodular hepatocellular lesions. Hepatology 22:983-993, 1995
PubMed
12) 中島 収, 渡辺次郎, 田中将也ほか:アルコール多飲者の肝過形成結節に関する臨床病理学的研究. 肝月蔵37:704-713, 1996
 
13) Kim SR, Hyayashi Y, Kudo M et al:Inflammatory pseudotumor of the liver in patient with chronic hepatitis C:Difficulty in differentiating it from hepatocellular carcinoma. Pathol Int 49:726-730, 1999
 
14) 伊集院裕康, 小野尚文, 山崎三樹ほか:肝細胞癌と鑑別が困難であった慢性肝疾患に合併した肝の炎症性偽腫瘍の2例. 肝臓42:536-542, 2001
 
15) 中島 収, 渡辺次郎, 田口 順ほか:肝の凝固壊死を呈する肉芽性結節に関する臨床病理学的研究. 肝臓35:527-535, 1994
 
16) Watanabe J, Nakashima O, Noguchi K (et al:Imaging and pathologic findings of pseudolipoma in the liver. Hepatology Research 12:225-232, 1998
 
17) Katayanagi K, Terada T, Nakanuma Y et al:Acase of pseudolymphoma of the liver. Pathol Int 44:704-711, 1994
 
18) Kim SR, Hayashi Y, Kang KB et al:A case of pseudolymphoma of the liver chronc hepatitis C. Journal of Hepatology 26:209-214, 1997
 
P.171 掲載の参考文献
1) 川田龍作ほか:各種悪性腫瘍に対する transcatheter arterial embolization therapyの経験. 脈管学18:563-571, 1978
 
2) Ohishi H et al:Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents. Radiology 154:25-29, 1985
PubMed
3) Uchida H et al:Transcatheter hepatic segmental arterial embolization using Lipiodol mixed with an anticancer drug and gelfoam particles for hepatocellular carcinoma. Cardiovasc Intervent Radiol 13:140-145, 1990
PubMed
4) Matsui O et al:Small hepatocellular carcinoma:Treatment with subsegmental transcatheter arterial embolization. Radiology 188:79-83, 1993
PubMed
5) Matsuo N et al:Optimal Lipiodol volume in transcatheter arterial chemoembolotherapy for hepatocellular carcinoma:Study based on Lipiodol accumulation patterns and histopathologic findings. Semin Oncol 24 (Sppl. 6):61-70, 1997
 
6) 阪口 浩ほか:抗癌剤混入リピオドール注人肝動脈塞栓術 (Lp-TAE) における抗癌剤の動態エマルジョン組成.作成法による差異とラット腸間膜動脈内注入後の変化-. 癌と化学療法18:1349-1355, 1991
 
7) 林 孝行ほか:Segmental SMANCS Lipiodol-TAE による肝細胞癌の治療. 癌と化学療法25:116-124, 1998
 
8) 松尾尚樹ほか:肝細胞癌に対する肝動脈塞栓術後の側副血行路塞栓術に関する検討. 脈管学25:361-365, 1985
 
9) Okazaki M et al:Chemoembolotherapy for recurrent hepatocellular carcinoma in the residual liver after Hepatectomy. Hepato-Gastroenterol 40:320-323, 1993
 
10) 阪口 浩:肝;肝癌門脈.胆管閉塞. 消化器病セミナー.70消化器疾患に対するIVR, 打田日出夫編:へるす出版, pp. 133-142, 1998
 
11) 板野 哲ほか:肝細胞癌の治療-適応, 手法, 成績-持続的動注化学療法. 消化器外科24:721-727, 2001
 
P.177 掲載の参考文献
1) 杉浦信之, 高良健治, 大藤正雄ほか:超音波映像下経皮的腫瘍内エタノール注入による小肝細胞癌の治療. 肝臓24:920, 1983
 
2) Shiina S, Imamura M, Omata M et al:Percutaneous ethanol injection therapy for malignant liver neoplasms. Semin lnterv Radiol 14:295-303, 1997
 
3) Livraghi T, Giorgio A, Marin G et al:Hepatocellular carcinoma and cirrhosis in 746 patients:long-temm results of percutaneous ethanol injection. Radiology 197:101-108, 1995
 
4) Lencioni R, Bartolozzi C, Caramella D et al:Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis of prognostic factors in 105 Westem patients. Cancer 76:1737-1746, 1995
 
5) Shiina S, Hata Y, Niwa Y et al:Multiple-needle insertion method in percutaneous ethanol injection therapy for liver neoplasms. Gastroenterol Jpn 26:47-50, 1991
PubMed
6) 日本肝癌研究会:第15回全国原発性肝癌追跡調査報告 (1998-1999), 2002
 
7) Ishii H, Okada S, Nose H et al:Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer 77:1792-1796, 1996
PubMed
8) Di Stasi M, Buscarini L, Livraghi T et al:Percutaneous ethanol injection in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complication rates. Scand J Gastroenterol 32:1168-1173, 1997
PubMed
9) Tanaka K, Okazaki H, Nakamura S et al:Hepatocellular carcinoma:treatment with a combination therapy of transcatheter arterial embolization and percutaneous ethanol injection. Radiol 179:713-717, 1991
 
10) Bartolozzi C, Lencioni R, Caramella D et al:Treatment of large HCC:transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology 197:812-818, 1995
PubMed
11) Seki T, Wakabayashi M, Nakagawa T et al:Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 74:817-825, 1994
PubMed
12) Seki T, Wakabayashi M, Nakagawa T et al:Percutaneous microwave coagulation therapy for patients With small hepatocellular carcinoma:comparison with percutaneous ethanol inj ection therapy. Cancer 85:1694-1702, 1999
 
13) 関 寿人:マイクロ波凝固治療, 消化器疾患の最新医療先端医療技術研究所, 東京, 247, 2001
 
14) Rossi S, Fornari F, Pathies C et al:Thermal lesions induced by 480 KHz localized current field in guinea pig and in pig liver. Tumori 76:54-57, 1990
PubMed
15) McGahan J, Browning P, Brock J et al:Hepatic ablation using radiofrequency electrocautery. Invest Radiol 25:267-270, 1990
PubMed
16) Rossi S, Buscarini E, Garbagnati F et al:Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. Am J Roentogenal 170:1015-1022, 1998
 
17) Livraghi T, Goldberg SN, Lazzaroni S et al:Small hepatocellular carcinoma:Treatment with Radiofrequency ablation versus ethanol injection. Radiology 210:655-661, 1999
PubMed
18) Buscarini L, Buscarini E, Di Stasi M et al:Percutaneous radiofrequency ablation of small hepatocellular carcinoma:Long-term resuits. Eur. Radiol 11:914-921, 2001
 
19) Curley SA, Izzo F, Ellis LM:Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 232:381-391, 2000
PubMed
20) Busucarini L, Busucarini E:Therapy of HCC-radiofrequency ablation. Hepatogastroenterology 48:15-19, 2001
 
21) Busucarini L, Busucarini E, Di Stasi M et al:Percutaneous radiofrequency thermal ablation combined with transcatheter arterial embolization in the treatment of hepatocellular carcinoma. Uitraschall Med 20:47-53, 1999
 
22) Rossi S, Garbagnati F, Lencioni R et al:Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 217:119-126, 2000
PubMed
P.185 掲載の参考文献
1) Nakayama A, Imamura H, Matsuyama Y, Kitamura H, Miwa S, Kobayashi A, Miyagawa S, Kawasaki S:Value of lipiodol computed tomography and digital subtraction angiography in the era of helical biphasic computed tomography as preoperative assessment of hepatocellular carcinoma. Ann Surg 234:56-62, 2001
PubMed
2) Minagawa M, Makuuchi M, Takayama T, Ohtomo K:Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg 233:379-84, 2001
PubMed
3) 幕内雅敏, 高山忠利, 山崎 普, 長谷川 博:肝硬変合併肝癌治療のStrategy. 外科診療29:1530-1536, 1987
 
4) Imamura H, Seyama Y, Kokudo N, Maema A, Sugawara Y, Sano K, Midorikawa Y, Takayama T, Makuuchi M:One thousand fifty six hepatectomies without mortality through eight years. Arch Surg. (In press).
 
5) Kim YK, Nakano H, Yamaguchi M, Kumada K, Takeuchi S, Kitamura N, Takahashi H, Hasebe S, Midorikawa T, Sanada Y:Prediction of postoperative decompensated liver function by technetium-99m galactosyl-human serum albumin liver scintigraphy in patients with hepatocellular carcinoma complicating chronic liver disease. Br J Surg 84:793-6, 1997
PubMed
6) Miki K, Kubota K, Kokudo N, Inoue Y, Bandai Y, Makuuchi M:Asialoglycoprotein receptor and hepatic blood flow using technetium-99m-DTPA-galactosyl human serum albumin. J Nucl Med 38:1798-807, 1997
PubMed
7) Makuuchi M et al:Safety of hemihepatic vascular occlusion during resection of the liver. Surg. Gynecol. Obstet 164 (2):155-158, 1987
PubMed
8) Serracino-Inglott F, Habib NA, Mathie RT:Hepaticischemia-reperfusion injury. Am J Surg 181 (2):160-6, 2001
 
9) Takayama T et al:Selective and unselective clamping in cirrhotic liver. Hepato-Gastroenterol 45:376-380, 1998
 
10) Clavien PA, Yafav S, Clavien PA, Yadav S et al:Protective effects of ischemic preconditioning for liver resection performed under inflow occlusion in humans. Ann Surg 232 (2):155-62, 2000
PubMed
11) Smyrniotis VE, Kostopanagiotou GG, Gamaletsos EL, Vassiliou JG, Voros DC, Fotopoulos AC, Contis JC:Total versus selective hepatic vascular exclusion in major liver resections. Am J Surg 183:173-8, 2002
PubMed
12) Makuuchi M:Abdominal intraoperative ultra-sonography, Igaku Shoin, 1987
 
13) Takayama T, Makuuchi M:Diagnosis and treatment of hepatocellular carcinoma, Greenwich Medical Media, p 279-294, 1997
 
14) Makuuchi M et al:Ultrasonially guided subsegmentectomy. Surg Gynecol Obstet 164:155-158, 1987
 
15) Makuuchi M et al:Four new hepatectomy procedures for resection of the right hepatic vein and preservation of the inferior right hepatic vein. Surg Gynecol Obstet 164 (1):68-72, 1987
PubMed
16) Kakazu T, Makuuchi M, Kawasaki S, Miyagawa S et al:Reconstruction of the middle hepatic vein tributary during right anterior segmentectomy. Sllrgery 117 (2):238-40, 1995
PubMed
17) Maema A, Imamura H, Takayama T, Sano K et al:Impaired volume regeneration of split livers with partial venous disruption:a latent problem in partial liver transplantation. Transplantation 73 (5):765-9, 2002
PubMed
18) Sano K, Makuuchi M, Miki K, Maema A, Sugawara Y, Imamura H, Matsunami H, Takayama T:Evaluation of hepatic venous congestion:proposed indication criteria for hepatic vein reconstruction. Ann Surg 236 (2):241-7, 2002
PubMed
19) 幕内雅敏:胆管癌に対する肝切前肝内門脈塞栓術. 日臨外会誌45:1558-1564, 1984
 
20) Mazzaferro V, Regalia E, Doci R, Andreola S et al:Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (11):693-9, 1996
PubMed

第7章 肝移植

P.191 掲載の参考文献
1) Mazzaferro V, Regalia E, Doci R et al:Liver Transplantation for The Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis. New Engl J Med 334:693-699, 1996
PubMed
2) O'Grady JD, Polson RJ, Rolles K et al:Liver Transplantation for Malignant Disease. Ann Surg 207:373-379, 1988
 
3) Ringe B, Pichlmayr R, Wittekind C et al:Surgical Treatment of Hepatocellular Carcinoma:Experience with Liver Resection and Transplantation in 198 Patients. World J. Surg 15:270-285, 1991
PubMed
4) Iwatsuki S, Starzl TE, Sheahan DG et al:Hepatic Resection Versus Transplantation for Hepatocellular Carcinoma. Ann Surg 214:221-229, 1991
PubMed
5) Bismuth H, Chiche L, Adam R et al:Surgical Treatment of Hepatocellular Carcinoma in Cirrhosis. Liver Resection or Transplantation? Transplant Proc 25:1066-1067, 1993
 
6) Regalia E, Coppa J, Pulvirenti A et al:Liver Transplantation for Small Hepatocellular Carcinoma in Cirrhosis-Analysis of Our Experience. Transplant proc 33:1442-1444, 2001
PubMed
7) Llovet JM, Fuster J, Bruix J for The Barcelona Clinic Liver Cancer Group:Intention-to-Treat Analysis of Surgical Treatment for Early Hepatocellular Carcinoma. Resection Versus Transplantation. Hepatology 30:1434-1440, 1999
 
8) Yao FY, Ferrell L, Bass NM et al:Liver Transplantation for Hepatocellular Carcinoma:Expansion of the Tumor Size Limits Does Not Adversely Impact Survival. Hepatology 33:1394-1403, 2001
 
9) Marsh W, Dvorchik I,Bonham A et al:Is the Pathologic TNM Staging System for Patients with Hepatoma Predictive of Outcome? American Cancer Society 88:538-543, 2000
 
10) Yao FY, Ferrell L, Bass NM et al:Liver Transplantation for Hepatocellular Carcinoma:Comparison of Proposed UCSF Criteria With the Milan Criteria and the Pittsburgh Modified TNM Criteria. Liver Transplantation 18:765-774, 2002
 
11) Serasin FP, Majno PE, Llovet JM et al:Living Donor Liver Transplantation for Early Hepatocellular Carcinoma. A Life-Expectancy and Cost-Effectiveness Perspective. Hepatology 33:1073-1079, 2001
 
12) Cheng SJ, Pratt DS, Freeman RB et al:Living-Donor Versus Cadaveric Liver Transplantation for Non-Resectable Small Hepatocellular Carcinoma and Compensated Cirrhosis:A Dection Analysis. Transplantation 72:861-868, 2001
 
13) Nagasue N, Galizia G, Kohno H:Adverse effect of preoperative hepatic artery chemoembolization for respectable hepatocellular carcinoma:a retrospective comparison of 138 liver resections. Surgery 196:81-91, 1989
 
14) Schwartz ME, Sung M, Mor E et al:A multi-disciplinary approach to hepatocellular carcinoma in patients with cirrhosis. J Am Coll Surg 180:596-603, 1995
 
15) Majno PE, Adam R, Bismuth H et al:Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients With ciiThosis. Ann. Surg 226:688-703, 1997
PubMed
16) Stone MJ, Klintmalm GB, Polter D et al:Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma:a pilot study in 20 patients. Gastroenterology 104:196-202, 1993
PubMed
17) Roayaie S, Frischer JS, Emre SH et al:Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 235:533-539, 2002
PubMed
18) Yokoyama I, Carr B, Saitsu H et al:Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer 68:2095-2100, 1991
PubMed
19) Vivarelli M, Bellusci R, Cucchetti A et al:Low recurrence rate of hepatocellular carcinoma after liver transplantation:better patient selection or lower immunosuppression? Transplantation 74:1746-1751, 2002
PubMed
20) Guba M, von Breitenbuch P, Steinbauer M et al:Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis:involvement of vascular endothelial growth factor. Nat Med 8:128-135, 2002
PubMed
P.196 掲載の参考文献
1) Angus PW:Review;hepatitis B and liver transplantation. J Gastroenterol Hepatol 12:217-223, 1997
PubMed
2) Tiollais P, Pourcel C, Dejean A:The hepatitis B virus. Nature 317:489-495, 1985
PubMed
3) Samuel D, Muller R, Alexander G et al:Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329:1842-1847, 1993
PubMed
4) Davies SE, Portmann BC, O'Grady JG et al:Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 13:150-157, 1991
 
5) Samuel D, bismuth A, Mathieu D et al:Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 337:813-815, 1993
 
6) Sawyer RG, McGory RW, Gaffey MJ et al:Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 227:841-850, 1998
PubMed
7) Ghany MG, Ayola B, Villamil FG et al:Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 27:213-222, 1998
PubMed
8) Protzer-Knolle U, Naumann U, Bartenschlager R et al:Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 27:254-263, 1998
PubMed
9) Lai CL, Chien RN, Leung NWY et al:A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339:61-68, 1998
 
10) Allen MI, Gauthier J, DesLauriers M et al:Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27:1670-1677, 1998
 
11) Mutimer D, Dusheiko G, Barrett C et al:Lamivudine without HBIg for prevention of graft reinfection by hepatitis B:long-term follow-up. Transplantation 70:809-815, 2000
PubMed
12) Perrillo R, Rakeka J, Dienstag J et al:Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 29:1581-1586, 1999
 
13) Markowitz JS, Martin P, Conrad AJ et al:Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28:585-589, 1998
PubMed
14) 上本伸二, 出中紘ー:肝移植におけるB型肝炎ウイルス感染防止の問題点. Pharma Medica 17:43-47, 1999
 
15) Lo CM, Fan ST, Liu CL et al:Prophylaxis and treatment of recurrent hepatitis B after liver transplantation. Transplantation 75:S 41-S 44, 2003
 
16) Buti M, Mas A, Prieto M et al:A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 38:811-817, 2003
 
17) Sanchez-Fueyo A, Rimola A, Grande L et al:Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination:A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 31:496-501, 2000
PubMed
18) Angelico M, DiPaolo D, Trinito MO et al:Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 35:176-181, 2002
 
19) Terrault NA:Treatment of recurrent hepatitis B infection in liver transplant recipients. Liver Transplantation 8:S 74-S 81, 2002
 
P.201 掲載の参考文献
1) 日本肝移植研究会:肝移植症例登録報告. 移植 37:245-251, 2002
Medical*Online
2) Forman LM, Lewis JD, Berlin JA et al:The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122:889-896, 2002
PubMed
3) Testa G, Crippin JS, Netto GJ et al:Liver transplantation for hepatitis C:recurrence and disease progression in 300 patients. Liver Transpl 6:553-561, 2000
PubMed
4) Berenguer M, Ferrell L, Watson J et al:HCV-related fibrosis progression following liver transplantation:increase in recent years. J Hepatol 32:673-684, 2000
PubMed
5) Berenguer M, Rayon JM, Prieto M et al:Are posttransplantation protocol liver biopsies useful in the long term? Liver Transp 17:790-796, 2001
 
6) Ghobrial RM, Steadman R, Gornbein J et al:A 10-year experience of liver transplantation for hepatitis C:analysis of factors detenmming outcome in over 500 patients. Ann Surg 234:384-393, 2001
 
7) Lim HL, Lau GK, Davis GL et al:Cholestatic hepatitis leading to hepatic failure in a patient, with organ-transmitted hepatitis C virus infection. Gastroenterology 106:248-251, 1994
 
8) Wiesner RH, Rakela J, Ishitani MB et al:Recent advances in liver transplantation. Mayo Clin Pro 78:197-210, 2003
 
9) Charlton M:Hepatitis C infection in liver transplantation. Am J Transplant 1:197-203, 2001
PubMed
10) Narayanan Menon KV, Poterucha JJ, El-Amin OM et al:Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin:lessons on tolerability and efficacy. Liver Transpl 8:623-629, 2002
PubMed
11) Rosen HR, Martin P:Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 66:1612-1616, 1998
PubMed
12) Mazzaferro V, Regalia E, Doci R et al:Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693-699, 1996
PubMed
13) Yao FY, Ferrell L, Bass NM et al:Liver transplantation for hepatocellular carcinoma:expansion of the tumor size limits does not adversely impact survival. Hepatology 33:1394-1403, 2001
 
P.206 掲載の参考文献
1) 川岸直樹, 大河内信宏, 藤盛啓成ほか:肝移植とアフェレシス. 日本アフェレシス学会雑誌20:133-138, 2001
 
2) Orii T, Ohkohchi N, Satomi S et al:Decreasing the Epstein-Barr virus load by adjusting the FK506 blood level. Transpl Int 15:529-534, 2002
PubMed
3) Kano H, Mizuta K, Sakakihara Y et al:Efficacy and safety of immunization for pre-and post-liver transplant children. Transplantation 27:543-550, 2002
 
4) Kasai M, Kimura S, Asakura Y et al:Surgical treatment of biliary atresia J Pediatr Surg 3:665-675, 1968
 
5) 大井龍司:Kasai手術の役割と限界-その現況と将来. 日小外会誌36:21-32, 2000
 
6) 仁尾正記, 大井龍司, 島岡 理ほか:胆道閉鎖症術後長期生存例の問題点-20歳以上症例の検討-. 小児外科 31:291-296, 1999
 
7) 日本肝移植研究会:肝移植症例登録報告. 移植 37:245-251, 2002
Medical*Online
8) 大井龍司, 田中紘-:胆道閉鎖症の治療-葛西手術と肝移植-. 日小外会誌33:1077-1079, 1997
 
9) Kasahara M, Kiuchi T, Inomata Y et al:Living-related liver transplantation for Alagille syndrome. Transplantation 75:2147-2150, 2003
PubMed
10) Kondo S, Hashimoto T, Suzuki T et al:Living related liver transplantation in two Byler disease families. Transplant Proc 32:2185-2186, 2000
PubMed
11) Schilsky ML:Diagnosis and treatment of Wilson's disease. Pediatric Transplantation 6:15-19, 2002
 
12) 池田修一:代謝性疾患の肝移植とQOL. 肝臓 42:76-79, 2001
 
13) Uchino T, Endo F, Matsuda I:Neurodevelopmental outcome of long-term therapy of urea cycle disorders in Japan. J Inherit Metab Dis 21:151-159, 1998
PubMed
14) Mohan N, McKiernan P, Preece MA et al:Indications and outcome of liver transplantation in tyrosinaemia type 1. Eur J Pediatr 158:S 49-S 54, 1999
 
15) Matern D, Starzl TE, Arnaout W et al:Liver transplantation for glycogen storage disease types I, III, and IV. Eur J Pediatr 158:S 43-S 48, 1999
 
16) Shirahata Y, Ohkohchi N, Kawagishi N et al:Living-donor liver transplantation for homozygous familial hypercholesterolemia from a donor with heterozygous hypercholesterolemia. Transpl Int16:276-279, 2003
 
P.211 掲載の参考文献
1) 日本肝移植研究会:肝移植症例登録報告. 日本移植学会雑誌37 (6):245-251, 2002
 
2) Kawasaki S, Hashikura Y, Ikegami T et al:First case of cadaveric liver transplantation in Japan. J Hepatobiliary Pancreat Surg 6:387-390, 1999
PubMed
3) Donckier V, Nakadi IE, Closset J et al:Domino Hepatic Transplantation using the liver from a patient with Primary Hyperoxaluria. Transplantation 71 (9):1346-1347, 2001
 
4) Azoulay D, Smuel D, Casting D et al:Domino liver transplants for metabolic disorders:Experience with familial amyloidotic polyneuropathy. J Am Coll Surg 189 (6):584-593, 1999
 
5) 勝野伸介, 笠原群生, 江川裕人ほか:ドミノ肝移植. 検査と技術 30(4):405-407, 2002
 
6) 安藤正幸, 安東由喜雄:FAP患者の摘出肝臓を用いたドミノ肝移植. 日本医事新報 3921:6-10, 1999
Medical*Online
7) Monteiro E, Perdigoto R, Furtado AL:Liver Transplantation For Familial Amyloid Polyneuropathy. Hepato-Gastroenterology 45:1375-1380, 1998
PubMed
8) Holmgren G, Ericzon BG, Groth CG et al:Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 341:1113-1116, 1993
PubMed
9) Furtado A, Tomel, Oliveikra FT et al:Sequential liver transplantation. Transplant Proc 29:467-468, 1997
 
10) Ikegami T, Kawasaki S, Ohno Y et al:Temporary auxiliary liver transplantation from a living donor to an adult recipient with familial amyloid polyneuropathy. Transplantation 73:628-630, 2002
 
11) Gubernatis G, Pichlmayr R, Kemnitz J et al:Auxiliary partial orthotopic liver transplantation (APOLT) for fulminant hepatic failure:First successful case report. World J Surg 15:660-666, 1991
PubMed
12) 小崎浩-, 江川裕人, 笠原群生ほか:自己肝温存同所生部分肝移植. 手術 57(3):261-268, 2003
 
13) 副島雄二, 杉町圭蔵:術式, ドミノ肝移植, Split liver transplantation. 日本外科学会雑誌 103 (5):423-427, 2002
 
14) 池上俊彦, 浦田浩-, 中澤勇-ほか:ドミノ肝移植.手術 57(3):253-260, 2003
 
15) Inomata Y, Nakamura T, Uemoto S et al:Domino Split-Liver transplantation from a living donor:Case reports of In Situ and Ex Situ splitting Liver. Transplantation 7(2):150-153, 2001
PubMed
16) Stangou AJ, Heaton ND, Rela M et al:Domino hepatic transplantation using the liver from a patient with familial amyloid polyneuropathy. Transplantation 65(11):1496-1498
 
17) 上本伸二:始まったドミノ肝移植-これからの課題. 外科治療82 (2):185-188, 2000
 
18) Hemming AW, Cattral MS, Chari CR et al:Domino liver transplantation for familial amyloid polyneuropathy. Liver transplantation and Surgery 4(3):236-238, 1998
 

第8章 胆道疾患と胆石症

P.216 掲載の参考文献
1) 谷村 弘, 小林展章, 小澤和恵:急性胆嚢炎と細菌感染. 胆と膵 6:1459-1465, 1985
 
2) 斧 康雄, 西谷 肇, 國井乙彦:難治性胆道感染症. 日本臨牀 (特別号) 46:373-382, 1988
 
3) 神田和亮, 古井純-郎, 兼松隆之:肝胆道感染症. 臨床と研究73:543-546, 1996
 
4) 松崎純宏, 兼松隆之, 宮崎義継ほか:肝.胆道系感染症. 化学療法の領域16:157-162, 2000
 
5) 寺西卓也, 岡本良之, 畑 憲幸ほか:MRSAが一次起因菌と思われる有石胆嚢炎に毒素性ショック症候群を発症した1例. 日消誌99:165-169, 2002
 
6) 羽生富士夫, 中村光司, 鈴木 衛:急性胆嚢炎の外科的治療. 胆と膵6:1525-1530, 1985
 
7) 初瀬一夫, 小野 聡, . 玉熊正悦:急性閉塞性化膿性胆管炎の病態と診断. 胆と膵16:563-568, 1995
 
8) Jorge A Soto, Matthew A Barish, E Kent Yucel et al:Magnetic resonance cholangiography:comparison with endoscopic retrograde cholangio-pancreatography. Gastroenterology 110:589-597, 1996
 
9) 土屋涼一, 井沢邦英, 織部孝史:急性閉塞性化膿性胆管炎の病態. 胆と膵1:961-970, 1980
 
10) McMahon AJ, Fischbacher CM, Frame SH et al:Impact of laparoscopic cholecystctomy:a population-based study. Lacet 356:1632-1637, 2000
 
11) Madan AK, Aliabadi-Wahle S, Tesi D et al:How early Is early laparoscopic treatment of acute cholecystitis? Am J surg 183:232-236, 2002
PubMed
12) 徳村弘実, 鹿郷昌之, 原田伸彦ほか:急性胆嚢炎に対する腹腔鏡下胆嚢摘除術早期手術と待機手術と PTGBDの比較. 消化器内視鏡14:1064-1069, 2002
 
13) Prakash K, Jacob G, Lekha V et al:Laparoscopic cholecystectomy In acute cholecystitis. Surg Endosc 16:180-183, 2001
PubMed
14) Van Lent AU, Bartelsman JF, Tytgat GN et al:Duration of antibiotic therapy for cholangitis after successful endoscopic drainage of the biliary tract. Gastrointest Endosc 55:518-522, 2002
PubMed
15) Chak A, Cooper GS, Lloyd LE et al:Effectiveness of ERCP In cholangitis:a community-based study. Gastrointest Endosc 52:484-489, 2000
PubMed
16) Hui CK, Lai CK, Yuen MF et al:Acute cholangitis-predictive factors for emergency ERCP. Aliment Pharmacol 15:1633-1637, 2001
 
17) Lee DW, Chan AC, Lam YH et al:Biliary decompression by nasobiliary catheter or biliary stent In acute suppurative cholangitis:a prospective randomized trial. Gastrointest Endosc 56:361-365, 2002
PubMed
18) Shrma VK, Howden CW:Metaanalysis of randomized controlled trials of endoscopic retrograde cholangiography and endoscopic sphincterotomy for the treatment of acute billiary pancreatitis. Am J Gastroenterol 94:3211-3214, 1999
 
19) Folsch UR, Nitsche R, Ludtke R et al:Early ERCP and papillotomy compared with conservative treatment for acute biliary pancreatitis. The German Study Group on Acute Biliary Pancreatitis. N Engl J Med 336:237-242, 1997
 
20) 急性膵炎の診療ガイドライン作成委員会, 日本腹部救急医学会, 日本膵臓学会, 厚生労働省特定疾患対策研究事業難治性膵疾患に関する調査研究班:エビデンスに基づいた急性膵炎の診療ガイドライン. 第1版, 金原出版, 東京, p81-86, 2003
 
P.219 掲載の参考文献
1) Hogan WJ, Geenen JE:Biliary dyskinesia. Endoscopy 20 Suppl 1:179-183, 1988
PubMed
2) Evans PR, Dowsett JF, Bak YT et al:Abnormal sphincter of Oddi response to cholecystokinin in postcholecystectomy syndrome patients with irritable bowel syndrome. The irritable sphincter. Dig Dis Sci 40:1149-1156, 1995
PubMed
3) Park SH, Watkins JL, Fogel EL et al:Long-term outcome of endoscopic dual pancreatobiliary sphincterotomy in patients with manometry-documented sphincter of Oddi dysfunction and normal pancreatogram. Gastrointest Endosc 57:483-491, 2003
PubMed
4) Kloiber R, Molnar CP, Shaffer EA:Chronic biliary-type pain in the absence of gallstones:the value ofcholecystokinin cholescintigraphy. AJR 159:509-513, 1992
PubMed
5) Craig AG, Peter D, Saccone GT et al:Scintigraphy versus manometry in patients with suspected biliary sphincter of Oddi dysfunction. Gut 52:352-357, 2003
PubMed
6) Toouli J, Roberts Thomson IC et al:Manometric disorders in patients with suspected sphincter of Oddi dysfunction. Gastroenterology 88:1243-1250, 1985
PubMed
7) Yost F, Margenthaler J, Presti M et al:Cholecystectomy is an effective treatment for biliary dyskinesia. Am J Surg 178:462-465, 1999
PubMed
8) Freeman ML, Nelson DB, Sherman S et al:Complications of endoscopic biliary sphincterotomy. N Engl J Med 335 (13):909-918, 1996
PubMed
9) Desautels SG, Slivka A, Hutson WR et al:Postcholecystectomy pain syndrome:pathophysiology of abdominal pain in sphincter of Oddi type III. Gastroenterology 116:900-905, 1999
PubMed
10) Tarnasky PR:Mechanical prevention of post-ERCP pancreatitis by pancreatic stents:results, techniques, and indications. JOP 4:58-67, 2003
PubMed
11) Toouli J, Roberts Thomson IC, Kellow J et al:Manometry based randomised trial of endoscopic sphincterotomy for sphincter of Oddi dysfunction. Gut 46:98-102, 2000
PubMed
P.224 掲載の参考文献
1) Diem HV, Evrard V, Vinh HT et al:Pediatric liver transplantation for biliary atresia:results of primary grafts in 328 recipients. Transplantation 75:1692-1697, 2003
PubMed
2) 戸谷拓二:先天性胆道拡張症の定義と分類. 胆と膵 16:715-717, 1995
Medical*Online
3) Vogel SB, Howard RJ et al:Evaluation of percutaneous transhepatic balloon dilatation of benign biliary strictures in high-risk patients. Am J Surg 149:73-79, 1985
PubMed
4) 森田荘二郎:良性胆道狭窄. 消化器病セミナー 70:153-164, 1998
 
5) Lopez Jr. RR, Cosenza CA, Lois J et al:Long-term results of metallic stents for benign biliary strictures. Arch Surg 136:664-669, 2001
 
6) Schwartz SL, Dale WA:Primary sclerosing cholangitis;review and report of six cases. Arch Surg 77:439-451, 1958
 
P.227 掲載の参考文献
1) Sandblom P:Hemorrhage into biliary tract following trauma."Traumatic hemobilia". Surgery 24:571-586, 1948
PubMed
2) Sandblom P, Mirkovitch V:Hemobilia:some salient features and their causes. Surg Clin North Am 57:397-408, 1977
PubMed
3) 谷村 弘, 笠野泰生, 野口浩平:胆-出血の診断と治療, 綜合臨床43:2450-2454, 1994
 
4) Hayashi N, Sakai T, Tagawa K:Metal US-guided left-sided biliary drainage:nine-year experience. Radiology 204:119-122, 1997
 
5) Corr P, Smit J, Hedley GP:An unusual case of haemobilia:biliary ascariasis. pediatr Radiol 27:348-349, 1997
 
6) Sandblom P, Mirkovitch V:Minor hemobilia clinical significance and pathophysiological back ground. Ann Surg 190:254-264, 1979
 
7) Monden M, Okamura J, Kobayashi N:Hemobilia after percutaneous transhepatic biliary drainage. Arch Surg 115:161-164, 1980
PubMed
8) 峯 徹哉, 飛田浩輔, 大谷泰雄:Vater乳頭部よりどんどん流出してくるHemobilia. 消化器内視鏡 15:260-262, 2003
 
P.232 掲載の参考文献
1) Yamagiwa H, Tomiyama H:Intestinal metaplasia-dysplasia-carcinoma sequence of the gallbladder. Acta Pathol Jpn 36:989-997, 1986
PubMed
2) Kozuka S, Tsubone N, Yasui A et al:Relation of adenoma to carcinoma in the gallbladder. Cancer 50:2226-2234, 1982
PubMed
3) 高木 進:膵.胆管合流異常症例の臨床的ならびに胆嚢粘膜の病理組織学的研究. 東京医科大学雑誌 47:3-17, 1989
Medical*Online
4) Hanada K, Itoh M, Fujii K et al:Pathology and cellular kinetics of gallbladder with an anomalous junction of the pancreaticobiliary duct. Am J Gastroenterol 91:1007-1011, 1996
PubMed
5) Kaneko K, Ando H, Ito T, Kasai K et al:Increased cell proliferation and transfouming growth factor-alpha (TGF alpha) in the gall-bladder epithelium of patients with pancreaticobiliary maljunction. Pathol Int 46:p253-260, 1996
 
6) Tokiwa K, Iwai N:Early mucosal changes of the gallbladder in patients with anomalousarrangement of the pancreaticobiliary duct. Gastroenterology 110:1614-1618, 1996
PubMed
7) Elfving G, Lehtonen T, Teir H:Clinical significance of primary hyperplasia of gallbladder mucosa. Ann Surg 165:61-69, 1967
PubMed
8) 五十嵐裕章:膵・胆管合流異常における胆嚢壁の特徴的変化に関する研究画像および病理組織学的所見について. 胆道5:517-525, 1991
 
9) Yamamoto M, Nakajo S, Tahara E et al:Mucosal changes of the gallbladder in anomalous union with the pancreatico-biliary duct system. Pathol Res Pract 187:241-246, 1991
PubMed
10) Iwase T, Nakazawa S, Yamao K et al:Ras gene point mutations in gallbladder lesions associated with anomalous connection of pancreatobiliary ducts. Hepatogastroenterology 44:1457-1462, 1997
PubMed
11) Tanno S, Obara T, Fujii T et al:Proliferative potential and K-ras mutation in epithelial hyperplasia of the gallbladder in patients with anomalous pancreaticobiliary ductal union. Cancer 83:267-275, 1998
 
12) Tanno S, Obara T, Fujii T et al:Epithelial hyperplasia of the gallbladder in children with anomalous pancreaticobiliary ductal union. Hepatogastroenterology 46:3068-3073, 1999
PubMed
13) Celoria GC, Rodrigues Otero JC, Proske SA et al:Papillary hyperplasia and cholesterolosis of the gallbladder. Medicina (B Aires) 54:31-34, 1994
 
14) 野口明宏:膵.胆管合流異常症例における胆道上皮の細胞動態 Bromodeoxyuridine (BrdU) モノクローナル抗体を利用した解析. 日本消化器外科学会 21, 210-220, 1988
 
15) Yang Y, Fujii H, Matsumoto Y et al:Carcinoma of the gallbladder and anomalous arrangement of the pancreaticobiliary ductal system:cell kinetic studies of gallbladder epithelial cells. J Gastroenterol 32:801-807, 1997
PubMed
16) Kamel D, Paakko P, Nuorva K et al:p 53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder. J Pathol 170:67-72, 1993
 
17) Ohashi K, Tstsumi M, Nakajima Y et al:Ki-ras point mutations and proliferation activity in biliary tract carcinomas. Br J Cancer 74:930-935, 1996
PubMed
18) Hanada K, Itoh M, Fujii K et al:K-ras and p 53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Cancer 77:452-458, 1996
 
19) Tomono H, Nimura Y, Aono K et al:Point mutations of the c-Ki-ras gene in carcinoma and atypical epithelium associated with congenital biliary dilation. Am J Gastroenterol 91:1211-1214, 1996
 
20) Matsubara T, Sakurai Y, Sasayama Y et al:K-ras point mutations in cancerous and noncancerous biliary epithelium in patients with pancreati-cobiliary maljunction, Cancer 77:1752-1757, 1996
 
21) Itoi T, Watanabe H, Yoshikawa T et al:K-ras mutations in gallbladder carcinomas in patients with anomalous arrangement of the pancreaticobiliary duct. Acta Med Biol 44:71-77, 1996
 
22) Wistuba II, Gazdar AF, Roa I et al:p 53 protein overexpression in gallbladder carcinoma and its precursor lesions:an immunohistochemical study. Hum Pathol 27:360-365, 1996
 
23) Matsubara T, Funabiki T, Jinno O et al:p 53 gene mutations and overexpression of p 53 product in cancerous and noncancerous biliary epithelium in patients with pancreaticobiliary maljunction. J Hepatobiliary Pancreat Surg 6:286-293, 1999
 
24) Shimotake T, Aoi S, Tomiyama H et al:DPC-4 (Smad-4) and K-ras gene mutations in biliary tract epithelium in children with anomalous pancreaticobiliary ductal union. J Pediatr Surg 38:694-697, 2003
 
25) Nagai M, Watanabe M, Iwase T et al:Clinical and genetic analysis of noncancerous and cancerous biliary epithelium in patients with pancreaticobiliary maljunction. World J Surg 26:91-98, 2002
PubMed
26) Tsuchida A, Nagakawa Y, Kasuya K et al:Immunohistochemical analysis of cyclooxygenase-2 and vascular endothelial growth factor in pancreaticobiliary maljunction. Oncol Rep 10:339-343, 2003
PubMed
27) Fumino S, Tokiwa K, Ono S et al:Cyclooxygenase-2 expression in the gallbladder of patients with anomalous arrangement of the pancreaticobiliary duct. J Pediatr Surg 38:585-589, 2003
PubMed
28) Watanabe Y, Toki A, Todani T:Bile duct cancer developed after cyst excision for choledochal cyst. J Hepatobiliary Pancreat Surg 6:207-212, 1999
PubMed
29) Hakamada K, Sasaki M, Endoh M:Late development of bile duct cancer after sphincteroplasty:a ten-to twenty-two-year follow-up study. Surgery 121:488-492, 1997
 
30) Strong RW:Late bile duct cancer complicating biliary-enteric anastomosis for benign disease. Am J Surg 177:472-474, 1999
PubMed
31) Kusano T, Isa T, Tsukasa K et al:Long-term results after cholecystectomy alone for patients with pancreaticobiliary maljunction without bile duct dilatation. Int Surg 87:107-113, 2002
PubMed
P.237 掲載の参考文献
1) Danzinger RG, Hofmann AF, Schoenfield LJ et al:Dissolution of cholesterol gallstone by chenodeoxycholic acid. N Eng J Med 286:1-8, 1972
 
2) 菅出文夫, 清水盈行:胆石陰影消失例の再検討. 日消誌 71:75-80, 1974
 
3) Nakagawa S, Makino I, Ishizaki T et al:Dissolution of cholesterol gallstones by ursodeoxycholic acid. Lancet 2:367-369, 1977
PubMed
4) ±屋幸浩, 大藤正雄, 矢澤孝文:超音波による胆石の種類と診断. 胆と膵7:1483-1491, 1986
 
5) Ohkuni K:New attempts using computed tomography in determining indication of gallstone dissolution therapy. Acta Med Biol 34:139-151, 1987
 
6) Walters JRF, Hood KA, Clesson D et al:Combination therapy with oral ursodeoxycholic and chenodeoxycholoc acids:pretreatment computed tomography of the gallbladder improves gall stone dissolution efficacy. Gut 33:375-380, 1992
 
7) Pereira SP, Veysey MJ, Kennedy C et al:Gallstone dissolution with oral bile acid therapy. Importance of pretreatment CT scanning and reasons for nonresponse. Dig Dis Sci 42:1775-1782, 1997
PubMed
8) 安部井誠人, 富田慎二:胆嚢結石に対するウルソデオキシコール酸 (UDCA) 長期投与の溶解効果と胆石発作抑制効果-長期経過観察例との対比. 胆道10:56, 1996
 
9) May GR, Sutherland LR, Shaffer EA:Efficacy of bile acid therapy for gallstone dissolution:a meta-analysis of randomized trials. Aliment Pharmacol Ther 7:139-148, 1993
PubMed
10) 大菅俊明:Urso therapyの現況. Tokyo Tanabe Quaeterly, 臨時増刊:82-87, 1986
 
11) 富田慎二, 田中直見, 正田純一ほか:経口的胆石溶解療法とESWLの適応基準, 胆道7:368, 1993
 
12) 高梨秀樹, 土屋幸浩, 大藤正雄:経口胆汁酸溶解療法のESWLとの比較による適応の再検討, 胆道 8:404-410, 1994
Medical*Online
13) Dowling RH:Gallstone prevention after successful treatment. Ulm Spling Meeting on Gallstone Disease:42-44, 1989
 
14) 田妻 進:胆嚢結石の治療:胆嚢温存療法, 田中 直見編集:図説消化器病シリーズ13, 胆道疾患, メジカルビュー社, 東京, p 60-69, 2000
 
15) Hood KA, Gleeson D, Ruppin DC et al:Gall stone recurrence and its prevention:the British/Belgian gall stone study group:s post dissolution trial. Gut 34:1277-1288, 1993
 
16) Tomida S, Abei M, Yamaguchi T et al:Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones;Acohot analysis. Hepatology 30:6-13, 1999
PubMed
17) Giovannucci E, Colditz GA, Stampeer MJ:Ameta-analysis of cholecystectomy and risk of colorectal cancer. Gastroenterology 105:130-141, 1993
 
18) Fort JM, Azpiroz F, Casellas F et al:Bowel habit after cholecystectomy:Physiological changes and clinical implications. Gastroenterology l l l:617-622, 1996
 
19) 花乃木睦己, 春間 賢, 畠 二郎ほか:胆嚢摘出の胃+二指腸運動に及ぼす影響, 消化器科23:535-541, 1996
 
20) Thistle JL, May GR, Bender CE et al:Dissolution of cholesrerol gallbladder stome by methyl tert-butyl ether administered by percutaneous transhepalic catheter. N Engl J Med 320:633-639, 1989
 
21) 安部井:誠人, 冨永達郎, 池田和穂ほか:経皮経肝胆嚢ドレナージ後のMTBE直接胆石溶解療法が奏功した高齢急性胆嚢炎合併多発大胆嚢結石の1例, 胆道16:73-78, 2002
 
P.243 掲載の参考文献
1) 谷村 弘, 石原扶美武, 小林展章ほか:日本胆道学会胆石調査プロジェクトニ1997年度胆石全国調査報告. 胆道12:276-293, 1998
 
2) 谷村 弘ほか:外科からみた胆嚢結石症の手術適応. 胆と膵11:1031-1036, 1990
 
3) 阿部展次, 森 俊幸, 跡見 裕:胆嚢摘出術.総胆管切石術. 消化器外科 25:1136-1144, 2002
 
4) 斎藤和好:胆石症の手術. 消化器外科 18:265-273, 1995
 
5) 佐々木 純, 中村 朗, 斎藤和好ほか:われわれの工夫した鉤引き助手のいらない胆摘用手形開創鉤. 手術 35:1467-1469, 1981
 
6) Anderson JE:Variations in the origin and course of the cystic artery. In Grant's Atlas of Anatomy. 8th ed, Williams&Wilkins, Baltimore:2-56, 1983
 
7) Smajda C, Blumgart H:The biliary tract and the anatomy of biliary exposure. In Surgery of the Liver and Biliary, ed by Blumgart H,1st ed, Churchill Livingstone, New York Tract vol.1:11-22, 1988
 
8) Millboum EW:On the importance of the remnant cystic duct in the development of postoperative biliary distress following cholecystectomy. Acta Chir Scand 100:448-495, 1950
 
9) 出月康夫:内視鏡外科手術に関するアンケート調査-第6回集計結果報告-. 日鏡外会誌 7:479-494, 2002
 
10) 佐々木 章, 旭 博史, 斎藤和好ほか:腹腔鏡下胆嚢摘出術. 手術 58:2004 (投稿中)
 
P.248 掲載の参考文献
1) 相馬 智, 立川 勲, 岡本弘泰ほか:内視鏡的乳頭切開術および遺残胆道結石摘出の試み. Gastroenterol Endosc 16:446-452, 1974
 
2) Kawai K, Akasaka Y Murakami K et al:Endoscopic sphincterotomy of the ampulla of Vater. Gastrointest Endosc 20:148-151, 1974
PubMed
3) Class M, Demling L:Endoskopische Sphinktero-tomie der Papilla Vateri und Steinextraktion aus dem Ductus Choledochus. Dtsch med Wschr 99:496-497, 1974
 
4) Staritz M, Ewe K, Meyer zum, Buschenfelde KH:Endoscopic papillary dilatation:an alternative to papillotomy?Dtsch Med Wschr 107:895-897, 1982
PubMed
5) Bergman JJ, GHM Rauws, EAJ Fockens P et al:Randomized trial of endoscopic balloon dilation versus endoscopic sphincterotomy for removal of bile duct stones. Lancet 349:1124-1129, 1997
 
6) Komatsu Y, Kawabe T, Toda N:Endoscopic papillary balloon dilatation for the management of common bile duct stones:experience of 226 cases. Endoscopy 30:12-17, 1998
 
7) Yasuda I, Tomita E, Moriwaki H et al:Endoscopic papillary balloon dilatation for common bile duct stones:efficacy of combination:with extracorporal shock wave lithotripsy for large stones. Eur. J. Gastroenterol Hepatol 10:1045-1050, 1998
 
8) Demling L, Seuberth K, Riemann JF:A Medichanical Lithotripter. Endoscopy l 4:100-101, 1982
 
9) Tanaka M, Yoshimoto H, Ikeda S et al:Tow approaches for electrohydraulic lithotripsy in the common bile duct. Surgery 98:313-318, 1985
 
10) Matsumoto S, Ikeda S, Tanaka M et al:Nonoperative removed of giant common bile duct calculi. Am J Surg 155:780-782, 1988
PubMed
11) 神津照雄, 山崎義和, 竜崇正ほか:胆道結石砕石におけるLaser Endoscopyの効果と限界. 日レーザー医学会誌3:39-46, 1982
 
12) 小越和栄:ワイヤーガイド下乳頭括約筋切開術と胆石除去術. 消化器内視鏡のコツと落とし穴, 第 1版. 中山書店, 東京, p 80-81, 1997
 
13) Martin DF, England R, Martin O:The safety sphincterotome:The device, the technique and preliminary results. Endoscopy 30:375-378, 1998
PubMed
14) 真口宏介, 高橋邦幸, 潟沼郎生ほか:Rapid Exchange Biliary System による総胆管結石の治療:臨床消化器内視鏡16 (9), 2001
 
15) Minami A, Maeta T, Kohi F et al:Endoscopic papillary dilation balloon and isosorbide dinitrate drip infusion for removing bile duct stones. Scand J Gastroenterol 33:765-768, 1998
PubMed
16) 有里智志, 中野靖弘, 吉田暁正ほか:EPBD の拡張時間の検討-バルーン拡張時間120秒と10秒の検討. 日消誌96:A O95, 1999
 
17) Cotton PB, Lehman G, Vennes J etal:Endoscopic sphincterotomy complications and their management:an attempt at consensus. Gastrointest Endosc 37:383-393, 1991
PubMed
18) Freeman ML, Nelson DB, Sherman S et al:Complications of endoscopic biliary sphincterotomy. N Engl J Med 335:909-918, 1996
PubMed
19) Ell C, Hochberger J, May A et al:Laser lithotripsy of difficut bile duct stones by means of a rhodamine-6G laser and an integrated automatic stone-tissue detection system. Gastrointest Endosc 39:755-762, 1993
 
P.253 掲載の参考文献
1) Sauerbruch T, Delius M, Paumgartner G et al:Fragmentation of gallstones by extracorporeal shock waves:N Engl J Med 324:818-822, 1986
 
2) Sackmann M, Niller H, Klueppelberg U et al:Gallstone recurrence rate after successful shockwave therapy. Gastroenterology 106:225-230, 1994
 
3) Becker CD, Fache JS, Gibney MB et al:Choledochohthiasis;Treatment with extracorporeal shock wave lithotripsy. Radiology 165:407-408, 1987
 
4) 土屋幸浩:体外衝撃波胆石破砕療法. 岡 博, 和田 攻編二医科学大辞典補遺8, 講談社, 東京 168, 1991
 
5) 深井利花, 山口嘉和:無症状結石の症状出現率と治療法の選択. 消化器科29:322-327, 1999
 
6) 山口嘉和, 斎藤昌三, 西山正孝ほか:肋骨上テーピングによるESWL施行時の疾痛の予防. 胆道 5:558-561, 1991
 
7) 内山和久, 谷村 弘, 石本喜和男ほか:体外衝撃波結石破砕装置による胆石の治療に関する全国調査と今後の展望. 胆と膵15:571-576, 1994
 
8) 埴谷一夫, 土屋幸浩, 大藤正雄:胆嚢胆石体外衝撃波破砕療法における治療効果の予測因子に関する研究. 胆道9:44-46, 1995
 
9) 平田信人, 藤田力也, 菅田文夫:体外衝撃波胆石破砕慮法-現況と問題点-. 胆と膵14:1-5, 1993
 
10) 深井利花, 西山正孝, 両角克朗:肝内結石.総胆管結石に対するESWL. 胆と膵17:361-364, 1996
 
11) 山口嘉和, 斎藤昌三, 西山IE孝:体外衝撃波による総胆管結石の治療. 超音波医学18:60-66, 1991
 
12) 山口嘉和, 深井利花, 角出 仁:胆石治療におけるESWLの適応と成績. 臨床と研究75:29-33, 1998
 

第9章 胆道癌の治療

P.257 掲載の参考文献
1) Suzuki M, Takahashi T, Ouchi K, Matsuno S:The development and extension of hepatohilar bile duct carcinoma. A three-dimensional tumor mapping in the intrahepatic biliary tree visualized with the aid of a graphics computer system. Cancer64 (3):658-666, 1989
PubMed
2) Titus JA, Garrido MA, Hecht T T et al:Human Tcells targeted with anti-T3 cross-linked toantitumor antibody prevent tumor growth in nude mice. J Immunol 138 (11):4018-4022, 1987
 
3) Saijyo S, Kudo T, Katayose Y et al:Anew in Vitromodel of specific targeting therapy of cancer:retargeting of PWM-LAK cells with bispecific antibodies greatly enhances cytotoxicity tohepatocellular carcinoma. Tohoku J Exp Med l 78 (2):113-127, 1996
 
4) Hinoda Y, Arimura Y, Itoh F et al:Primary structure of the variable regions of a monoclonal antibody MUSE11 recognizing the tandem repeat domain of a mucin core protein, MUC1. J Clin Lab Anal 7 (2):100-104, 1993
PubMed
5) Saijyo S, Kudo T, Suzuki M et al:Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med 177 (1):61-71, 1995
PubMed
6) Katayose Y, Kudo T, Suzuki M et al:MUC1-specific targeting immunotherapy with bispecific antibodies:inhibition of xenografted human bile duct carcinoma growth. Cancer Res56 (18):4205-4212, 1996
PubMed
7) Kodama H, Suzuki M, Katayose Y et al:Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies. Immunol Lett 81 (2):99-106, 2002
PubMed
8) Boss MA, Kenten JH, Wood CR, Emtage JS:Assembly of functional antibodies from immunoglobulin heavy and light chains synthesised in E. coli. Nucleic Acids Res 12 (9):3791-3806, 1984
 
9) Holliger P, Prospero T, Winter G."Diabodies":small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A 90 (14):6444-6448, 1993
PubMed
10) Takemura S, Asano R, Tsumoto K et al:Functional Fv fragment of an antibody specific for CD28:Fv-mediated co-stimulation of T cells. FEBS Lett 476 (3):266-271, 2000
PubMed
11) Shinoda M, Kudo T, Suzuki M et al:Effective adoptive immunotherapy by T-LAK cells retargeted with bacterial superantigen-conjugated antibody to MUCI in xenografted severe combined immunodeficient mice. Cancer Res 58 (13):2838-2843, 1998
 
12) Sakurai N, Kudo T, Suzuki M et al:SEA-scFv as a bifunctional antibody:construction of a bacterial expression system and its functional analysis. Biochem Biophys Res Commun 256 (1):223-230, 1999
PubMed
13) Takemura S, Kudo T, Asano R et al:A mutated superantigen SEA D227A fusion diabody specific to MUCl and CD3 in targeted cancer immunotherapy for bile duct carcinoma. Cancer Immunol Immunother 51 (1):33-44, 2002
 
14) Klijn JG, Berns PM, Schmitz PI, Foekens JA:The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer:a review on 5232 patients. Endocr Rev 13 (1):3-17, 1992
PubMed
15) Niikura H, Sasano H, Sato S, Yajima A:Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Int J Gynecol Pathol 16 (1):60-68, 1997
PubMed
16) Mendelsohn J, Baselga J:The EGF receptor family as targets for cancer therapy. Oncogene 19 (56):6550-65, 2000
 
17) Salomon DS, Brandt R, Ciardiello F, Nonmanno N:Epidernlal growth factor-related peptides and their receptors in human malignancies. C. rit Rev Oncol Hematol 19 (3):183-232, 1995
 
18) Nonomura A, Ohta G, Nakanuma Y et al:Simultaneous detection of epidermal growth factor receptor (EGF-R), epidermal growth factor (EGF) and ras p 21 in cholangiocarcinoma by an immunocytochemical method. Liver 8 (3):157-166, 1988
 
19) Kawamoto T, Sato JD, Le A et al:Growth stimulation of A431 cells by epidermal growth factor:identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A 80 (5):1337-1341, 1983
PubMed
P.263 掲載の参考文献
1) Pisters PW, Hudec WA, Hess KR et al:Effect of preoperative biliary decompression on pancrea-ticoduodenectomy-Associated morbidity in 300 consecutive patients. Ann Surg 234:47-55, 2001
 
2) Nimura Y, Hayakawa N, Kamiya J et al:Staging of biliary carcinoma:Cholangiography and cholangioscopy. Endoscopy 25:76-80, 1993
 
3) Kitagawa Y, Nagino M, Kamiya J et al:Lymph node metastasis from hilar cholangiocarcinoma:Audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg 233:385-392, 2001
PubMed
4) Kondo S, Nimura Y, Hayakawa N et al:Regional and paraaortic lymphadenectomy in radical surgery for advanced gallbladder carcinoma. Br J Surg 87:418-422, 2000
 
5) Uesaka K, Nimura Y, Nagino M:Changes in hepatic lobar function after right portal vein embolization. Ann Surg 223:77-83, 1996
PubMed
6) Nimura Y, Hayakawa N, Kamiya J et al:Hepatic segmentectomy with caudate lobe resection for bile duct carcinoma of hepatic hilus. World J Surg 14:535-544, 1990
PubMed
7) Nagino M, Nimura Y, Kamiya J et al:Segmental liver resections for hilar cholangiocarcinoma. Hepatogastroenterology 45:7-13, 1998
PubMed
8) Yamaguchi R, Nagino M, Oda K et al:Perineural invasion has a negative impact on survival of patients with gallbladder carcinoma Br J Surg 89:1130-1136, 2002
 
9) Nagino M, Kamiya J, Kanai M et al:Hepaticojejunostomy using a Roux-en-Y jejunal limb via the retrocolic-retrogastric route. Langenbeck's Arch Surg 387:188-189, 2002
 
10) Ebata T, Nagino M, Kamiya J et al:Hepatectomy with portal vein resection for hilar cholangiocarcinoma:Audit of 52 consecutive cases. Ann Surg (in press)
 
11) Nimura Y, Hayakawa N, Kamiya J et al:Hepatopancreatoduodenectomy for advanced carcinoma of the biliary tract. Hepato-gastroenterology 38:170-175, 1991
PubMed
12) Pichlmayr R, Weimann A, Klempnauer J et al:Surgical treatment in proximal bile duct carcinoma:A single-center experience. Ann Surg 224:628-638, 1996
PubMed
13) Iwatsuki S, Todo S, Marsh JW et al:Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 187:358-364, 1998
PubMed
14) Neuhaus P, Jonas S, Bechstein WO et al:Extended resection for hilar cholangiocarcinoma. Ann Surg 230:808-819, 1999
PubMed
15) Cherqui D, Benoist S, Malassagne B et al:Major liver resection for carcinoma in jaundiced patients without preoperative biliary drainage. Arch Surg 135:302-308, 2000
PubMed
16) Makuuchi M, Thai BL, Takayasu K et al:Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma. Surgery lO7:521-527, 1990
 
17) Nagino M, Nimura Y, Kamiya J et al:Selective percutaneous transhepatic embolization of the portal vein in preparation for extensive liver resection:The ipsilateral approach. Radiology 200:559-563, 1996
PubMed
18) Nagino M, Nimura Y, Kamiya J et al:Right or left trisegment portal vein embolization before hepatic trisegmentectomy for hilar bile duct carcinoma. Surgery 117:677-681, 1995
 
19) Kyokane T, Nagino M, Sano T et al:Ethanol ablation for segmental bile duct leakage after hepatobiliary resection. Surgery 131:111-113, 2002
PubMed
P.268 掲載の参考文献
1) 永川宅和, 旦原正都:胆道癌治療成績からみた胆道癌治療の実態. 胆道14:23-28, 2000
 
2) Mani S, Sciortino D, Samuels B et al:Phase II trialof uracil/tegafur (UFT) plus leucovorin inpatients with advanced biliary carcinoma. Invest New Drugs 17:97-101, 1999
 
3) Malik IA, Aziz Z:Prospective evaluation of efficacy and toxicity of 5-FU and folinic acid (Mayo clinic regimen) in patients with advanced cancer of the gallbladder. Am J Clin Oncol 26:124-126, 2003
 
4) Patt YZ, Jones Jr DV, Hoque A et al:Phase II trialof intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 14:2311-2315, 1996
 
5) Chen JS, Jan YY, Lin YC et al:Weekly 24 h infusionof high-dose 5-fluorouracil and leucovorin inpatients with biliary tract carcinomas. Anticancer Drugs 9:393-397, 1998
 
6) Gabia V, Majello E, Testa A et al:Treatment of adenocarcinomas of the exocrine pancreas and gallbladder with 5-fluoruracil, high dose levoflolinic acid and oral hydroxyurea on weekly schedule. Cancer 78:1300-1307, 1996
 
7) 0kada S, Ishii H, Nose H et al:A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology 51:515-517, 1994
PubMed
8) Taal BG, Audisio RA, Bleiberg H et al:Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC gastrointestinal tract cancer cooperative group study. Ann Oncol 4:607-609, 1993
 
9) Jones Jr DV, Lozano R, Markowitz A et al:Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 14:2306-2310, 1996
 
10) Pazdur R, Royce ME, Rodriguez GI et al:Phase II trial of docetaxel for cholangiocarcinomas. Am J CIin Oncol 22:78-81, 1999
 
11) Papakostas P, Kouroussis Ch, Androulakis N et al:First-line chemotherapy with docetaeel for unresectable or metastatic carcinoma of biliary tract. A multicenter phase II study. Eur J Cancer 37:1833-1838, 2001
PubMed
12) Raderer M, Hejna MHL, Valencak JB et al:Two consecutive phse II studies of 5-fluorouracil / leucovorin / mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 56:177-180, 1999
 
13) Gallado JO, Rubio B, Fodor M et al:A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 12:1403-1406, 2001
 
14) Penz M, Kornek GV, Raderer M et al:Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 12:183-186, 2001
PubMed
15) Ducreux M, Rougier P, Fandi A et al:effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 9:635-656, 1998
 
16) 辻 晃仁, 森田荘二郎, 堀見忠司ほか:手術不能進行.再発胆嚢癌に対する少量:cisplatin・5-fluorouracil療法の初期成績. 癌と化学療法27:233-237, 2000
 
17) Taleb J, Mitry E, Boige V et al:Optimization of 5-fluorouracil (5-FU) / cisplatin combination chemotherapy with anew schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol 13:1192-1196, 2002
 
18) Sanz-Altamia PM, Ferrante K, Jenkins RL et al:A phase n trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 82:2321-2325, 1997
 
19) Patt YZ, Hassan MM, Lozzano RD et al:Phase II trial of cisplatin, interferon α-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res 7:3375-3380, 2001
 
20) Ellis PA, Norman A, Hill A et al:Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumors. Eur J Cancer 31A:1594-1598, 1995
PubMed
21) 古瀬純司, 住 一, 丸 泰司ほか:日本における胆道, 膵癌化学療法の現況-進行胆嚢癌-化学療法の適応と成績. 胆と膵21:835-840, 2000
 
22) Chen JS, Lin YC, Jan YY et al:Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampular carcinomas. Anticancer Drugs 12:339-343, 2001
 
23) Harvey JM, Smith FP, Schein PS:5-fluorouracil, mitomycin, and Doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 11:1245-1248, 1984
 
24) Malik IA, Aziz Z, Zaidi SHM et al:gemcitabine and cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of gallbladder. Am J Clin Oncol 26:174-177, 2003
 
25) Kuhn R, Hribaschek A, Ichelmann K et al:outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas. Invest Nem Drugs 20:351-356, 2002
 
26) Falkson G, Macintyre JM, Moertel CG:Eastern cooperative oncology group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 54:965-969, 1984
PubMed
27) Takada T, Nimura Y, Katoh H et al:Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma:multicenter randomized trial. Hepatogastroenterology 45:2020-2026, 1998
PubMed
28) 高田忠敬, 加藤紘之, 松代 隆ほか:日本における胆道, 膵癌化学療法の現況-進行胆嚢癌-FAM 療法の適応と成績. 胆と膵21:847-851, 2000
 
29) Takada T, Amano H, Yasuda H et al:Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma?A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95:1685-1695, 2002
PubMed
30) Cooke SP, Boxer GM, Lawrence L et al:Astrategy for antitumor vascular therapy by targeting the vascular endothelial growth factor:receptor complex. Cancer Res 61:3653-3659, 2001
 
31) Debouck C, Goodefellow PN:DNA microarrays in drug discovery and development. Nature Genet 21:48-50, 1999
 
32) Chakravarti A:It's ranning SNPs, hallelujah? Nature Genet l 9:216-217, 1998
 

第10章 重症急性膵炎

P.275 掲載の参考文献
1) 林 櫻松, 玉腰暁子, 大野良之ほか:急性膵炎の全国疫学調査成績, , 厚生科学研究特定疾患対策事業特定疾患の疫学に関する研究班平成11年度研究業績集:72-78, 2000
 
2) エビデンスに基づいた急性膵炎のガイドライン, 第1版, 金原出版, 東京, 2003
 
3) Ranson JH, Rifkind KM, Roses DF, Fink SD, Eng K, Spencer FC:Prognostic signs and the role of operative management in acute pancreatitis. Surg Gynecol Obstet. Jul;139(1):69-81, 1974
PubMed
4) Ranson JH:Etiological and prognostic factors in human acute pancreatitis:a review. Am J Gastroenterol. Review Sep 7;7(9):633-8, 1982 Imrie CW, Benjamin IS, Ferguson JC, McKay AJ, Mackenzie I, O'Neill J, Blumgart LH:A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis.Br J Surg. May; 65(5):337-41, 1978
 
5) Osbome DH, Imrie CW, Carter DC:Biliary surgery in the same admission for gallstone-associated acute pancreatitis. Br J Surg. Nov;68 (11):758-61, 1981
 
6) Blamey SL, Imrie CW, O:Neill J, Gilmour WH, Carter DC:Prognostic factors in acute pancreatitis. Gut. Dec; 25(12):1340-6, 1984
 
7) Bank S, Wise L, Gersten M:Risk factors in acute pancreatitis. Am J Gastroenterol. Oct; 78(10):637-40, 1983
PubMed
8) Forell MM:Die konservative Behanduling der Pancreaserkrankungen. Internist 5:453-457, 1964
 
9) Damman DH, Dopner M, Wichert PV et al:Die beurteilung der fruhprognose der akute pankrestitis. Zentralbl Chir 106:154-160, 1981
 
10) Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II:a severity of disease classification system. Crit Care Med. Oct;13(10):818-29, 1985
PubMed
11) Larvin M:Assessment of severity and prognosis in acute pancreatitis. Eur J Gastroenterol Hepatol Review. Feb; 9(2):122-30, 1997
PubMed
12) Wilson C, Heath DI, Imrie CW:Prediction of outcome in acute pancreatitis:a comparative study of APACHE II, clinical assessment and multiple factor scoring systems.Br J Surg. Nov; 77(11):1260-1264, 1990
PubMed
13) Dervenis C, Johnson CD, Bassi C, Bradley E, Imrie CW, McMahon MJ, Modlin I:Diagnosis, objective assessment of severity, and management of acute pancreatitis. Santorini consensus conference. Int J Pancreatol. Review. Jun; 25(3):195-210, 1999
PubMed
14) 編集齋藤洋一:日本における重症急性膵炎, 診断と治療の手引き, 国際医書出版, 東京, 1991
 
15) 小川道雄, 広田昌彦, 早川哲夫ほか:急性膵炎の Stage分類. 小川道雄編:厚生省特定疾患消化器系疾患調査班, 難治性膵疾患分科会, 平成10年度報告書:19-22, 1999
 
16) 編集齋藤洋一:日本における重症急性膵炎, 診断と治療の手引き, 国際医書出版, 東京, p 1-10, 1991
 
17) Dickson AP, Imrie CW:The incidence and prognosis of body wall ecchymosis in acute pancreatitis. Surg Gynecol Obstet. Oct;159 (4):343-347, 1984
PubMed
18) Vessers RS, Abu Landon RB et al:Amylase and lipase in the emergency department evaluation of acute pancreatitis. J Emerg Med 17:1027-1037, 1999
 
19) Silverstein W, Isikoff MB, Hill MC, Barkin J:Diagnostic imaging of acute pancreatitis:prospective study using CT and sonography. AJR Am J Roentgenol. 1981 Sep;137 (3):497-502
 
20) Laing FC, Jeffrey RB Jr, Wing VW, Nyberg DA:Biliary dilatation:defining the level and cause by real-time US. Radiology. Jul;160(1):39-42, 1986
PubMed
21) 小川道雄, 広田昌彦, 早川哲夫ほか:急性膵炎の Stage分類. 厚生労働省特定疾患対策研究事業難治性膵疾患分科会平成11年度研究報告書;19-22, 1999
 
22) 北川元二, 成瀬 達, 早川哲夫ほか:急性膵炎の重症化. 予知についての検討-全国集計からの解析. 膵臓16:95-102, 2001
 
23) 大槻 眞:急性膵炎の重症化の実態. 厚生労働科学研究研究費補助金, 特定疾患対策研究事業難治性膵疾患に関する調査研究, 平成14年度総括・分担研究報告書;32-40, 2003
 
24) Dickson AP, Imrie CW:The incidence and prognosis of body wall ecchymosis in acute pancreatitis. Surg Gynecol Obstet. Oct;159 (4):343-347, 1984
PubMed
25) Bem J, Bradley EL 3rd:Subcutaneous manifestations of severe acute pancreatitis. Pancreas. May;16(4):551-555, 1998
PubMed
26) Dervenis C, Johnson CD, Bassi C, Bradley E, Imrie CW, McMahon MJ, Modlin I:Diagnosis, objective assessment of severity, and management of acute pancreatitis. Santorini consensus conference. Int J Pancreatol. Review. Jun;25 (3):195-210, 1999
PubMed
27) Lankisch PG, Petersen M, Gottesleben F:High, not low, amylase and lipase levels indicate severe acute pancreatitis! Z Gastroenterol. Apr; 32(4):213-215, 1994
 
28) Larvin M, McMahon MJ:APACHE-II score for assessment and monitoring of acute pancreatitis. Lancet. Jul 22;2(8656):201-5, 1989
 
29) Vesentini S, Bassi C, Talamini G, Cavallini G, Campedelli A, Pederzoli P:Prospective comparison of C-reactive protein level, Ranson score and contrast-enhanced computed tomography in the prediction of septic complications of acute pancreatitis. Br J Surg. Jun; 80(6):755-7, 1993
PubMed
30) 武田和憲, 松野正紀:CT Gradingによる急性壊死性膵炎に対する手術術式および治療法の選択. 日腹救誌 18:961-965, 1998
 
31) 松野正紀:急性膵炎のCT Grade分類の再検討. 小川道雄編:厚生省特定疾患消化器系疾患調査班難治性膵疾患分科会 平成10年度報告書. ;42-47, 1999
 
32) 上田 隆, 竹川宜典, 黒田嘉和:重症急性膵炎の重症度判定基準と治療法の選択. 消化器科29 (1):91-98, 1999
 
P.282 掲載の参考文献
1) 小川道雄, 広田昌彦:急性膵炎の症例調査. 厚生労働省特定疾患対策研究事業難治性膵疾患に関する調査研究班. 平成11～13年度総合研究報告書:p 17-35, 2002
 
2) 下瀬川 徹:急性膵炎重症化の背景因子の解明と重症化の予知と予防.治療法の研究. 厚生労働省特定疾患対策研究事業難治性膵疾患に関する調査研究班. 平成14年度研究報告書:p41-44, 2003
 
3) Neoptolemos JP, Kemppainen EA, Mayer JM, Fitzpatrick JM et al:Earlyprediction of severity inacute pancreatitis by urinary trypsinogen activation peptide:a multicentre study. Lancet355:1955-60, 2000
 
4) Mayer JM, Rau B, Siech M, Beger HGi Local and systemic zymogen activation in human acute pancreatitis. Digestion 62:164-70, 2000
 
5) 早川哲夫, 島崎修次, 杉山 貢, 中野 哲, 上原 総-郎, 遠藤重厚ほか:急性膵炎の重症化の予知に関する研究. 厚生省特定疾患対. 策研究.事業:重症急性膵炎の救命率を改善するための研究班. 平成11年度研究報告書:p15-23, 2000
 
6) Satoh A, Shimosegawa T, Kimura K, Moriizumi S, Masamune A, Koizumi M, Toyota T:Nitric oxide is overproduced by peritoneal macrophages in rat taurocholate pancreatitis:the mechanism of inducible nitric oxide synthase expression. Pancreas17:402-411, 1998
PubMed
7) Fujita M, Masamune A, Satoh A, Sakai Y, Satoh K, Shimosegawa T:Ascites of rat experimental model of severe acute pancreatitis induces lung injury. Pancreas22:409-418, 2001
PubMed
8) Satoh A, Shimosegawa T, Fujita M, Kimura K, Masamune A, Koizumi M, Toyota T:Inhibition of nuclear factor-kB activation improves the survival of rats with taurocholate pancreatitis. Gut44:253-8, 1999
 
9) Masamune A, Shimosegawa T, Kimura K, Fujita M, Sato A, Koizumi M, Toyota T:Specific induction of adhesion Molecules in human vascular endothelial cells by rat experimental pancreatitis-associated ascitic fluids. Pancreas18:141-150, 1999
PubMed
10) Masamune A, Sakai Y, Yoshida M, Satoh A, Satoh K, Shimosegawa T:Lyso-phosphatidylcholine activates transcription factor NF-kappa B and AP-1 in AR42J cells. Dig Dis Sci46:1871-81, 2001
 
11) Masamune A, Shimosegawa T, Fujita M, Satoh A, Koizumi M, Toyota T:Ascites of severe acute pancreatitis in rats transcriptionally up-regu-lates expression of interleukin-6 and-8 in vascular endothelium and mononuclear leukocytes. Dig Dis Sci45:429-37, 2000
 
12) Satoh A, Shimosegawa T, Masamune A, Fujita M, Koizumi M, Toyota T:Ascitic fluid of experimental severe acute pancreatitis modulates the function of peritoneal macrophages. Pancreas 19:268-75, 1999
 
13). 下瀬川 徹, 正宗 淳, 木村憲治:フサンの多彩な薬理作用を探る-急性膵炎と補体系医薬の門-42:21-28, 2002
 
14) Sakai Y, Masamune A, Satoh A, Nishihira J, Yamagiwa T, Shimosegawa T:Macrophage migration inhibitory factor is a critical mediator of severe acute pancreatitis. Gastroenterology124:725-36, 2003
PubMed
15) 山本正博, 齋藤洋一:全国集計の面よりみた重症急性膵炎.胆と膵 9:1669-83, 1988
 
16) 小川道雄, 広田昌彦, 早川哲夫, 松野正紀ほか:重症急性膵炎全同調査-不明例の追加調査を加えてた最終報告-. 厚生省特定疾患消化器系疾患調査研究班難治性膵疾患分科会. 平成10年度研究報告書:p23-35, 1999
 
17) Volk HD, Thieme M, Heym S et al:Alterations in function and phenotype of monocytes from patients with septic disease-predictive value and new therapeutic strategies. Behring Inst mitt88:208-215, 1991
PubMed
18) Satoh A, Miura T, Satoh K, Masamune A, Yamagiwa T, Sakai Y, Shibuya K, Takeda K, Kaku M, Shimosegawa T:Human leukocyte antigen-DR expression on peripheral monocytes as a predictive marker of sepsis during acute pancreatitis. Pancreas25:245-250, 2002
PubMed
19) Satoh A, Masamune A, Kimura K, Kaneko K, Sakai Y, Yamagiwa T, Satoh M, Shibuya K, Kikuta K, Asakura T, Shimosegawa T:Nuclear factor kappa B expression in peripheral blood mononuclear cells of patients with acute pancreatitis. Pancreas 26:350-356, 2003
 
20) Takeyama Y, Takas K, Ueda T, Hori Y:Goshima M, Kuroda Y:Peripheral lymphocyte reduction in severe acute pancreatitis is caused by apoptotic cell death. J Gastrointest Surg4:379-87, 2000
 
21) Yasuda T, Takeyama Y, Ueda T, Takase K, Nishikawa J, Kuroda Y:Splenic atrophy in experimental severe acute pancreatitis. Pancreas 24:365-72, 2002
PubMed
22) Ueda T, Takeyama Y, Takase K, Hori Y, Kuroda Y, Ho HS:Hematin is one of the cytotoxic factors in pancreatitis-associated ascitic fluid that causes hepatocellular injury. Surgery131:66-74, 2002
PubMed
23) Takeyama Y, Hori Y, Takase K, Ueda T, Yamamoto M, Kuroda Y:Apoptotic cell death of hepatocytes in rat experimental severe acute pancreatitis. Surgery127:55-64, 2000
PubMed
24) Bone RC:Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 24:1125-28, 1996
 
25) 小川道雄, 広田昌彦, 野澤文昭, 岡部明宏, 柴田 宗征:急性膵炎における血中サイトカイン動態と多臓器障害. 厚生労働省特定疾患対策研究事業難治性膵疾患に関する調査研究班. 平成11～13年度総合研究報告書:p77-82, 2002
 
P.290 掲載の参考文献
1) 松野正紀:重症急性膵炎の治療指針, 難病・重症急性膵炎-診療の手引き-, 松野正紀監修, 早川哲夫, 武m和憲編. 集, 医学図書出版, 東京, p1-12, 1997
 
2) 伊佐地秀司:急性膵炎のEvidence-based Medicine. 日消誌 98:1037-1047, 2001
Medical*Online
3) エビデンスに基づいた急性膵炎の診療ガイドライン (第1版) , 急性膵炎の診療ガイドライン作成委員会編, 金原出版, 東京, 2003
 
4) 角川陽一郎, 武田和憲, 砂村眞琴ほか:十二指腸盲管法による実験的急性膵炎に対する蛋白分解酵素阻害剤持続動注療法の効果. 日消誌 87:1444-1450, 1990
 
5) 伊佐地秀司, 上本伸二:重症急性膵炎における感染の病態と制御. 胆と膵23:825-830, 2002
 
6) Buchler M, Malfertheiner P, Friess H et al:Human pancreatic tissue concentration of bactericidal antibiotics.Gastroenterology 103:1902-1908, 1992
PubMed
7) Hayashi J, Kawarada Y, Isaji S et al:Therapeutic effects of continuous intraarterial antibiotic infusion in preventing Pancreatic infection in experimental acute necrotizing Pan-creatitis. Pancreas 13:184-192, 1996
 
8) Takagi K, Isaji S:Therapeutic efficacy of continuous arterial infusion of an antibiotic and a protease inhibitor via the superior mesenteric artery for acute pancreatitis in an animal model Pancreas 21:279-289, 2000
 
9) Miyahara S, Isaji S:Liver injury in acute pancreatitis and mitigation by continuous arterial infusion of an antibiotic via the superior mesenteric artery. Pancreas 23:204-211, 2001
PubMed
10) 武田和憲, 砂村眞琴, 角川洋一郎:重症急性膵炎に対するprotease inhibitor持続動注療法. 膵臓 4:113-121, 1989
 
11) Takeda K, Matsuno S, Sunamura M et al:Continuous regional arterial infusion of protease inhibitor and antibiotics in acute pancreatitis. Am J Surg 171:394-398, 1996
PubMed
12) 松野正紀, 小川道雄, 渡辺伸一郎ほか:重症急性膵炎に対する膵酵素阻害剤.抗生物質持続動注療法の施行状況, 効果についての調査. 厚生省特定疾患消化器系疾患調査研究班, 難治性膵疾患分科会, 平成9年度研究報告書, p29-39, 1998
 
13) 伊佐地秀司, . 長沼達史, 高木馨子ほか二重症急性膵炎に対する特殊療法の選択-特に膵局所動注療法の効果と問題点. 消化器科29:114-120, 1999
 
14) 松野正紀, 跡見 裕, 早川哲夫ほか:重症急性膵炎に対する動注療法の治療効果-1999～2001年症例の調査報-告-厚生労働省特定疾患消化器系疾患調査研究班, 難治性膵疾患分科会, 平成13年度研究報告書, p69-39, 2002
 
15) 松野正紀:膵hypoperfusionと膵壊死は同義語か?-急性膵炎早期の膵循環障害へのアプローチ. 膵臓 18:1-8, 2003
 
16) 松田兼一, 北村伸哉, 平澤博之:重症急性膵炎と 血液浄化法. 集中治療 5:1067-1078, 1993
 
17) 松田兼一, 平澤博之, 織田成人ほか:各種操作条件による持続的血液濾過透析 (CHDF) の物質除去性能の検討-小分子量物質およびcytokine除去効率の検討を中心に-. ICUとCCU 26別冊号:s66-68, 2002
 
18) 北村伸哉, 平澤博之, 織田成人ほか:重症急性膵炎に対する血液浄化法. ICUとCCU 24:655-664, 2000
Medical*Online
19) Isaji S, Suzuki M, Frey CF et al:Role of bacterial infection in diet-induced acute pancreatitis in mice. Int J Pancreatol 11:49-57, 1992
PubMed
20) 上田 隆, 竹山宜典, 黒田義和:重症急性膵炎の総合的初期治療と問題点. 胆と膵 21:43-47, 2000
 
21) Luiten EJ, Hop WC, Lange JF, Bruining HA; Controlled clinical trial of selective decontamination for the treatment of severe acute pancreatitis. Ann Surg 222:57-65, 1995
PubMed
22) 小川道雄, 広田昌彦:急性膵炎の症例調査. 厚生労働省特定疾患消化器系疾患調査研究班, 難治性膵疾患分科会,平成13年度研究報告書, p 17-35, 2002
 
23) Platell C, Cooper D, Hall JC:Ameta-analysis of peritoneal lavage for acute pancreatitis. J Gastroenterol Hepatol 16:689-9, 2001
 
P.294 掲載の参考文献
1) 急性膵炎の診療ガイドライン作成委員会編:エビデンスに基づいた急性膵炎の診療ガイドライン. 金原出版, 東京, 2003
 
2) Gerzof SG, Banks PA, Robbins AH et al:Early diagnosis of pancreatic infection by computed tomography-guided aspiration. Gastroenterology 93:1315-1320, 1987
PubMed
3) Garcia-Sabrido JL, Tallado JM, Christou NV et al:Treatment of severe intra-abdominal sepsis and/or necrotic foci by an open-abdomen approach. Zipper and zipper-mesh techniques. Arch Surg 123:152-156, 1988
PubMed
4) Carter CR, McKay CJ, Imrie CW:Percutaneous necrosectomy and sinus tract endoscopy in the management of infected pancreatic necrosis:an initial experience. Ann Surg 232:175-180, 2000
PubMed

第11章 慢性膵炎の最新治療

P.300 掲載の参考文献
1) 厚生省特定疾患難治性膵疾患調査研究班 (班長:齋藤洋一):慢性膵炎の治療指針の改訂について. 昭和62年度研究報告書:23-27, 1988
 
2) Conwell DL, Vargo JJ, Zuccaro G et al:Role of differential neuroaxial blockade in the evaluation and management of pain in chronic pancreatitis. Am Coll Gastroenterology 96:431-436, 2001
 
3) Tarnasky PR, Hoffman B, Aabakken L et al:Sphincter of Oddi dysfunction is associated with chronic pancreatitis. Am J Gastroenterol 92:1125-1129, 1997
PubMed
4) Di Siebastiano P, di Mola FF, Febbo CD et al:Expression of interleikin 8 (IL-8) and substance P in human chronic pancreatitis. Gut 47:423-428, 2000
 
5) Schlosser W, Schloose S, Ramadani M et al:Cyclooxygenase-2 is overexpressed in chronic pancreatitis. Pancreas 25:26-30, 2002
 
6) Kloppel G, Maillet B:Pathology of acute and chronic pancreatitis. Pancreas 8:659-670, 1993
PubMed
7) Friess H, Zhu ZW, di Mola FF et al:Nerve growth factor and its high-affinity receptor in chronic pancreatitis. Ann Surg 230:615-624, 1999
PubMed
8) Di Sebastiano P, Fink T, Weihe E et al:Immune cell infiltration and growth-associated protein 43 expression correlate with pain in chronic pancreatitis. Gastroenterology 112:1648-1655, 1997
PubMed
9) Di Sebastiano P, di Mola FF, Bockman DE et al:Chronic pancreatitis:the perspective of pain generation by neuroimmune interaction. Gut 52:907-911, 2003
PubMed
10) Steinhoff M, Vergnolle N, Young SH et al:Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 6:151-158, 2000
PubMed
11) Brain SD:New feeling about the role of sensory nerves in inflammation. Nat Med 6:134-135, 2000
 
12) American Gastroenterological Association:American Gastroenterological Association medical position statement:Treatment of pain in chronic pancreatitis. Gastroenterology 115:763-764, 1998
 
13) Warshaw AL, Banks PA, Femandez-Del Castillo C:AGA technical review:Treatment of pain in chronic pancreatitis. Gastroenterology 115:765-776, 1998
 
14) 早川哲夫:慢性膵炎の診断と治療, 日消誌96:1-7, 1999
 
15) 下瀬川 徹:慢性膵炎の治療方針, 小川道雄編:消化器病セミナー90, へるす出版, 東京, p 87-100, 2003
 
16) 厚生省特定疾患難治性膵疾患調査研究班 (班長:早川哲夫):慢性膵炎の予後調査. 平成10. 年度研究報.告書:10, 1996
 
17) 白鳥敬子:慢性膵炎, 中村丁次ほか編:ビジュアル臨床栄養実践マニュアル第2巻, 小学館, 東京, p 158-161, 2002
 
18) Shea JC, Bishop MD, Parker EM et al:An enteral therapy containing medium-chain triglycerides and hydrolyzed peptides reduces postprandial pain associated with chronic pancreaitits. Pancreatology 3:36-40, 2003
PubMed
19) Malfertheiner P, Mayer D, Buchler M et al:Treatment of pain in chronic pancreatitis by inhibition of pancreatic secretion with octreotide. Gut 36:450-454, 1995
PubMed
20) Shiratori K, Takeuchi T, Satake K et al:Clinical evaluation of oral administration of a cholecystokin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis:a multicenter dose-response study in Japan. Pancreas 25:e1-e5, 2002
 
21) Wilder-Smith CH, Hill L, Osler W et al:Effect of tramadol and morphine on pain and gastrointestinal motor function in patients with chronic pancreatitis. Dig Dis Sci 44:1107-1116, 1999
PubMed
22) Eisenach JC, Carpenter R, Curry R:Analgesia from aperipherally active k-opioid receptor agonist in patients with chronic pancreaitis. Pain 101:89-95, 2003
 
23) 税所宏光:慢性膵炎-治療, 図説消化器病シリーズ14:メジカルビュー社, 東京, p 121-135, 2001
 
24) 伊藤俊哉, 千葉憲哉, 門原留雄ほか:慢性膵炎における疾痛寛解を目的として胸腔鏡下大内臓神経切除術, 膵臓9:360-366, 1994
 
25) Takahashi T, Kakita A, Izumika H et al:Thoracoscopic splanchnicectomy for the relief of intractable abdominal pain. Surg Endosc 10:65-68, 1996
PubMed
26) Lin Y, Tamakoshi A, Hayakawa T et al:Cigarette smoking as a risk factor for chronic pancreatitis:a case-control study in Japan. Pancreas 21:109-114, 2000
PubMed
27) Ammann RW:The natural history of alcoholic chronic pancreatitis. Internal Med 40:368-375, 2001
 
P.308 掲載の参考文献
1) Sarles H, Sarles JC, Muratore R et al:Chronic inflammatory sclerosis of the pancreas-an autonomous pancreatic disease?Am J Dig Dis 6:688-698, 1961
PubMed
2) Etemad B, Whitcomb DC:Chronic Pancreatitis:Diagnosis, Classification, and New Genetic Developments. Gastroenterology 120:682-707, 2001
PubMed
3) 慢性膵炎診断基準 (日本膵臓学会, 1995):慢性膵炎診断基準検討委員会最終報告. 膵臓10:(会告) xxiii-xxv, 1995
 
4) 日本膵臓学会:日本膵臓病学会自己免疫性膵炎診断基準2002年, 膵臓17:585-587, 2002
 
5) Okazaki K, Chiba T:Autoimmune-related pancreatitis. Gut 51:14, 2002
 
6) Okazaki K, Uchida K, Chiba T:Recent concept of autoimmune-related pancreatitis, J Gastroenterol 36:293-302, 2001
PubMed
7) Okazaki K, Uchida K, Ohana M et al:Autoimmune-related pancreatitis is associated with autoantibodies and Th1/Th2-type cellular immune response. Gastroenterology 118:573-581, 2000
PubMed
8) 神澤輝美, 屠 聿揚, 江川直人ほか:膵管狭細型慢性膵炎の臨床病理学的検討. 日消誌98:5-24, 2001
 
9) Hamano H, Kawa S, Ochi Y et al:Hydronephrosis associated with retroperitoneal fibrosis and sclerosing pancreatitis. Lancet 359 (9315):1403-1404, 2002
PubMed
10) Uchida K, Okazaki K, Asada Y et al:A case of chronic pancreatitis involving an autoimmune mechanism that extends to retroperitoneal fibrosis. Pancreas 26 (1):92-94, 2003
 
11) Hamano H, Kawa S, Horiuchi A et al:High serum IgG4 cncentrations in patients with sclerosing pancreatitis. The New England Journal of Medicine 344:732-738, 2001
 
12) Kawa S, Ota M, Yoshizawa K et al:HLA DRB1*0405-DQB1*0401 haplotype is associated with autoimmune pancreatitis in the Japanese population. Gastroenterology 122:1264-1269, 2002
 
13) Tsubakio K, Kiriyama K, Matsushima N, Taniguchi M, Shizusawa T, Katoh T, Manabe N, Yabu M, Kanayama Y, Himeno S:Autoimmune pancreatitis successfully treated with ursodeoxycholic acid. Intern Med Dec. 41 (12):1142-1146, 2002
PubMed
P.313 掲載の参考文献
1) 日本膵臓学会慢性膵炎診断基準委員会:慢性膵炎臨床診断基準 (日本膵臓学会, 1995). 膵臓 10:xxiii-.xxvi, 1995
 
2) 高瀬 優, 須田耕一, 江口正信, 小山敏雄:腫瘤形成性膵炎の病理学的検討. 胆と膵 20:271-275, 1995
 
3) Neff CC, Simeone JF, Wittenberg J et al:Inflammatory pancreatic masses. Radiology 150:35-38, 1984
PubMed
4) Lammer J, Herlinger H, Zalaudek G et al:Pseudotumorous pancreatitis. Gastrointest Radiol 8:217-219, 1986
 
5) 鄭 容錫, 横松秀明, 仲田文造ほか:膵疾患における糖鎖抗原, CEA, elastase-1測定の意義. 膵臓 5:1-7, 1990
 
6) Nakao A, Ohshima K, Nomoto S et al:Clinical Usefulness of CA19-9 in Pancreatic Carcinoma. Semin Surg Oncol 15:15-22, 1998
 
7) 堀口祐爾, 北野 徹, 大瀧正夫ほか:超音波像からみた腫瘤形成性膵炎と膵癌の鑑別診断. Jpn J Med Ultrasonics 12:310-320, 1985
 
8) 木本英三, 中澤三郎, 内藤靖夫ほか:慢性膵炎と膵癌の鑑別診断. 腹部画像診断4:243-251, 1984
 
9) 小林 剛, 藤田直孝, 野田 裕ほか:ERCPと EUSによる腫瘤形成性膵炎の鑑別診断. 胆と膵 23:643-652, 2002
Medical*Online
10) 安田健治郎, 中島正継, 趙 栄済ほか:腫瘤形成性膵炎と膵管癌の内視鏡的鑑別診断. 胆と膵 20:297-304, 1999
 
11) 堀口祐爾, 今井英夫, 瀬古口 凡ほか:超音波検査による慢性膵炎と膵癌の鑑別について-特に腫瘤形成性膵炎と膵癌の鑑別について-. 胆と膵 14:405-412, 1993
 
12) 山口武人, 松浦直孝, 石原 武ほか:腫瘤を形成する慢性膵炎-Dynamic CTによる鑑別診断-. 胆と膵 23:653-657, 2002
Medical*Online
13) 小林 剛, 藤田直孝, 野田 裕ほか:ERCPと EUSによる腫瘤形成性膵炎の鑑別診断. 胆と膵 23:643-652, 2002
Medical*Online
14) 木下壽文, 今山裕康, 緒方俊郎ほか:Contrast Enhanced Ultrsonography および直接膵静脈造影による鑑別診断. 胆と膵20:305-310, 1999
 
15) 廣川直樹, 小井戸一光, 市村 健ほか:膵腫瘍における造影エコー法, 特に膵管癌と腫瘤形成性膵炎の鑑別について-Time-intensity Curve-. 胆と膵 23:529-535, 2002
Medical*Online
16) 飛田浩輔, 大谷泰雄, 堂脇昌一ほか:膵臓癌におけるPETの有用性の検討. 膵臓 16:471-477, 2001
Medical*Online
17) Matsubayashi H, Watanabe H, Ajioka Y et al:Different amounts of K-ras mutant epithelial cells in pancreatic carcinoma and mass-forming pancreatitis. Pancreas 21:77-85, 2000
PubMed
18) 山雄健次, 大橋計彦, 中村常哉ほか:EUS-FNAB による膵癌と腫瘤形成性膵炎の鑑別診断. 消化器画像4:286-290, 2002
 
19) 雀 仁換, 有山 嚢, 須山正文ほか:MRCPによる腫瘤形成性膵炎と膵癌の鑑別. 胆と膵 20:293-295, 1999
 
20) 北郷 実, 相浦浩一, 鈴木慶一ほか:腫瘤形成性慢性膵炎と膵癌との鑑別,-血流評価を含めた画像解析とそのスコア化-. 胆と膵23:673-678, 2002
 
P.317 掲載の参考文献
1) Ibbehoj N, Svendsen LB, Madsen P et al:Pancreatic tissue pressure in chronic obstructive pancreatitis. Scand J Gastroenterol 19:1066-1068, 1984
 
2) Bockman DE, B chler MW, Malfertheiner P et al:Analysis of nerves in chronic pancreatitis. Gastroenterology 94:1459-1469, 1988
 
3) Widmaier U, Schmidt A, Schlosser W et al:Die duodenumerhaltende Pankreaskopfresektion in der Therapie des Pankreas divisum. Chirurg 68:180-186, 1997
 
4) Lankisch PG, Lohr-Happe A, Otto J et al:Natural course in chronic pancreatits. Pain, exocrine and endocrine pancreatic insufficiency and prognosis of the disease. Digestion 54:148-155, 1993
 
5) Beger HG, Krautzberger W, Bittner R et al:Duodenum-preserving resection of the head of the pancreas in patients with severe chronic pancreatitis. Surgery 97:467-473, 1985
PubMed
6) Frey CF, Smith GJ:Description and rational of a new operation for chronic pancreatits. Pancreas 2:701-707, 1987
 
7) Beger HG, Witte C, Kreutzberger W et al:[Experiences with duodenum-sparing pancreas head resection in chronic pacreatitis]. Chirurg 51:303-307, 1980
 
8) Takada T, Yasuda H, Uchiyama K et al:Duodenum-preserving pancreatoduodenostomy. A new technique for complete excision of the head of the pancreas with preservation of the biliary and alimentary integrity. Hepatogastroenterology 40:356-359, 1993
PubMed
9) Partington PF, Rochelle RE:Modified Puestow procedure for retrograde drainage of the pancreatic duct. Ann Surg 152:1037-1042, 1960
PubMed
10) Prinz RA, Aranha GV, Greenlee HB:Redrainage of the pancreatic duct in chronic pancreatitis. Am J Surg 151:150-156, 1986
PubMed
11) Izbicki JR, Bloechle C, Broering C et al:Longitudinal V-shaped excision of the ventral pancreas for small duct disease in severe chronic pancreatitis. Prospective evaluation of a new surgical procedure. Ann Surg 227:213-219, 1998
 
12) Gloor B, Friess H, Uhl W et al:A Modified technique of the Beger and Frey procedure in patients with chronic pancreatitis. Dig Surg 18:21-25, 2001
PubMed
13) Traverso LW, Longmire WP Jr.:Preservation of the pylorus in pancreatoduodenectomy Surg Gynecol Obstet 146:959-862, 1978
PubMed
14) Buchler NW, Friess H, Muler NW et al:Randmized trial of duodenum-preserving pancreatic head resection versus pylorus-preserving Whipple in chronic pancreatitis. Am J Surg 169:65-70, 1995
 
15) Izbicki JR, Bloechle C, Broering DC et al:Extended drainage versus resection in surgery for chronic pancreatitis n Prospective randomized trial comparing the longitudinal pancreaticojejunostomy combined with local pancreatic head excision with the pylorus preserving pancreatoduodenectomy. Ann Surg 228:771-779, 1998
 
16) Izbicki JR, Bloechle C, Knoefel WT et al:Duodenum-preserving resection of the head of the pancreas in chronic pancreatitis. A prospective, randmized trial. Ann Surg 221:350-358, 1995
 
P.324 掲載の参考文献
1) Bradley EL III:Pancreatic duct pressure in chronic pancreatitis. Am J Surg 144:313-316, 1982
 
2) 熊澤孝朗:疼痛の発生.伝達機構と修飾-膵性疼痛をめぐって. 膵臓10:337-344, 1995
 
3) Zollinger RM, Keith LM Jr, Ellison EH:Pancreatitis. New Engl J Med 251:497-502, 1954
PubMed
4) DuVal MK Jr.:Caudal pancreatojejunostomy for chronic relapsing Pancreatitis. Ann Surg 110:775-785, 1954
 
5) Puestow CB, Gillesby WJ:Retrograde surgical drainage of pancreas for chronic relapsing pancreatitis. Arch Surg 76:898-904, 1958
PubMed
6) Partington PF, Rochelle REL:Modified Puestow procedure for retrograde drainage of the pancreatic duct. Ann Surg 152:1037-1043, 1960
 
7) Cremer M, Deviere J, Delhaye M et al:Stenting in severe chronic pancreatitis:results of medium-tenm follow-up in seventy-six patients. Endoscopy 23:171-176, 1991
 
8) Smits ME, Badiga SM, Rauws EAJ et al:Long-temm results of pancreatic stents in chronic pancreatitis. Gastrointest Endosc 42:461-467, 1995
 
9) Binmoeller KF, Jue P, Seifert H et al:Endoscopic pancreatic stent drainage in chronic pancreatitis and a dominant stricture:long-term results. Endoscopy 27:638-644, 1995
 
10) Ikenberry SO, Sherman S, Hawes RH et al:The occlusion rate of pancreatic stents. Gastrointest Endosc 40:611-613, 1994
PubMed
11) Lehman GA, Sherman S:Chronic pancreatitis, DiMarino Jr AJ, Benjamin SB eds:Gastrointestinal disease. An endoscopic approach, 2nd Ed, SLACK Incorporated, USA, p1277-1296, 2002
 
12) McCarthy J, Geenen JE, Hogan WJ:Preliminary experience with endoscopic stent placement in benign pancreatic diseases. Gastrointest Endosc 34:16-18, 1988
PubMed
13) Lans JI, Geenen JE, Johanson JF et al:Endoscopic therapy in patients with pancreas divisum and acute pancreatitis:a prospective randomized controlled clinical trial. Gastrointest Endosc 38:430-434, 1992
PubMed
14) Sherman S, Alvarez C, Robert M et al:Polyethylene pancreatic duct stent-induced changes in the normal dog pancreas. Gastrointest Endosc 39:658-664, 1993
PubMed
15) Kozarek RA:Pancreatic stents can induce ductal changes consistent with chronic pancreatitis. Gastrointest Endosc 36:93-95, 1990
PubMed
16) Smith MT, Sherman S, Ikenberry SO et al:Alterations in pancreatic ductal morphology following polyethylene pancreatic stent therapy. Gastrointest Endosc 44:268-275, 1996
PubMed
17) Shemman S, Hawes R, Stein P et al:Stent-induced pancreatic ductal and parenchymal changes:correlation of endoscopic ultrasound with ERCP. Gastrointest Endosc 44:276-282, 1996
 
18) 石原 武, 山口武人, 露口利夫ほか:新しく試作された膵管ステント (Tilde型ステント) の使用経験. 胆と膵 22:171-175, 2001
Medical*Online

第12章 膵癌の治療と治療法選択

P.330 掲載の参考文献
1) Rosenberg SA:Progress in human tumour immunology and immunotherapy. Nature 411:380-384, 2001
PubMed
2) Kawakami Y, Rosenberg SA:Human tumor antigens recognized by T-cells. Immunol Res 16:313-339, 1997
 
3) Old LJ, Chen YT:New paths in human cancer serology. J Exp Med 187:1163-1167, 1998
PubMed
4) Barnd DI., Lan MS, Metzgar RS et al:Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci U S A 86:7159-7163, 1989
 
5) Anda M, Vlad SM, Mare Cudic, Hans Paulsen, Laszlo Otvon, Jr, Franz-Georg Hanisch, Olivera J, Finn:Complex Carbohydrates Are Not Removed During Processing of Glycoproteins by Dendritic cells:Processing of Tumor Antigen MUCl Glycopeptodes for Presentation to Major Histocompatibility Complex Class 2-resstriced T Cells. J. Exp. Med 196:1435-1446, 2002
 
6) Goydos JS, Elder E, Whiteside TL et al:A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 63:298-304, 1996
PubMed
7) Gjertsen MK, Buanes T, Rosseland AR et al:Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant:Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 92:441-450, 2001
PubMed
8) Banchereau J, Steinman RM:Dendritic cells and the control of immunity. Nature 3921245-252, 1998
 
9) Marincola FM, Jaffee EM, Hicklin DJ et al:Escape of human solid tumors from T-cell recognition:molecular mechanisms and functional significance. Adv Immunol 74:181-273, 2000
 
10) Banchereau J, Paczesny S, Blanco P et al:Dendritic cells:controllers of the immune system and a new promise for immunotherapy. Ann N Y Acad Sci 987:180-187, 2003
 
11) Nestle FO, Alijagic S, Gilliet M et al:Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 4:328-332, 1998
PubMed
12) Schott M, Feldkamp J, Lettmann M et al:Dendritic cell immunotherapy in a neuroendocrine pancreas carcinoma. Clin Endocrinol (Oxf) 55:271-277, 2001
 
13) Pecher G, Haring A, Kaiser L et al:Mucin gene (MUC1) transfected dendritic cells as vaccine:results of a phase I/II clinical trial. Cancer Immunol Immunother 51:669-673, 2002
PubMed
14) Rosenberg SA, Yannelli JR, Yang JC et al:Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lyniphocytes and interleukin 2. J Natl Cancer Inst 86:1159-1166, 1994
PubMed
15) Kobari M, Egawa S, Shibuya K et al:Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer. Br JSurg 87:43-48, 2000
PubMed
16) Childs R, Chemofr A, Contentin N et al:Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750-758, 2000
PubMed
17) Takeda K, Kaisho T, Akira S:Toll-like receptors. Annu Rev lmmunol 21:335-376, 2003
PubMed
18) Hurwitz AA, Foster BA, Kwon ED et al:Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60:2444-2448, 2000
 
P.336 掲載の参考文献
1) Willet CG, Safran H, Abrams RA et al:Clinical research in pancreatic cancer:The Radiation Therapy Oncology Group trials. Int J Radiat Oncol Biol Phys 56:31-37, 2003
 
2) McGinn CJ, Zalupski MM:Radiaiton therapy with once-weekly gemcitabine in pancreatic cancer:Current status of clinical trials. Int J Radiat Oncol Biol Phys 56:10-15, 2003
 
3) Moertel CG, Frytak S, Hahn RG et al:Therapy of locally unresectable pancreatic carcinoma:a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluorouracil), and high dose radiation+5-fluorouracil:The Gastrointestinal Tumor Study Group. Cancer 48:1705-1710, 1981
 
4) Gastrointestinal Tumor Study Group:Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer 56:2563-2568, 1985
PubMed
5) http://www.cancer.gov/cancerinfo/pdq/treatment/pancreatic/healthprofessional/
 
6) Staley CA, Lee JE, Cleary KR et al:Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 171:118-124, 1996
 
7) Hoffman JP, Lipsitz S, Pisansky T et al:Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas:an Eastern Cooperative Oncology Group Study. J Clin Oncol 16:317-323, 1998
 
8) Breslin TM, Hess KR, Harbison DB et al:Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas:Treatment variables and survival duration. Ann Surg Oncol 8:123-132, 2001
PubMed
9) Klinkenbijl JH, Jeekel J, Sahmoud T et al:Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region:phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230:776-782, 1999
PubMed
10) Neoptolemos JP, Dunn JA, Stocken DD et al:Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer:a randomised controlled trial. Lancet 358:1576-1585, 2001
PubMed
11) Kokubo M, Nishimura Y, Shibamoto Y et al:Analysis of the clinical benefit of intraoperative radiotherapy in patients undergoing macroscopically curative resection for pancreatic cancer. Int J Radiat Oncol Biol Phys 48:1081-1087, 2000
PubMed
12) Klaassen DJ, MacIntyre JM, Catton GE et al:Treatment of locally unresectable cancer of the stomach and pancreas:a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil:an Eastern Cooperative Oncology Group Study. J Clin Oncol 3:373-378, 1985
 
13) Burris HA 3rd, Moore MJ, Andersen J et al:Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:arandomized trial. J Clin Oncol 15:2403-2413, 1997
 
14) Lawrence TS, Eisbruch A, Shewach DS:Gemcitabine-mediated radiosensitization. Semin Oncol 24:S 7-24-S 7-28, 1997
 
15) Blackstock AW, Bernard SA, Richards F et al:Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol l 7:2208-2212, 1999
 
16) McGinn CJ, Zalupski MM, Shureiqi I et al:Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19i 4202-4208, 2001
 
17) Ikeda M, Okada S, Tokuuye K et al:A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 86:1551-1554, 2002
PubMed
18) Poggi MM, Kroog GS, Russo A et al:Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 54:670-676, 2002
PubMed
19) Mohiuddin M, Regine WF, Stevens J et al:Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas. J Clin Oncol 13:2764-2768, 1995
PubMed
P.348 掲載の参考文献
1) 伊藤壽記, 杉谷 篤, 石橋道男ほか:臓器移植法実施後に施行された脳死下膵腎同時移植の1症例, 移植 36 (3):174, 2001
Medical*Online
2) Banting FG, Best CH et al:Pancreatic extracts in the treatment of diabetes mellitus. Canad. Med. Ass. J 12:141, 1922
PubMed
3) Lillehei RC, Idezuki Y et al:Transplantation of stomach, intestine, and pancreas:experimental and clinical observations. Surgery 62 (4):721, 1967
PubMed
4) Idezuki Y, Lillehei RC et al:Pancreaticoduodenal allotransplantation in dogs. Vascular Diseases 5 (2):78, 1968
PubMed
5) Lillehei RC, Simmons RL, Najarian JS et al:Pancreatico-duodenal allotransplantation:experimental and clinical experience. Annals of Surgery 172 (3):405, 1970
PubMed
6) Gliedman ML et al:Clinical segmental pancreatic transplantation with ureter-pancreatic duct anastomosis for exocrine drainage. Surgery 74 (2):171, 1973
PubMed
7) Largiader F et al:Farewell to pancreatic organ transplantation? Europ. Surg. Research 9 (6):399, 1977
 
8) Calne RY et al:Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs:32 kidneys, 2pancreases, and 2 livers. Lancet 2 8151:1033, 1979
PubMed
9) Groth CG et al:Successful outcome of segmental human pancreatic transplantation with enteric exocrine diversion after modifications in technique. Lancet 2 8297:522, 1982
PubMed
10) Dubernard JM et al:Anew method of preparation of segmental pancreatic graft. s for transplantation:trials in dogs and in man. Surgery 84 (5):633, 1978
 
11) Sutherland DE et al:Segmental pancreas transplantation from living related and cadaver donors:aclinical experience. Surgery 90 (2):159, 1981
 
12) Sollinger HW et al:Technical aspects of pancreas transplantation ASTS abstract book, 1985
 
13) Nghiem DD, Gonwa TA, Corry RJ et al:Metabolic effects of urinary diversion of exocrine secretion in pancreatic transplantation. Transplantation 43:70, 1987
PubMed
14) Wahlberg JA, Belzer FO et al:72-hour preservation of the canine pancreas. Transplantation 43:5, 1987
PubMed
15) Pinna AD, Sugitani A et al:Rapid en bloc technique for liver and pancreas procurement. Transplant. Proc 29:647, 1997
PubMed
16) Starzl TE, Iwatsuki S et al:Pancreaticoduodenal transplantation in humans. Surg. Gynecol. Obstet 159 (3):265, 1984
PubMed
17) Corry RJ, Sugitani A, Starzl TE et al:Enteric drainage of pancreas transplants revisited. Transplant. Proc 27 (6):3048, 1995
PubMed
18) Bartlett ST et al:Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosupPression with percutaneous biopsy. Armals of Surgery 224 (4):440, 1996
PubMed
19) Shapiro AM, Lakey JR et al:Islet transplantation in seven patients with type l diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. [comment]. New Eng. J. Med 343 (4):230, 2000
 
20) 寺岡 慧, 谷口 洋, 馬場園哲也ほか:我が国における糖尿病患者と膵移植の現況-特に推定膵移植適応患者数について-, 最新医学 3:14-27, 1998
 
21) Dodson F, Corry R et al:Advantages of the rapid en bloc technique for pancreas/liver recovery. Transplant. Proc 27 (6):3050, 1995
PubMed
22) Drachenberg CB et al:Evaluation of pancreas transplant needle biopsy:reproduciblity and revision of histologic grading system. Transplantation 63 (11):1579, 1997
 
P.354 掲載の参考文献
1) Higashi T, Saga T, Nakamoto Y, Ishimori T, Fujimoto K, Doi R et al:Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FGD PET). Usefulness and limitation in"clinical reality". Ann Nucl Med 17 (4):261-279, 2003
 
2) Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Imamura M et al:Contribution of PET in the detection of liver metastases from pancreatic tumours. Clin Radiol 54 (4):248-52, 1999
PubMed
3) Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al:Improvenlents in survival and clinical benefit with genlcitabine as first.-line therapy for patients with advanced pancreas cancer:arandomized triaL J Clin Oncol 15 (6):2403-13, 1997
 
4) Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C et al:Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas:a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 228 (4):508-17, 1998
 
5) Kalser MH, Ellenberg SS:Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120 (8):899-903, 1985
PubMed
6) Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH et al:Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region:phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230 (6):776-82;discussion 782-4, 1999
 
7) Neoptolemos JP, Dum JA, Stocken DD, Almond J, Link K, Beger H et al:Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer:arandomised controlled trial. Lancet 358 (9293):1576-85, 2001
 
8) Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P et al:Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 234 (6):758-68, 2001
PubMed
P.361 掲載の参考文献
1) 日本膵臓学会癌登録委員会:日本膵臓学会膵癌登録, 20年間の総括. 膵臓 18:101-169, 2003
 
2) 日本膵臓学会編:膵癌取扱い規約, 第4版, 金原出版, 東京, 1993
 
3) 湯浅典博, 神谷順一, 近藤 哲ほか:膵癌に対する治療成績の評価. 消化器外科 21:1063-1070, 1998
 
4) 佐野 力, 神谷順一, 梛野正人ほか:膵癌治療の最近の問題点. 胆と膵 20:475-481, 1999
Medical*Online
5) 上坂克彦, 二村雄次, 早川直和ほか:下部胆管癌に対する幽門輪温存膵頭十二指腸切除術の適応-臨床病理学的検討-. 日消外会誌26:1233-1238, 1993
 
6) 梛野正人, 二村雄次, 神谷順一ほか:膵, 胆道癌に対する門脈合併切除術. 静脈学4:63-70, 1993
 
7) Ishikawa O, Ohigashi H, Sasaki Y et al:Practical grouping of positive lymphnodes in pancreatic head cancer treated by an extended pancreatectomy. Surgery 121:244-249, 1997
 
8) Geer RJ, Brennan MF:Prognostic indications for survival after resection of pancreatic adeno-carcinoma. Am J Surg l 65:68-73, 1993
 
9) Yeo CJ, Cameron JL, Lillemoe KD et al:Pancreaticoduodenectomy for cancer of the head of the pancreas:201 patients. Ann Surg 221:721-733, 1995
PubMed
10) 二村雄次, 鈴木雄彦, 早川直和ほか:膵頭部癌に対する外科治療上の問題点;主に膵癌の神経叢浸潤と膵全摘術の意義について. 日外会誌 83:1005-1008, 1982
 
11) 二村雄次:全摘膵における膵癌の膵内進展様式と膵管X線造影像に関する臨床病理学的研究. 日外会誌 86:923-932, 1985
 
12) 久米明倫, 二村雄次, 神谷川頁, ほか:膵頭部癌の膵管上皮内進展の術中超音波による診断. 日超医論文集 56:599-600, 1990
 
13) 早川直和, 二村雄次, 神谷順一ほか:特異な進展様式を示した膵体尾部癌に対する膵全摘の1例. 日消外会誌16:2022-2025, 1983
 
14) Shimizu Y, Nimura Y, Kamiya J et al:Pyrolus-preserving pancreatoduodenectomy is applicable to patients with carcinoma of the head of the pancreas:Studies of lymphnode metastasis and quality of life. J Hep Bil Pallcr Surg 2:150-155, 1994
 
15) 松出真佐男, 二村雄次:膵頭部癌における神経叢侵襲. 日外会誌 84:719-728, 1983
 
16) 金井道夫, 二村雄次, 早川直和ほか:根治切除困難な膵頭部癌, この症例における検査の進め方と治療方針.-外科の立場から-. 外科 55:714-720, 1993
 
17) Hirata K, Sato T, Mukaiya M et al:Results of 1OOl pancreatic resections for invasive ductal adenocarcinoma of the pancreas. Arch Surg 132:771-776, 1997
PubMed
18) 山本正博, 大橋 修, 斉藤洋一:膵癌の標準手術と治療成績. 外科治療 78:46-52, 1998
 
19) Yeo CJ, Cameron JL, Sokm TA et al:Pancreaticoduodenectomy with or without extended retroperitoneal lymphadencctomy for periampullary adenocarcinoma:Comparison of morbidity and mortality and short-term outcome. Ann Surg 229:613-622, 1999
PubMed
20) 早川直和:上腸問膜動脈周囲神経叢隔清のコツ, 二村雄次編集:胆道外科の要点と盲点, 文光堂, 東京, P 220-222, 2002
 
P.367 掲載の参考文献
1) Kalser MH, Ellenberg SS:Pancreaqtic cancer:adjuvant conbined radiation and chemotherapy following curative resection. Arch Surg 120:899-903, 1985
 
2) Bakkevold KE, Amesjo B, Dahl O, Kambestad B:Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater:results of a controlled, prospective, randomized multicentre study. Eur J Cancer 5:698-703, 1993
 
3) Klinkenbijl JH, Jeekel J, Sahmoud T et al:Adjuvant radiotherapy and 5-flluorouracil after curative resection of cancer of the pancreas and periampullary region. Ann Surg 230:776-84, 1999
 
4) Neoptolemos JP, Dunn JA, Stocken DD et al:Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer:a randomized controlled trial. Lancet 358:1576-85, 2001
PubMed
P.373 掲載の参考文献
1) 日本膵臓学会:日本膵臓学会膵癌登録20年間の総括. 膵臓18:101-169, 2003
 
2) Casper ES, Green MR, Kelsen DP et al:Phase II trial of gemcitabine (2, 2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drug 12:29-34, 1994
PubMed
3) Rothenberg ML, Moore MJ, Cripps MC et al:A phase II trial of gemcitabine in patients with 5-FUrefactory pancreas cancer. Ann Oncol 7:347-353, 1996
PubMed
4) Burris HA 3rd, Moore MJ, Andersen J et al:Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial. J Clin Oncol 15:2403-2413, 1997
 
5) Okada S, Ueno H, Okuaka T et al:Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Jap J Clin Oncol 31:7-12, 2001
 
6) Rougier P, Adenis A, Ducreux M et al:A phase II study:docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 36:1016-1025, 2000
PubMed
7) Okada S, Okusaka T, Ueno H et al:Aphase II and pharmacokinetic trial of S-1 in patients with advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol 21:171a, 2002
 
8) Moore M, Hamm J, Eisenberg P et al:A Comparison between gemcitabine and the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced pancreatic cancer, Proc Am Soc Clin Oncol 19:A930, 2000
 
9) Bramhall SR, Rosemurgy A, Brown PD et al:Marimastat as first-line therapy for patients with unresectable pancreatic cancer:arandomized trial. J Clin Oncol 19:3447-3455, 2001
 
10) Huguier M, Barrier A, Valinas R et al:Randomized trial of 5-fluorouracil, leucovorin and cisplatin in advanced pancreatic cancer. Hepatogastroenterol 48:875-878, 2001
 
11) Ducreux M, Rougier P, Pignon JP et al:A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 13:1185-1191, 2002
PubMed
12) Berlin JD, Catalano P, Thomas JP et al:Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma:Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270-3275, 2002
PubMed
13) Colucci G, Giuliani F, Gebbia V et al:Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma:aprospective, randomized phase III study of the Gruppo Oncologia dell Italia Meridionale. Cancer 94:902-910, 2002
 
14) Heinemann V, Quietzsch D, Gieseler F et al:A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma. Proc Am Soc Clin Oncol 22:A1003 , 2003
 
15) Van Cutsem E, Karasek P, Oettle H et al:Phase III trial comparing gemcitabine+R115777 (Zamestra) versus gemcitabine+placebo in advanced pancreatic cancer. Proc Am Soc Clin Oncol 21:A517, 2002
 
16) Bramhall SR, Schulz J, Nemunaitis J et al:A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161-167, 2002
 
17) Ishii H, Okada S, Tokuuye K et al:Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 79:1516-1520, 1997
PubMed
18) Talamonti MS, Catalano PJ, Vaughn DJ et al:Phase Itrial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer:aregimen with unexpected early toxicity. J C. lin Oncol 18:3384-3389, 2000
 
19) Storniolo AM, Enas NH, Brown CA et al:An investigational new drug treatment program for patients with gemcitabine:results for over 3000 patients with pancreatic carcinoma. Cancer 85:1261-1268, 1999
PubMed

第13章 診断のニューテクノロジー

P.381 掲載の参考文献
1) Wilentz RE, Lacobuzio-Donahue CA, Argani P et al:Loss of expression of DPC4 in pancreatic intraepithelial neoplasia:evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 60:2002-2006, 2000
 
2) Ha A, Watanabe H, Yamaguchi Y et al:Usefulness of supernatant of pancreatic juice for genetic analysis of K-ras in diagnosis of pancreaticcarcinoma. Pancreas 23:356-363, 2001
 
3) Watanabe H, Miyagi C, Yamaguchi Y et al:Detection of K-ras mutations at codon 12 inpancreatic juice for the diagnosis of pancreaticcancer by hybridization protection assay:Asimplemethod for the determination of the types of pointmutations. Jpn J Cancer Res 87:466-474, 1996
 
4) Watanabe H, Yamaguchi Y, Ha A et al:Quantitativedetermination of K-ras mutations in pancreaticjuice for diagnosis of pancreatic cancer usinghybridization protection assay. Pancreas 17:341-347, 1998
PubMed
5) Wang Y, Yamaguchi Y, Watanabe H et al:Usefulness of p 53 gene mutations in thesupernatant of bile for diagnosis of biliary tractcarcinoma:comparison with K-ras mutation. JGastroentrol 37:831-839, 2002
 
6) Watanabe H, Ha A, Hu YX et al:K-ras mutations induodenal aspirate without secretin stimulation forscreening of pancreatic and biliary tractcarcinoma. Cancer 86:1441-1448, 1999
 
7) Yamaguchi Y, Watanabe H, Songur Y et al:Detection of mutations of p53 tumor suppressorgene in pancreatic juice and its application todiagnosis of patients with pancreatic cancer:comparing with K-ras mutation. Clin Cancer Res
 
9) Lu X, Xu T, Qian J et al:Detecting K-ras and P 53 gene mutation from stool and pancreatic juice fordiagnosis of early pancreatic cancer. Clin Med J115:1632-1636, 2002
 
10) Wang Y, Yamaguchi Y, Watanabe H et al:Detection of p 53 gene mutations in the supernatant of pancreatic juice and plasma from patients with pancreatic carcinomas. Pancreas (in press)
 
11) Ishimaru S, Itoh M, Hanada K et al:Immunocytochemical detection of p 53 protein from pancreatic duct brushings in patients with pancreatic carcinoma. Cancer 77:2233-2239, 1996
 
12) Iwao T, Hanada K, Tsuchida A et al:The establishment of a preoperative diagnosis of pancreatic carcinoma using cell specimens from pancreatic duct brushing with special attention to p53 mutations. Cancer 82:1487-1494, 1998
PubMed
13) van ES JM, van den Berg FM, Ramsoekh TB et al:Molecular markers for diagnostic cytology of neoplasmas in the head region of the pancreas:mutation of K-ras and overexpression of the P53 protein product. J Clin Pathol 48:218-222, 1995
 
14) Iwao T, Hiyama E, Yokoyama T et al:Telomerase activity for preoperative diagnosis of pancreatic cancer. J Natl Cancer Inst 89:1621-1623, 1997
PubMed
15) Suehara N, Mizumoto K, Tanaka M et al:Telomerase activity in pancreatic juice differentiates ductal carcinoma from adenoma and pancreatitis. Clin Cancer Res 3:2479-2483, 1997
PubMed
16) Uehara H, Nakaizumi A, Tatsuta M et al:Diagnosis of pancreatic cancer by detecting telomerase activity in pancreatic juice:comparison with K-ras mutations. Am J Gastroenterol 94:2513-2518, 1999
 
17) Myung SJ, Kim MH, Kim YS et al:Telomerase activity in pure pancreatic juice for the diagnosis of pancreatic cancer may be complementary to K-γas mutation. Gastrointest Endosc 51:708-713, 2000
 
18) Seki K, Suda T, Aoyagi Y et al:Diagnosis of pancreatic adenocarcinoma by detection of hurnan telomerase reverse transcriptase messenger RNA in pancreatic juice with sample qualification. Clin Cancer Res 7:1976-1981, 2001
 
19) Fukushima N, Walter KM, Ueki T et al:Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic juice. Cancer Biol Ther 2:78-83, 2003
 
20) Klump B, Hsieh CJ, Nehls O et al:Methylation status of p 14 ARF and p161NK 4a as detected in pancreatic secretions. Brit Med J 88:217-222, 2003
 
21) Sato N, Ueki T, Fukushima N et al:Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasmas of the pancreas. Gastroenterology 123:365-372, 2002
 
22) Matsubayashi H, Sato N, Fukushima N et al:Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clin Cancer Res 9:1446-1452, 2003
PubMed
5:1147-1153, 19998) Kaino M, Kondoh S, Okita S et al:Detection of Krαs and p 53 gene mutations in pancreatic juice forthe diagnosis of intraductal papillary mucinoustumors. Pancreas 18:294-299, 1999
 
P.388 掲載の参考文献
1) Weissleder R, Stark DD, Engelstad BL et al:Superparamagnetic iron oxide:pharmacokinetics and toxicity. Am J Roentgenol 152:167-173, 1989
 
2) Ward J, Naik KS, Guthrie JA et al:Hepatic lesion detection;comparison of MR imaging after the administration of superparamagnetic iron oxide with dual-phase CT by using alternative-free response receiver operating characteristic analysis. Radiology 210:459-466, 1999
PubMed
3) Seneterre E, Taourel P, Bouvier Y et al:Detection of hepatic metastases:ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CTduring arterial portography. Radiology 200:785-792, 1996
PubMed
4) Hori M, Murakami T, Kim T et al:Detection ofhypervascular hepatocellular carcinoma;comparison of SPIO-enhanced MRI with dynamichelical CT. J Comput Assist Tomogr 26:701-710, 2002
PubMed
5) Elizondo G, Weissleder R, Stark DD et al:Hepaticcirrhosis and hepatitis;MR imaging enhanced withsuperparamagnetic iron oxide. Radiology 174:797-801, 1990
PubMed
6) Brancatelli G, Federle MP, Grazioli L et al:Focalnodular hyperplasia;CT findings with emphasis onmultiphasic helical CT in 78 patients. Radiology219:61-68, 2001
 
7) Beets-Tan RG, Van Engelshoven JM, Greve JW:Hepatic adenoma and focal nodular hyperplasia;MR findings with superparamagnetic iron oxideenhanced MRI. Clin Imaging 22:211-215, 1998
PubMed
8) Grangier C, Tourniaire J, Mentha G et al:Enhancement of liver hemangiomas on T1-weighted MR SE images by superparamagneticiron oxide particles. J Comput Assist Tomogr 18:888-896, 1994
PubMed
9) Yoshimitsu K, Honda H, Jimi M et al:MR diagnosisof adenomyomatosis of the gallbladder anddifferentiation from gallbladder carcinoma:importance of showing Rokitansky-Aschoffsinuses. AJR Am J Roentgenol 172:1535-1540, 1999
 
10) Yoshimitsu K, Honda H, Aibe H et al:Radiologic diagnosis of adenomyomatosis of the gallbladder:comparative study among MRI, helical CT, and transabdominal US. J Comput Assist Tomogr 25:843-850, 2001
PubMed
11) Demartines N, Eisner L, Schnabel K et al:Evaluation of magnetic resonance cholangiography in the management of bile duct stones. Arch Surg 135:148-152, 2000
PubMed
12) Irie H, Honda H, Kuroiwa T et al:Pitfalls in MR cholangiopancreatographic interpretation. Radiographics 21:23-37, 2001
PubMed
13) Sugiyama M, Baba M, Atomi Y et al:Diagnosis of anomalous pancreaticobiliary junction:value of magnetic resonance cholangiopancreatography. Surgery l 23:391-397, 1998
 
14) Lam WW, Laln TP, Saing H et al:MR cholangiography and CT cholangiography of pediatric patients with choledochal cysts. Am J Roentgenol 173:401-405, 1999
 
15) Fulcher AS, Tumer MA, Franklin KJ et al:Primary sclerosing cholangitis:evaluation with MR cholangiography-a case-control study. Radiology 215:71-80, 2000
 
16) Yoshida K, Toki F, Takeuchi T et al:Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci 40:1561-1568, 1995
PubMed
17) Irie H, Honda H, Baba S et al:Autoimmune pancreatitis:CT and MR characteristics. Am J Roentgenol 170:1323-1327, 1998
 
18) Pruessmann KP, Weiger M, Scheidegger MB et al:SENSE:sensitivity encoding for fast MRI. Magn Reson Med 42:952-962, 1999
PubMed
19) Yoshioka H, Takahashi N, Yamaguchi M et al:Double arterial phase dynamic MRI with sensitivity encoding (SENSE) for hypervascular hepato-cellular carcinomas. J Magn Reson Imaging 16:259-266, 2002
 
20) Brenner D, Elliston C, Hall E et al:Estimated risks of radiation-induced fatal cancer from pediatric CT. Am J Roentgenol 176:289-296, 2001
 
P.395 掲載の参考文献
1) Weg N, Scheer MR, Gabor MP:Liver lesions:improved detection with dual-detector-array CT and routine 2.5-mm thin collimation. Radiology 209:417-426, 1998
PubMed
2) Kawata S, Murakami T, Kim T et al:Multidetector CT:diagnostic impact of slice thickness on detection of hypervascular hepatocelluar carcinoma. AJR 179:61-66, 2002
 
3) Kim T, Murakami T, Takahashi S et al:Optimal phases of dynamic CT for detecting hepatocellular carcinoma:evaluation of unenhanced and triple-phase images. Abdom Imaging 24:473-480, 1999
PubMed
4) Foley WD, Mallisee TA, Hohenwalter MD et al:Multiphase hepatic CT with a multirow detector CT scanner. AJR 175:679-685, 2000
PubMed
5) Murakami T, Kim T, Takamura M et al:Hypervascular hepatocellular carcinoma:detection with double arterial phase multi-detector row helical CT. Radiology 218:763-767, 2001
PubMed
6) Kamel IR, Kruskal JB, Keogan MT et al:Multidetector CT of potential right-lobe liver donors. AJR 177:645-651, 2001
PubMed
7) Ochotorena IJ, Kiyosue H, Hori Y et al:The local spread of lower bile duct cancer:evaluation by thin-section helical CT. Eur Radiol 1O:1106-1113 , 2000
 
8) Fleischmann D, Ringl H, Schofl R et al:Three-dimentional spiral CT cholangiography in patients with suspected obstructive biliary disease:comparison with endoscopic retrograde cholangiography. Radiology 198:861-868, 1996
 
9) Valls C, Andia E, Sanchez A et al:Dual-phase helical CT of pancreatic adenocarcinoma:assessment of resectability before surgery. AJR 178:821-826, 2002
PubMed
10) Taouli B, Vilgrain V, Vullierme MP et al:Intraductal papillary mucinous tumors of the pancreas:helical CT with histopathologic correlation. Radiology 217:757-764, 2000
PubMed
11) Kim T, Murakami T, Takamura M et al:Pancreatic mass due to chronic pancreatitis:correlation of CT and MR imaging features with pathologic findings. AJR 177:367-371, 2001
 
12) Prokesch RW, Chow LC, Beaulieu CF et al:Local staging of pancreatic carcinoma with multi-detector row CT:use of curved planar reformations initial experience. Radiology 225:759-765, 2002
PubMed
13) Fishman EK, Horton KM, Urban BA:Multidetector CT angiography in the evaluation of pancreatic carcinoma:preliminary observations. J Comput Assist Tomogr 24:849-853, 2000
PubMed
P.400 掲載の参考文献
1) Higashi T, Tamaki N, Honda T et al:Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study, J Nucl Med 38:1337-1344, 1997
PubMed
2) Higashi T, Tamaki N, Torizuka T et al:FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 39:1727-1735, 1998
PubMed
3) Higashi T, Saga T, Nakamoto Y et al:Relationship between retention index in dual-phase isF-FDG PET, hexokinase-II and glucose transporter-1 expression in pancreatic cancers. J Nucl Med 43:173-180, 2002
 
4) Smith TA:FDG uptake, tumour characteristics and response to therapy:areview. Nucl Med Commun Feb;19 (2):97-105, 1998
 
5) Hustinx R, Dolin RJ, Benard F et al:Impact ofattenuation correction on the accuracy of FDGPET in patients with abdominal tumors:afreeresponse ROC analysis. Eur J Nucl Med 27 (9):1365-1371, 2000
 
6) (社) 日本アイソトープ協会医学薬学部会サイクロトロン核医学利用専門委員会, FDG PETワーキンググループ鳥塚莞爾:公表された文献によるFDG PET検査の臨床的有用性の評価に関する調査報告. 核医学38:363-372, 2001
 
7) (社) 日本アイソトープ協会医学薬学部会サイクロトロン核医学利用専門委員会:FDG PETワーキンググループ:FDG PET検査の臨床的有用性と医療経済効果に関する全国調査報告. RADIOISOTOPES, vol. 49:NO. 3, 2000
 
8) Torizuka T, Tamaki N, Inokuma T et al:In vivoassessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 36:1811-1817, 1995
 
9) Delbeke D, Martin WH, Sandler MP et al:Evaluation of benign vs malignant hepatic lesionswith positron emission tomography. Arch Surg May;133 (5):510-515, 1998
 
10) Iwata Y, Shiomi S, Sasaki N et al:Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors. Ann Nucl Med. Apr;14 (2):121-126, 2000
 
11) Trojan J, Schroeder O, Raedle J et al:Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol Nov; 94 (11):3314-3319, 1999
PubMed
12) Wudel LJ Jr, Delbeke D, Morris D et al:The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg 69:117-124, 2003
PubMed
13) Abdel-Nabi H, Doerr RJ, Lamonica Dm et al:Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET:correlation with histopathologic and CT findings. Radiology 206 (3):755-760, 1998
PubMed
14) Nakamoto Y, Higashi T, Sakahara H et al:Contribution of PET in the detection of liver metastases from pancreatic tumours. Clinical Radiology 54:248-252, 1999
PubMed
15) Frohlich A, Diede血chs CG, Staib L et al:Detection of liver metastases from pancreatic cancer using FDG-PET. J Nucl Med 40:250-255, 1999
 
16) Delbeke D:Oncological applications of FDG PET imaging:brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med Apr;40 (4):591-603, Review, 1999
PubMed
17) Anderson GS, Brinkmann F, Soulen MC et al:FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med 28:192-197, 2003
PubMed
18) Langenhoff BS, Oyen WJ, Jager Gj et al:Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases:a prospective study. J Clin Oncol 20:4453-4458, 2002
PubMed
19) Kato T, Tsukamoto E, Kuge Y et al:Clinical role of (18) F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur I Nucl Med Mol Imaging 29:1047-1054, 2002
PubMed
20) Kluge R, Schmidt F, Caca K et al:Positron emission tomography with{ (18) F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 33:1029-1035, 2001
PubMed
21) Inokuma T, Tamaki N, Torizuka T et al:Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose:comparison with CT and US. Radiology 195:345-352, 1995
 
22) Bares R, Klever P, Hellwig D et al:Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose:method and first results. Nucl Med Commun Jul;14 (7):596-601, 1993
PubMed
23) Atabulated summary of the FDG PET literature:J Nucl Med 42:Supplement 1.1S-93S, 2001
 
24) Higashi T, Saga T, Nakamoto Y et al:Diagnosis of pancreatic cancer using fluorine-18 fluoro-deoxyglucose positron emission tomography (FDG PET) Usefulness and limitation in"clinical reality". Annals Nucl Med 17 (4):261-279, 2003
 
25) Nakamoto Y, Saga T, Ishimori T et al:FDG-PET of autoimmune-related pancreatitis:preliminary results. Eur J Nucl Med Dec;27 (12):1835-1838, 2000
PubMed
26) Ishimori T, Saga T, Mamede M et al:Increased (18) F-FDG uptake in a model of inflammation:concanavalin A-mediated lymphocyte activation. J Nucl Med May;43 (5):658-663, 2002
 
27) Delbeke D, Rose DM, Chapman WC et al:Optimal intelpretation of FDG-PET in the diagnosis, staging and management of pancreatic carcilloma. J Nucl Med 40:1784-1791, 1999
PubMed
28) Higashi T, Sakahara H, Torizuka T et al:Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET. J Nucl Med 40:1424-1433, 1999
 
29) Higashi T, Saga T, Ishimori T et al:Diagnostic Value of i":F Fluorodeoxyglucose Positron Emission Tomography in Patients With Cystic Pancreatic Tumors, inchlding Intraductal Papillary Mucinous Tumor (IPMT) (abstract). J Nucl Med43 (supplement):p298, 2002
 
P.405 掲載の参考文献
1) Moriyasu F, Ban N, Nishida O et al:Measurement of portal vasucular resistence in patinets with portal hypertension:Gastroenterology 85:1160-1164, 1986
 
2) Namekawa K, Kasai C, Tsukamoto M et al:J UItrasound Med Biology 8:138, 1982
 
3) Rubin JM, Bude RO, Carson PL et al:Power Doppier US:apotentially useful alternative to mean frequency-based color Doppler US. Radiology 190:853-856, 1994
 
4) Matsuda Y, Yabuuchi 1:hepatic tumors:US contrast enhancement with US microbubbles. Radiology 161:701-705, 1986
 
5) Burns PN:Haromonic imaging with ultrasound contrast agents. Clin Radiol 51:50-55, 1996
PubMed
6) Kudo K:Moiphological diagnosis of heaptocellular carcinoma:special emphasis on intranodular hemodynamic imaging. Hepato-gastroenterology 45:1226-1231, 1998
 
7) Ding H, Kudo M, Onda H et al:Contrast-enhanced subtraction harmonic sonography for evaluating treatment response in patinets with hepatocellular carcinoma, AJR 179:661-666, 2001
 
8) Ota T, Fleishman CE, Li J et al:Real-time, three dimensional cardiography feasibility of dynamic right ventricular volume measurment using sarine contrast. Aln Heart J 137:958-966, 1999
 
9) 蜂屋弘之:超音波医学19:633-639, 1992
 
10) Tamada K, Ido K, Ueno N et al:Preoperative staging of eztrahepatic bile duct cancer using intraductal ultrasonography. Am J Gastroenterology 89:239-246, 1995
 
11) Minami Y, Kudo M, Kawasaki T et al:Transarterial chemoembolization of hepatocellular carcinoma:Usefulness of coded phase-inversion harmonic sonography. AJR 180:703-708, 2003
 

第14章 各種製品の臨床評価

P.409 掲載の参考文献
1) Naylor CD, 0:Rourke K, Detsky AS et al:Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis. Gastro-enterol 97:1033-1039, 1989
 
2) Alexander WF, Spindel E, Harty RF et al:The usefulness of branched chain amino acids in patients with acute or chronic hepatic ence-phalopathy. Am J Gastroenterol 84:91-97, 1989
PubMed
3) 渡邊明治, 沖田美佐子:肝疾患の栄養管理の実際. 肝臓病と栄養治療, 第-.出版, 東京, p 208-230, 1992
 
4) Petrides AS, Vogt C, Schulze-Berge D et al:Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 19:616-627, 1994
 
5) 盛合 理, 鈴木.幸, 加藤章信ほか:肝硬変に対する高分枝鎖アミノ酸製剤療法. JJPEN 14:717, 1992
 
6) 市田文弘, 佐藤俊一, 柴崎浩市ほか:肝不全用経腸栄養剤 SF1008C の肝硬変患者における臨床評価. 肝胆膵 12:653-662, 1986
 
7) 市田文弘, 柴崎浩一, 武藤泰敏ほか二肝性脳症を伴う非代償性肝硬変患者に対する特殊アミノ酸経腸栄養剤の臨床的研究-Historical Dataの比較研究. 肝臓29:1051-1061, 1988
 
8) Marchesini G, Bianchi G, merli M et al:Nutritional supplement with branched-chain amino acids in advanced cirrhosis:Adoubule-blind randomized trial. Gastroenterol 124:1792-1801, 2003
 
9) 加藤章信, 鈴木一幸, 金田泰一:肝硬変に対する分岐鎖アミノ酸製剤の効果と使い分け. JJPEN 20:177, 1998
 
10) 加藤章信, 鈴木一幸, 佐藤俊一:分岐鎖アミノ酸療法/治療の実際;川崎寛中編:肝臓病-今日の診断と最新の治療, 国際医書出版, 東京, 131-140, 1997
 
P.411 掲載の参考文献
1) 金田悟郎, 高橋俊毅:総胆管結石症手術. 胸.腹腔鏡下外科手術, メジカルビュー社, 111-118, 1993
 
2) 大橋秀-:腹腔鏡下胃内手術, 手術48:333-337, 1994
 
3) 金田悟郎, 高橋俊毅ほか:Intragastric surgeryにおける腸管内空気遮断法の工夫, Progress of Digestive Endoscopy 48:51-54, 1996
 
P.416 掲載の参考文献
1) Liebman et al:Desgamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 310:1427-1431, 1984
 
2) 本原邦彦:乳児ビタミンK欠乏性出血症第2報 PIVKA-II モノクローナル抗体を用いた ELISA 法 (2抗体サンドイッチ法) による血中PIVKA-II の定量. 日児誌88:1508-1514, 1984
 
3) 楢木 徹ほか:モノクローナル抗体とポリクローナル抗体とを用いたサンドイッチ EIA (Enzyme Immunoassay) 法による PIVKA-II 測定試薬キットの開発と測定条件の検討. 免疫薬理18:479-492, 1986
 
4) 高津和子ほか:エイテストモノP-II 改良試薬EDO36 の性能特性の検討. 臨床と研究74:239-244, 1997
 
5) 鈴木 宏ほか:PIVKA-II 測定キット ED-036 の臨床評価. 肝胆膵33:1069-1076, 1996
 
6) 鈴木 宏:多施設集計結果. 犬山シンポジウム第 H部記録集, メディカルジャーナル社, 1996
 
7) 斎藤 聡ほか:肝細胞癌の早期診断に対する高感度PIVKA-II の有用性. 第5回全国PIVKA-II 研究会記録集, メディカルジャーナル社, 1998
 
8) 斎藤聡:腫瘍マーカーの応用. 肝胆膵36:231-235, 1998
 
9) 藤山重俊ほか:肝細胞癌とPIVKA-II 肝胆膵18:599-608, 1989
 
10) 崎園賢治ほか:モノクローナル抗体を用いた異常プロトロンビン (PIVKA』) 測定法の基礎的検討および臨床応用. 衛生検査39:92-94, 1990
 
11) 石井 史ほか:抗結核剤によるビタミンK欠乏症に関する研究. 日消誌94:389-397, 1997
 
12) MOhhira et al:Increase of Serum Des-gamma-Carboxy Prothrombin in Alcoholic Liver Disease Without Hepatocellular Carcinoma. Alcohol Clin Exp Res 23:67-70, 1999
 
P.418 掲載の参考文献
1) 原 耕平ほか:細菌性肺炎に対するCiprofloxacin 注射薬の臨床評価-Ceftazidimeを対照薬とした第III相臨床比較試験-. 日本化学療法学会雑誌 45:901-922, 1997
 
2) 小林宏行ほか:Ciprofloxacin注射薬の後期第II相臨床試験. 日本化学療法学会雑誌45:846-871, 1997
 
3) 相川直樹ほか:外科.婦人科領域の重症あるいは難治性感染症におけるciprofloxacin注射薬の臨床的検討. 45:936-950, 1997
 
4) 遠藤重厚ほか:救命救急領域における注射用シプロフロキサシン (シプロキサン注) の臨床的有用性. 化学療法の領域17:980-986, 2001
 
5) 一山 智ほか:重症感染症臨床分離菌の各種抗菌薬に対する感受性サーベイランス. Jpn J Antibiotics 54:401-447, 2001
 
6) 谷村 弘ほか:1997年度胆石全国調査報告. 胆道 12:276-293, 1998
Medical*Online
7) Parry MF et al:Hepatobiliary kinetics and excretion of ciprofloxacin. Antimicrob Agent Chemother 32:982-985, 1988
 
8) Sung JJY et al:Intravenous ciprofloxacin as treatment for patients with acute suppurative cholangitis:a randomized, controlled clinical trial. J Antimicrob Chemother 35:855-864, 1995
 

技術資料編

P.424 掲載の参考文献
1) 亀田康雄ほか:Chemotherapy 35 (S-1):76, 1987
 
2) 五島瑳智子ほか:Chemotherapy 35 (S-1):1, 1987
 
3) 横田 健ほか:Chemotherapy 35 (S-1):33, 1987
 
4) 村上和久ほか:Chemotherapy 35 (S-1):108, 1987
 
5) 清水喜八郎:Jpn. J. Antibiot 41 (12):1809, 1988
 
6) 馬場駿吉ほか:耳鼻と臨床35 (S-1):375, 1989
 
7) 馬場駿吉ほか:耳鼻と臨床35 (S-1):394, 1989
 
8) 厚生省薬務局:医薬品研究28 (6):494, 1997
 
9) 松原 肇ほか:新薬と臨床49 (10):1033, 2000
 
P.429 掲載の参考文献
1) Takeda M, Takagi T, Yamashita Y et al:Effet of anew potent H,-blocker, 3-[[2-[ (diamio methylene) amino]-4-thiazolyl]methyl]thio]-N,-sulfamoyl propionamide (YM-II 170), on gastric secretion, ulcer formation and weight of male accessory sex organs in rats, Arzneim-Forsch/Drug Res 32:734-737, 1982
 
2) Takeda M, Takagi T, Maeno H:Kinetics of antisecretoy action of a new H2-antagonist, YM-11170, in conscious dogs, Eur J Pharcol 91:371-376, 1983
PubMed
3) 竹田正明, 高木徳一, 藤原 明ほか:Famotidineの薬理作用-特にCimetidine および Ranitidine との比較-, 基礎と臨床 18:6125-6134, 1984
Medical*Online
4) Harada M, Terai M, Maeno H:Effect of a new potent H, ,-receptor antagonist 3[[2-[ (diamio methylene) amino]4 thiazolilyl]methyl]thiol-N2-sulfamoyl propionamide (YM-11170), on gastric mucosal histamine-sensitive adenylate cyclase from guinea pig, Biochem Pharmacol 32:1635-1640, 1983
 
5). 高木徳一, 竹田正明, 藤原 明ほか:H, 遮断薬Famotidine (YM-II 170) の一般薬理作用, 応用薬理26:599-611, 1983
 
6) 竹田正明, 高木徳-, 藤原 明ほか:Famotidineの薬理作用基礎と臨床18:6125-6134, 1984
 
7) 大江慶治ほか:H,-受容体拮抗剤famotidine (YM-11170) の胃酸分泌抑制効果に関する研究第1報基礎酸分泌に及ぼす影響, 内科宝函 30:365-378, 1983
 
8) 大江慶治ほか:H, 受容体拮抗剤famotidine (YM-11170) の胃酸分泌抑制効果に関する研究第2報ベタゾールならびにテトラガストリン刺激分泌抑制効果に関する検討, 内科宝函 31:11-24, 1984
 
9) 渡部汁三ほか:Famotidine (YM-11170) のインスリン刺激に対する胃酸分泌抑制試験, 薬理と治療11:3637-3650, 1983
 
10) 三好秋馬ほか:H, 受容体拮抗剤 Famotidine 注による胃酸分泌抑制作用-基礎分泌抑制作用について-, 基礎と臨床7:2909-2916, 1983
 
11) 三好秋馬ほか:H, 受容体拮抗剤Famotidine 注の胃液分泌抑制作用--テトラガストリン, ベタゾール刺激分泌抑制効果-, 基礎と臨床 7:2917-2927, 1983
 
12) 川井龍:太郎ほか:H, ,-receptor遮断薬 Famotidine (YM-11170) の生体内動態 (第2 報) イヌおよびヒトにおける吸収および排泄, 応用薬理27:73-77, 1984
 
13) Somogyi A, Gugler R:Drug interactions with cimetidine, Clin Pharmacokinet 7:23-41, 1982
PubMed
14) Winters SJ, Banks JL, Loriaux DL:Cimetidine is an antiandrogen in the rat, Gastroenterology 76:504-512, 1979
PubMed
15) Bertaccin G, Coruzzi G:Cholinergic-like effects of the new histamine H2-receptor antagonist ranitidine, Agents and Actions 12:168-171, 1982
 
16) Re L, Di Sarra B:Effects of famotidine at the mouse neuromuscular junction compared with those of cimetidine and ranitidine, Phamacology 39:200-204, 1989
 
17) Locniskar A et al:Interaction of diazepam with Famotidine and Cimetidine, two H,-Receptor antagonist, J Clin Phramacol 26:299, 1986
 
18) 竹田正明, 高木徳一, 藤原 明ほか:Famotidine の薬理作用-特にCirnetidineおよびRanitidineとの比較, 基礎と臨床18:6125-6134, 1984
 
19) 末永高寛, 今井康彦, 橋本加代子:ファモチジン新口腔内崩壊錠の生物学的同等性試験および口腔粘膜吸収試験, 薬理と臨床8:637-647,1998
 
20) 吉田行雄, 木平 健, 木村 健:PPIの酸分泌抑制作用24時間pHモニタリングによる検討-胃潰瘍・十二指腸潰瘍-, G. 1. Research 1:239-245, 1993
 
21) Chassany O, Berfmann JF et al:The comparative effects of single intravenous doses of cimetidine, ranitidine, famotidine, and omeprazole on intragastric pH, Curr Ther Res 57:159-167, 1996
 
22) 大江慶治ほか:H, 受容体拮抗剤 famotidine (YM-11170) の胃酸分泌抑制効果に関する研究:第3報夜間分泌抑制作用についての検討, 内科宝函31:51, 1984
 
23) Katsube T, Adachi K, Kinoshita Y et al:Helicobacter pyloli nfection influences nocturnal gastlic acid breakthrough, Aliment Pharmacol Ther 14:1049-1056, 2000
 
24) Peghini PI., Katz PO, Bracy NA, Castell DO:nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors, Am J Gastroenterol 93:763-767, 1996
 
25) 陶山匡一郎:慢性胃潰瘍.十二指腸潰瘍 (心身症) に対する最新の心身医学的治療, Ther Res 6:884-890, 1987
 
26) 大森浩明, 旭 博史, 安部 正ほか:Famotidine の健常人胃粘膜血流に及ぼす影響について, Gastroenterol Endosc 29:2016-2021, 1987
 
27) 毛戸祥博ほか:非ステロイド抗炎症薬およびビスホスホネート誘起胃粘膜傷害に対するFamotidineの抑制効果, 薬理と治療31:485-493, 2003
 
28) Mikawa K, Akamatsu H, Niwa Y et al:The Effects of Cimetidine, Ranitidine, and Famotidine on Human Neutrophil functions, Anesth Analg 89:218-224, 1999
PubMed
29) 内藤裕二, 吉川敏一, 近藤元治ほか:ヒスタミンH, , 受容体拮抗薬の抗酸化作用と抗炎症作用-cimetidine, ranitidine, roxiatidine, famotidine, nizatidineの比較検討-, Pharma Medica 17:133-142, 1999
 
30) Taha A, Dahill S, Russell R:Neutrophils, Helicobacter pylori, and nonsteroidal Anti-inflammatory Drug Ulcers, Gastroenterology 116:254-258, 1999
PubMed
31) 三好秋馬ほか:胃潰瘍を対象とした Famotidine就寝前1回投与法の検討-二重盲検法による1日2回投与法との比較-, 内科宝函34:391-403, 1987
 
32) 三好秋馬ほか:十二指腸潰瘍を対象とした Famotidine就寝前1回投与法の検討-:二重盲検法による1日2回投与法との比較-, 内科宝函 34:405-417, 1987
 
33) 関口利和ほか:逆流性食道炎に対する famotidinel日1回就寝前投与の臨床評価, 医学と薬学 18:172-163, 1987
 
34) 三好秋馬ほか:急性胃炎および慢性胃炎に伴う急性胃粘膜病変に対するファモチジン就寝前1回投与法の臨床効果, 二重盲検法による1日2回投与法との比較, 医学と薬学 19:147-163, 1988
Medical*Online
35) 城所 仙, 長尾房大, 水戸廻朗ほか:上部消化管出血に対するfamotidineの臨床効果-二重盲検法によるcimetidineとの比較-, 薬理と治療12:333-351, 1984
 
36) 三好秋馬ほか:上部消化管出血に対する Omeprazole 注射剤の臨床的研究-Famotidine 注射剤を対照薬とした二重盲検比較試験-, 薬理と治療23:1593-1608, 1995
 
37) 山之内製薬社内集計
 
38) Lim SG et al:The Absorption of fluconazole and itraconazole under conditions of low intragastric acidity, Aliment Pharmacol Ther 7:317-321, 1993
PubMed
39) 猪爪信夫ほか:腎機能障害時および高齢者におけるファモチジンの適正投与, Prog Med 16:2897-2903, 1996
Medical*Online
40) 山内眞義ほか:H2受容体拮抗薬と胃粘膜 ADH 14:103-107, 1996
 
P.434 掲載の参考文献
1) Coates A et al:On the receiving end-patient perception of the side-effects of the cancer chemotherapy. Eur J Cancer Clin Oncol 19 (2):203-208, 1983
 
2) Miller AD et al:Mechanisms of vomiting induced by serotonin 3 receptor agonists in the cat:Effect of vagotomy, splanchnicectomy or area postrema lesion. J Pharmacol Exp Ther 260 (2):509-517, 1992
PubMed
3) Fukui H et al:Increase in serotonin levels in the dog ileum and blood by cisplatin as measured by microdialysis. Neuropharmacology 32 (10):959-968, 1993
PubMed
4) Kamano T et al:Mechanisms of cisplatin and m-chlorophenylbiguanide-induced emesis in ferrets. Eur J Phaumacol 238:369-376, 1993
 
5) Richard J Gralla et al:Recommendations for the Use of Antiemetics:Evidence-Based, Clinical Practice Guidelines. J CIin Oncol 17 (9):2971-2994, 1999
 
6) Miyata K et al:Phanmacologic profile of (R)-5-( (1-methyl-3-indolyl) carbonyl)-4,5,6,7-tetra-hydro-1H-benzimidazole hydrochloride (YM060), apotent and selective 5-hydroxy-tryptamine 3 receptor antagonist, and its enantiomer in the isolated tissue. J Pharmacol Exp Ther 259 (1):15-21, 1991
 
7) Miyata K et al:Serotonin (5-HT, ,) receptor blocking activities of YM060, a novel 4,5,6,7-tetrahydro-benzimidazole derivative, and its enantiomer in anesthetized rats. J Pharmacol Exp Ther 259 (2):815-819, 1991
 
8) Ito H et al:Comparative Study of the Affinities of the 5-HT3 Receptor Antagonists, YM060, YM 114 (mm-393), Granisetron and Ondansetron in Rat Vagus Nerve and Cerebral Cortex. Neuropharmacology 34 (6):631-637, 1995
PubMed
9) Miyake K et al:Molecular cloning of human 5-hydroxytryptamine 3 receptor:heterogeneity in distribution and function among species. Mol Pharmacol 48:407-416, 1995
 
10) 藤原 明ほか:Ramosetron Hydrochlorideのヒト 5-HT, 受容体に対する親和性ならびにフェレットにおける5-HT, 受容体拮抗作用および嘔吐抑制作用. 基礎と臨床30 (8):1955-19(}4, 1996
 
11) Akuzawa S et al:Comparative Study of (3H) Ramosetron and(3H)Granisetron Binding in the Cloned Human 5-Hydroxytryptamine3 Receptors. Jpn J Pharmacol 78 (3):381-384, 1998
PubMed
12) 藤原 明ほか:フェレットのcisplatin誘発嘔吐に対する新規5-HT, 受容体拮抗薬YM060の抑制作用. 基礎と臨床28 (8):2337-2347, 1994
 
13):占江 尚:癌化学療法における悪心.嘔吐対策. 癌治療と宿主4 (1):75-85, 1991
 
14) 中島光好ほか:YM060の第1相臨床試験-健常成人男子における単回静脈内投与試験-. 臨と研71 (9):2461-2468, 1994
 
15) 関野久之ほか:YM060の第1相臨床試験-健常成人男子における反復静脈内投与時の忍容性および薬物体内動態-. 薬理と治療22 (9):3877-3888, 1994
 
16) 野田起一郎ほか:抗悪性腫瘍剤投与により発現する悪心.嘔吐に対するYM060注射剤の臨床第II相試験-至適用量設定試験-. 臨と研 71 (10):2753-2764, 1994
Medical*Online
17) 野田起一郎ほか:抗悪性腫瘍剤投与により発現する悪心.嘔吐に対するYM060注射剤の臨床第III相試験-プラセボを対照とした多施設二重盲検群間比較試験-. 臨と研 71 (10):2765-2776, 1994
Medical*Online
18) 野田起一郎ほか:抗悪性腫瘍剤投与シスプラチン誘発の悪心.嘔吐に対するYM060注射剤の臨床第III相試験-グラニセトロンを対照とした比較試験-. 臨と研43 (11):2241-2255, 1994
 
19) 武谷雄二ほか:抗悪性腫瘍剤誘発の悪心.嘔吐に対するYM060注射剤の臨床評価. 産と婦 61 (12):1759-1770, 1994
 
20) 川畑幸嗣ほか:抗悪性腫瘍剤による悪心・嘔吐に対するYM060の臨床評価と薬物血中動態に関する検討-臨床第III相試験-. 西日泌 56 (11):1445-1456, 1994
 
21) 武谷雄二ほか:抗悪性腫瘍剤誘発の悪心.嘔吐に対するYM060注射剤の臨床評価-乳酸処方製剤における臨床第III相試験-. 産婦の世界 46 (12):965-973, 1994
 
22) 森 昌造ほか:抗悪性腫瘍剤投与により発現する悪心.嘔吐に対するYM060注射剤の臨床評価-予防的投与についての検討-. 臨成人病 24 (12):2257-2265, 1994
 
23) YK Kang et al:Ramosetron for the Prevention of Cisplatin-induced Acute Emesis:a Prospective Randomized Comparison with Granisetron. J Int Med Res 30:220-229, 2002
 
P.438 掲載の参考文献
1) 日本薬剤師研修センター:JPDI2001, 826, 2001
 
2) 藤沢保仁ほか:西日泌尿 37:240-244, 1975
 
3) 加賀谷寿考ほか:診療と新薬 35:829-855, 1998
 
4) 崎村恭也ほか:薬理と治療 26:1027-1053, 1998
Medical*Online
5) 大和 滋:臨床と薬物治療 20:937-939, 2001
 
6) 遠藤 剛:薬理と治療 29:961-965, 2001
Medical*Online
7) 吉田製薬株式会社社内資料
 
8) 丘 龍祥ほか:医学と薬学 49:941-948, 2003
Medical*Online
9) 高橋るみのほか:医薬品相互作用研究 10:149-157, 1986
 

書評

最近チェックした商品履歴

Loading...